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1.1. Metabolomics 
 
 
Metabolomics is the study of all low molecular weight compounds present in a 
biological sample. It examines the whole metabolism, which ultimately reflects 
dietary and environmental exposures and the behaviour of different patterns of genes, 
gene transcripts and proteins [1, 2]. It describes the large scale analysis of endogenous 
metabolites that comprise the entire collection of small molecules in a cell, tissue, 
organism or biofluid, including compounds such as sugars, organic acids, amino 
acids, fatty acids and nucleotides [1, 2]. Sequencing an organism’s genome does not 
provide any details of its enzyme and their encoding genes, therefore the field of 
‘omics’ technologies was created to better understand the sequence information. 
These techniques have become important tools and have contributed to the 
understanding of an organisms metabolism [3], namely through the use of ‘genomics’, 
‘transcriptomics’, ‘proteomics’ and ‘metabolomics’, which should all play important 
roles in understanding complex biological systems [4]. 
 
Introduction to Metabolomics 
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Genomics concentrates on the study of genomes of an organism. Within functional 
genomics, the levels of the transcriptome, the proteome and metabolome reveal the 
complete set of mRNA molecules, proteins or metabolites present in a cell (Figure 1-
1).  For example, genomics may identify an individual with a particular disease; while 
proteomics and metabolomics allows the possible discovery and study of the 
progression of a disease as it develops [5]. By relating the effects that a stress or a 
disease state has on the activity of various biological pathways (and by investigating 
changes in the chemicals produced in and through those pathways) metabolomics 
provides insights into cellar physiology that promises to allow the development of 
new small molecule and biotechnologically-developed drugs, reduce the cost of 
research and development and enable new industrial uses of biotechnology [6]. 
 
The first experiment involving metabolomics can be traced back as far as 1966, when 
researchers from Baylor College of Medicine, (United States) described the use of 
gas-liquid chromatography (GLC) to separate metabolites from urine and tissue 
extracts. Many terms have been defined in order to refer to studies in the 
metabolomics field, with the most common being: ‘global metabolomics’ and 
‘targeted analysis’ [7]. Global metabolomics involves the identification of as many 
metabolites as possible while so-called ‘target analysis’ focuses on specific individual 
or chemical classes of metabolites. Metabolites can be viewed as downstream 
products of genome and proteome regulatory processes, and thus provide a plethora of 
information about the catalytic or regulatory properties of gene products. 
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Figure 1-1: The physiology state of the cell measured at several levels in a functional 
genomic approach, all which interact with one another to form a highly interconnected 
network [8]. 
Mitchell et al. emphasise the significant potential of metabolomics and state that the 
discipline of metabolomics promises an-all-encompassing approach to understanding 
the total, yet fundamental, changes occurring in disease processes, drug toxicity and 
TRANSCRIPTOME 
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cell function [9]. This potential has been aided greatly by the formation of the Human 
Metabolome Database (HMDB) (www.hmdb.ca), which contains a collection of 
records for 37,166 annotated metabolites (September 2012)[10]. It comprises an 
average of 90 separate data fields including a comprehensive compound description, 
names and synonyms, structural information, physico-chemical data, MS spectra, 
typical biofluid concentrations and disease associations [10]. One of the fundamental 
precepts of metabolomics is that the study of the metabolome can sense when a 
system is out of ‘control’ or is not ‘normal’. Therefore to be able to have a better 
understanding as to why the concentration levels of metabolites of interest are outside 
a ‘normal’ range (and more significantly to forecast how variation in factors can affect 
the metabolism) an understanding of how these biochemical pathways and their 
reactive functions operate is required. Still, defining this ‘normal’ state is often a 
challenging task. This was expressed by Saude and co-workers who studied the 
variation of metabolites in human urine [11]. Generally metabolite homeostasis, 
control of an individual’s metabolic profile, is assumed to take place, but it is still 
required to determine the intra-and inter-metabolite variation which could be response 
and variation in genetics, ethnicity, diet, exercise, stress etc. within the control group, 
before any conclusions are made in regards to changes due to a diseased state. 
To this day the number of metabolites present in different types of biological samples 
remains a subject of debate and depends on the definition of exactly what type of 
components should be included and on the analytical platform used. Numbers ranging 
from a few thousands to hundreds of thousands of small molecules have been 
proposed.  For example, a microorganism such as Escherichia coli (E. coli) has been 
reported to contain 1,170 metabolites and with a molecular weight of less than 300 
g/mol for the major metabolites [12]. In addition, the plant kingdom can contain up to 
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200,000 primary and secondary metabolites (for e.g. phenolics and nitrogen-
containing compounds)[13]. Primary metabolites are essential for the growth and 
development of the plant, while the secondary metabolites are usually associated with 
the defense response in the plant [14]. The accumulation of such in-depth knowledge 
is highly advantageous for elucidating functions of novel genes and gives cause for 
thought about their genetic manipulation with regard to organisms improvement [15]. 
Improvements are still required for many organisms such as yeast, which has been 
used over centuries for the production of wines, bakery products and beer. For 
example, eukaryotic cells are more complex to analyse than prokaryotic cells as their 
metabolite levels differ greatly depending on their location in the organelles.  
There are many advantages associated with metabolomics, although currently there is 
no metabolomics analysis platform that allows for the comprehensive analysis of the 
whole metabolome [16]. This is mainly due to the large number of cellular 
metabolites, as well as the chemical variation observed; therefore it is unclear what 
coverage of the metabolome the analyst can obtain in relation to the full metabolome 
composition - despite the progress in the past few years where 500 different 
metabolites can be analysed in a single chromatographic run [17]. As implied earlier, 
metabolomic information complements data obtained from other fields that comprise 
the new biology: genomics, transcriptomics and proteomics by describing the effects 
that a stress or disease state has on the activity of various biological pathways, and the 
difference in the concentration of different components in the metabolome referred to 
as “fluxomics” is estimated to vary from the pmol to mmol concentration range [18, 
19].  
Chapter 1: Introduction to Metabolomics 
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Quantitative and qualitative analysis in targeted mode is generally concerned with 
only a small number of ‘interesting’ metabolites and the use of an internal standard 
for each metabolite. Metabolic profiling concentrates on a specific class of 
metabolites to be analysed, for e.g. amino acids, sugars, fatty acids, organic acids, 
amines etc.  This type of analysis allows for the complete qualitative analysis (and 
subsequent quantification of specific metabolites of interest) for all metabolites 
identified within the profiles, and this is of particular importance for metabolite 
recovery [20]. Metabolic fingerprinting encompasses a ‘global’ type of analysis, 
which generally does not require comprehensive chromatographic separation and 
metabolites are not usually identified - instead datasets are sorted into categories and 
compared, with conclusions regarding individual samples being made [21]. There is 
also some overlap in terminology with ‘metabonomics’, which has been defined as the 
“quantitative measurement of time-related multiparametric metabolic response of 
multicellular systems to pathophysiological stimuli or genetic modification”[22] and 
is usually used in toxicological studies with NMR for global metabolite screening 
[23].  
The main differences between the two terms lies mainly in the fact that metabonomics 
is not involved in the identification of individual signals, but rather the metabolomic 
response as a whole [24]. Eventually, the technology used to make an assessment 
should be capable of not only detecting the metabolites, but also identifying the 
molecular mechanism and logical strategy for correcting the process. In addition, 
broad phenotypic analyses are necessary in order to progress from prediction to 
experimental validation of gene function [25].The standardization of methods has also 
become important in order to obtain dependable data sets. Method standardization 
includes the optimization of culture and sampling conditions, extraction and 
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derivatization methods and interpretation of data, which is necessary to obtain 
accurate reproducible and validated consistent performance [26]. Without a consistent 
approach, analytical methodology may limit the application of metabolomic analysis, 
in spite of its enormous potential. Nevertheless, the optimization of metabolic 
profiling for many researchers remains a challenging task in regards to maximising 
the recovery of identifiable components. Fortunately, improvement in analytical 
platforms, e.g. one dimensional (1D) compared to multi-dimensional techniques, and 
computational platforms, aid efforts to improve and enlarge metabolic databases. 
However, integrated metabolomic data do not by themselves cover a complete 
understanding of metabolism. In order to understand the data, the metabolites of 
interest need to be appreciated firstly in the framework of their biochemical pathways 
[27].Recent efforts (online software) have been made to link metabolites of interest 
(possible biomarkers’) to the biochemical pathways, for example: IMPALA 
(http://impalia.molgen.mpg.de/),MPEA,(http://ekhidna.biocenter.helsinki.fi/poxo/mpe
a/mpea), Consensus Path (http://cpdb.molgen.mpg.de/), BioCyc (http://biocyc.org/) 
etc. The combination of these procedures (analytical capabilities, data and statistical 
processing, and biochemical interpretation) has allowed metabolomics to gain much 
interest, with the recent formation of the Metabolomics Society 
(http://www.metabolomicssociety.org) and its dedicated journal Metabolomics are 
evidence of this [28].  
Metabolism is a key process with respect to phenotype, and therefore the need to 
establish and analyse the complex distribution of metabolites is the obvious course in 
the expansion of functional genomics. Over the years much research has been 
conducted on individual metabolic analyses, with cholesterol as one example of this 
type of approach. Cholesterol is used as a single biomarker diagnostic for selected 
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metabolism-based disease. Biomarkers are specific metabolites that have a unique 
molecular feature, which allows for their use in measuring the progress of a disease or 
effects for treatment. Single biomarkers fail to provide accurate, trustworthy 
conclusions about how to diagnose and treat the development of metabolic disease 
process [29]. This is a result of the fact that the single measurement does not provide 
enough information to construe why an individual accumulates e.g. cholesterol, nor 
does it suggest a suitable diagnosis. For example, serum cholesterol can be high due 
to several reasons, as the individual can: 
 Absorb cholesterol extraordinarily well through the intestine 
 By endogenous synthesis produce too much cholesterol 
 Convert cholesterol to bile acids at different rates 
The current standard total blood cholesterol measurement cannot differentiate 
between the three, but if sterols and their metabolites are also considered in the 
analytical measurement, then it is possible to make an accurate conclusion. Therefore 
more than one single marker of a disease is necessary to be measured in order to make 
a conclusion about a specific disease, with the ultimate aim being the assignment of a 
molecular function to each biomarker. While the potential of biomarkers and their 
categorization are clear, the course for biomarker discovery and clinical assay 
development is littered with complex challenges and uncertainty. The selection and 
clinical validation of biomarkers is a monumental endeavour. As described by 
Sawyers and Zolg, introducing a metabolite as a possible biomarker into the market 
requires three phases: biomarker discovery, where biomarkers are identified; 
prototype development, where immunological assays are created; and 
commercialization, where assays are readied for clinical use [30, 31].  
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Today, most studies are concerned with the identification of possible biomarkers, and 
a much large emphasis needs to be given to the validation stage before these 
biomarkers can be used for clinical purposes [32]. 
1.2. Applications of metabolomics using GC 
 
1.2.1. Human Metabolomics 
 
 
Metabolomics is increasingly being used in a variety of health applications including 
pharmacology, pre-clinical drug trials, toxicology, transplant monitoring, newborn 
screening and clinical chemistry [33]. Scientists around the world are now beginning 
to realize that metabolic profiling could have a significant impact on the diagnosis, 
prediction, prevention and monitoring of many genetic, infectious and environmental 
diseases [11].  However, a key limitation to metabolomics is the fact that the human 
metabolome is not at all well characterized. One of the major achievements of 
research in this field over the past 100 years has been the understanding of 
biochemical pathways that comprise human metabolism. The biochemical interaction 
that takes place in the enzymes, substrates, products and intermediates are more 
completely understood nowadays than almost any other aspect of human biology. As 
a result of this knowledge guiding human health has been a major advantage, through 
the development of drugs, foods and agricultural chemicals.  Today, the healthcare 
system is faced with various challenges, which with the knowledge attained in human 
metabolomics will help solve many of the problems encountered. Nutritional 
deficiencies do not seem to be a major challenge, but the optimization of human 
metabolism through the correct functioning of metabolic pathways would be 
beneficial.  Most diseases can be found in: 
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 Malfunctioning enzyme activity (genetics, toxicology) 
 Substrate imbalance (nutrition) 
 Faulty metabolic regulation (genetics, lifestyle, nutrition etc) 
All of the above can be observed through the quantitative measurement of the human 
metabolome. Table 1-1 lists the extrinsic and intrinsic factors which are likely to 
affect the human nutritional metabolome.  
 
Table 1-1: Extrinsic and intrinsic factors likely to affect the human nutritional 
metabolome (reproduced from [34]) 
 
 
Human metabolomics empathises on the different functions that biological fluids may 
play in the identification and treatment of disease, or changes in the metabolites as a 
function of treatment conditions. The priority is to identify disease-related differences 
in the endogenous metabolites present in biological fluids. Blood (plasma and blood 
serum), urine and sometimes saliva are the usual biofluids of choice, in some 
instances samples as diverse as fecal water have been used to understand gut 
microflora [35-37]. Plasma and blood serum are interchangeably used in many 
Extrinsic factors The Metabolome Intrinsic factors 
   
Diet (nutrients and 
nonnutrients 
The sum of all 
endogenous and 
exogenous metabolites 
Body composition 
Drugs 
 
 Tissue turnover 
Physical activity 
 
 Resting metabolic rate 
Colonic flora 
 
 Age 
Stress  Genotype 
 
  Health status 
 
  Reproductive status 
 
  Diurnal cycle 
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laboratories, plasma tends to be more stable and the protein profiles attained from 
plasma and serum are very different. GC/MS metabolic profiling for body fluids can 
be traced back as early as 1970 [38]. Since then, much emphasis has been put on 
analysis for metabolic profiling of diseases using GC/MS. Jellum published a review 
on metabolic profiling of urinary organic acids in ‘normal’ compared to ‘diseased’ 
states [39].  Kuhara et al. used GC/MS to diagnose inborn errors of metabolism 
(IEMs) [40] , and reviewed this area [41]. A particular study from this group involved 
40, 000 newborns that were examined in four different Japanese institutions, and 33 
out of the 40, 000 cases detected inborn errors of metabolism [40]. Although the 
number of cases of inborn errors of metabolism is small, early detection is of vital 
importance. Early detection allows for the development of different therapies which 
include: 
 Dietary alterations 
 Enzyme replacement therapy  
 Enzyme inhibitors  
GC/MS was first used for both qualitative and quantitative analyses of urinary 
metabolites and many IEMs including isovaleric academia [42], propionic academia 
[43], pyroglutamic academia [38] and 3-methylcrotonylglycinemia [44] have been 
discovered using this technique.  Tanaka and co-workers developed a method in 
which 155 metabolites were identified, which also helped prove the importance of 
GC/MS in diagnostic medicine [45]. Selected biomarkers for cancer research are 
currently used routinely for population screening, disease diagnosis, prognosis and 
prediction of therapeutic response. However the problem of poor specificity arises as 
it leads to many false positives and false negatives, thus current biomarkers do not 
appropriately satisfy the required clinical applicability. For instance, similarly 
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selection ion monitoring (SIM) ions may exist for a selected biomarker and other 
metabolites, therefore incorrect metabolite identification results in false positives. 
Philips and co-workers have been involved in a great amount of research involving 
the development of a ‘breathalyzer’, which is used in the detection of volatile organic 
compounds (VOC) from different types of cancer [37, 46-53] using GC/MS. The 
application of statistical analysis (analysis of variance (ANOVA), principal 
component analysis (PCA), and partial least squares (PLS)) has also been shown to be 
useful in distinguishing between kidney cancer patients from normal subjects using 
GC/ToFMS analysis [54]. Recently GC/ToFMS was also used to identify different 
metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors 
[55]. A total of 291 compounds were detected using this method, with 114 being 
identified as known compounds, using PCA and supervised predictive models 
established 88% of the borderline tumours from the carcinomas.  
Metabolites of interest are extracted in a similar manner from both blood plasma and 
urine.  Sample extraction with acetonitrile [56], methanol [57], or ethanol [58] 
followed by drying, methoximation of the supernatant, derivatization (silylation) and 
finally injection into GC/MS is a typical approach.  Jiye and co-workers [57] applied 
design of experiment methods to determine choice of extraction solvent (methanol, 
ethanol, chloroform, acetonitrile, acetone ) and derivatization conditions. The study 
found that ethanol was the most efficient solvent. The method proposed by Jiye et al. 
can be applied globally for both blood plasma and urine for analysis by GC/MS: 100 
µL of sample is extracted with 800 µL of methanol, vortexed, centrifuged, 200 µL of 
supernatant collected, dried, methoximated and derivatised, and finally injected into 
the GC/MS for analysis. The general analytical procedure is described in Figure 1-2. 
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Figure 1-2: Metabolomics method for biomarker screening in urine, blood, and tissue 
(reproduced from [57]) 
Vortex, centrifuge and dry supernatant under N2 
Addition of methoxyamine hydrochloride  
Conventional (30 mins) derivatization with MSTFA + 1% TMCS 
GC analysis 
Deconvolution, alignment, identification 
Statistical analysis 
Identification of biomarkers of interest 
Addition of 
acetonitrile, ethanol or 
methanol 
Addition of ethanol 
or methanol 
Tissue 
Heat after addition 
of urease (30 mins) 
Addition of 
H2O:CH3OH:CHCl3 at a 
ratio of (2:5:2) 
Blood      Urine 
Homogenization 
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Quantitative data for the 32 different endogenous metabolites showed good precision 
and linearity, and the areas of 500 resolved peaks were used as response variables for 
the solvent and derivatization designs. Furthermore, partial least squares (PLS) was 
used to show the efficiency of methanol extraction. It was considered also highly 
reproducible as eight selected endogenous metabolites agreed well with the analyses 
by independent methods from accredited laboratories.  
In addition, recent studies show that GC/TOFMS can be used to analyse the metabolic 
effects of physical exercise. The study illustrated similar differences between normal 
and human samples. Subjects undertook a specific regimen involving 15 mins bed rest 
followed by 90 mins of cycling, with serum samples being taken pre- and post-
exercise. Overall a total of 420 metabolites were identified, with 34 of these 
metabolites being potential biomarkers of interest. Table 1-2 shows selected reports of 
the use of one-dimensional and two-dimensional GC approaches for metabolic 
profiling of biological-based samples.  
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Table 1-2: Selected high-impact reports of use of GC/MS for metabolic profiling 
 
 
 
 
TECHNOLOGY STUDY GOAL REFERENCE 
GC/qMS Linking the genotype and 
phenotype 
[1] 
GC/qMS Organic acid analysis by 
GC/MS-Pyroglutamic aciduria 
[38] 
GC/qMS Challenges and development in 
GC/MS based metabolite 
profiling 
[59] 
GC/TOFMS Analysis of a D-Galactosamine/ 
Lipoplysaccharide 
[60] 
GC/TOFMS Huntington disease patients and 
transgenic mice have similar pro-
catabolic serum metabolite 
[61] 
GC-HRMS Organic acid analysis of human 
urine using GC/HRMS 
[62] 
GC/MS-MS Tyrosine metabolites and 
metabolism inhibitor in 
biological fluids 
[63] 
GCxGC/TOFMS General metabolite profiling, 
GCxGC/TOFMS and GC/qMS 
[64] 
GC/qMS Extraction and GC/MS analysis 
of the human blood plasma 
metabolome 
[52] 
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1.2.2. Plant Metabolomics 
 
As with all organisms, plants are forced to evolve within a range of environmental 
conditions that are crucial for their growth and development.  They must respond and 
adapt to surroundings that deviate from the optimal, such as: low/high temperature, 
dehydration, high salinity, oxidative stress, heavy metals and nutrient deficiency [20, 
65, 66]. Even though plants and animals have common response mechanisms to 
adverse environmental conditions, plants as sessile organisms, have developed 
efficient ways of response [67].  These stresses can be investigated using 
metabolomics, where stress associated with temperature and nutrition are best defined 
using metabolomic profiling [66, 67]. Due to great interest for both basic and applied 
research, many scientist have long, addressed the understanding of the mechanism 
underlying the stress response and the identification of the specific gene/metabolite 
that are responsible for tolerance phenotype. 
 
In recent years metabolite profiling has allowed analysis of the changes caused by 
environmental stresses, confirming data previously possible with target analysis and 
therefore broadening the scope of investigation [68].  
Metabolomic changes observed in plants subjected to stress conditions depend on 
different causes; therefore they have different significances. Changes in the 
metabolome composition due to unfavourable environmental conditions may depend 
on:  
i) the stability and and catalytic activity of enzymes involved in the 
production or degration of specific metabolites 
ii) the production of abnormal concentration of normal compounds 
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iii) the adjustment of concentration of some metabolites to restore 
homeostasis and normal metabolic fluxes  
iv) accumulation of compounds involved in mediating tolerance 
mechanisms 
The main reason for investigating metabolic changes during stress responses is to 
classify metabolites belonging to (iii) and (iv) groups that are responsible for stress 
tolerance [17]. During exposure to osmotic stress as a result of low temperature, 
draught and high salinity plants accumulate a range of compounds, which vary among 
species and include sugars (sucrose, glucose, fructose, etc), and amino acids such as 
proline [69].  Many of these metabolites are known to play a role as osmo protectants, 
acting as low molecular weight compounds (usually act as stress signals), therefore 
identifying these metabolites could improve the understanding of the adaption 
mechanisms. Stress associated with temperature and nutrition are best defined using 
metabolic profiling [67]. A variety of analytical techniques such as GC/MS, LC-
DAD-MS, FT-IR and NMR have been successfully employed for analysis and have 
been performed on a diverse array of plant species, including Arabidopsis, tomato, 
potato, wheat and  eucalyptus [17, 68].  
 
Tiessen and co-workers identified the site at which starch synthesis was inhibited after 
detaching a growing potato tuber from the mother plant [68]. ADP-glucose 
pyrophosphorylase (AGPase) was identified as the site regulation after metabolites in 
the pathway between sucrose and starch were analyzed. Optimised preparation 
methods are developed on a case-by-case basis, as there are many steps involved in 
the process, with the most vital step in plant metabolic profiling being the extraction 
procedure. Extraction efficiency and maintenance of crucial components must be 
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preserved through the homogenous crushing of the plant material, e.g. grinding with 
mortar and pestle under liquid nitrogen, milling in vibration mills with chilled holders, 
homogenization using a metal pestle connected to an electric drill and turrax devices. 
Generally metabolites are extracted by shaking the homogenized plant tissue at low or 
high temperature preferably in organic solvents [20]. Polar metabolites are usually 
extracted using: methanol, ethanol, while lipophilic compounds are usually extracted 
with chloroform. However to date, many other extraction techniques have become 
routinely applicable (i.e. microwave-assisted extraction (MAE) , supercritical fluid 
extraction (SFE) and pressurized liquid extraction (PLE) [70]. 
 
Roessner and co-workers [71] performed plant metabolite profiling on potato tubers 
and Arabidopsis thaliana leaf extracts [17] using GC/MS. Another example is the 
metabolic profiling of volatile compounds of 94 varieties of tomato fruits, analysed by 
headspace GC/MS [72-74]. The metabolite examination related with this study 
recognized about 20,000 specific, non-identified mass spectral tags (MSTs), and after 
reducing the data set through the use of hierarchical clustering analysis, 322 exclusive 
compounds were established [74]. The theory behind this work is that MSTs of 
metabolites from a specific pathway are expected to show a significant relationship, 
which means that information on peaks that remain unidentified can be associated 
with the known metabolites in order to allocate MSTs for that specific pathway. Main 
properties linked with MST are: i) GC retention time (or retention index), ii) specific 
ions fragmentation which are characterised by mass-to-charge ratio (m/z). In 
metabolomics this is often viewed as the single most demanding task [75], as each 
MST has properties which enable absolute identification of the parent metabolite, 
following comparison to the pure reference compound. Metabolomic approaches have 
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been applied to flux analysis to explain plant metabolism, for the profiling of pumpkin 
[76], GM potato tubers [77] and nutrition research [78].  
Differing genotypes and environmentally generated phenotypes can be clustered 
according to their metabolic variation, through the use of statistical techniques such as 
principal component analysis (PCA) and hierarchical cluster analysis (HCA) [75-78]. 
1.3. Analytical Techniques 
 
 
Metabolomics is challenged by the remarkable heterogeneity and complexity 
exhibited by metabolites. Metabolites span concentration ranges of the order 10
9
, 
polarity ranges of 10
20
 and mass ranges of the order of 1500 amu [79]. Moreover, 
most extraction procedures do not provide complete representation, resulting in only a 
portion of the metabolome being analysed. A comprehensive coverage of the 
metabolome therefore, necessitates multiple extraction techniques and different 
sample preparation strategies to encompass such diversity. Today, metabolomics is 
commonly considered as the combination of analytics for metabolite determination 
with appropriate informatics for data extraction, mining and finally biochemical 
interpretation. It is usually focused in one of the two main areas of research: plant 
metabolomics and human metabolomics, and these have gained a lot of popularity in 
this field. Many analytical technologies are employed including: GC/MS [59], LC/MS 
[80], CE/MS [81], and NMR [82]. These methodologies have been reviewed 
extensively and Dunn and co-workers discuss their relative strengths and weaknesses 
in much detail [18].  
This thesis is concerned with GC platforms, including multidimensional techniques, 
with mass spectrometric detection for metabolic profiling of microorganism and 
biological-based samples i.e. GC/MS, GCT-oa-ToFMS, MDGC/MS and 
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GCxGC/TOFMS. Although other instrumental platforms have been used and found to 
be useful for metabolomics i.e. Fourier transform infrared spectroscopy, thin layer 
chromatography, high pressure liquid chromatography and Raman spectroscopy [83], 
the advantages of GC/MS over other techniques for metabolic analyses include: high 
sensitivity for a small sample amount, higher resolution of compounds in the gas than 
in liquid phase, detailed compound databases and experimental designs, generally 
lower cost of instrumentation and often user-friendly methods.  
 
The main limitation of metabolomic application can be associated with the limited 
knowledge of many secondary metabolite pathways [75]. This is mainly due to the 
lack of available standards for many secondary metabolites of biological sample 
types. Quantification of metabolites was the first means to comprehensively study the 
constituents of biological-based samples through the measurement of metabolite pool 
size for example the metabolic phenotype [1]. Therefore for accurate quantitative 
analyses pure metabolites are essential due to the fact that the accurate identification 
and determination of linearity, detection limit and inherent method variability are only 
possible when pure metabolites are available to the analyst. Recovery analyses are 
also required as it evaluates the effects of sample composition on quantitative 
detection which is often referred to as the matrix effect [84]. Stable isotopes are also 
often recommended for quantification, through either isotope-dilution [85] or in vivo 
labelling [86]. From a validation point of view it is quite difficult to obtain analyte-
free samples of the authentic biological matrix, and therefore the preparation of 
reference samples has to be approached with more caution.  
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1.4. Sample preparation and methods for metabolic profiling. 
 
Sample preparation is in most cases meant to be the isolation and/or (on-line or off-
line) pre-concentration of some components of interest or target analytes from various 
matrices, making the analytes more suitable for separation and detection. Sample 
preparation impacts nearly all the later assayed steps and is hence critical for 
identification, confirmation and quantification of analytes. A clean sample assists to 
improve separation and detection, while a poorly treated sample may invalidate the 
whole assay. Use of ideally cleaned samples also reduces the time to maintain 
instruments and in turn the cost of assay. It is because of the importance of sample 
preparation that some excellent reviews on this topic have appeared in books [87, 88] 
and special journal issues [89]. In 2002, Pawliszyn [88] summarized the fundamental 
aspects of sample extraction (equilibrium and kinetics related to mass transfer), which 
were necessary for the development of methods, with special considerations of on-site 
and in situ extractions. Smith [89] provided many examples on extraction and 
concentration of analytes from solid, liquid and gas matrices.  
 
Selective extraction methods with molecularly imprinted polymers (MIPs) and 
affinity columns have also been considered. In 2004 and 2006, Raynie [90, 91] 
reviewed the experimental and fundamental developments on sample extraction, and 
related methodology appeared during the calendar years of 2002–2005, with an 
exclusion of general application articles but an inclusion of some individual steps. 
Sample preparation is a major part of analysis, capable of taking up to 80% of the 
total time of a complete separation-based analytical process, which typically includes 
five steps, that is sampling, sample preparation, separation, detection and data 
analysis. Sample preparation has developed increasingly during recent years and 
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numerous method have been discussed i.e. liquid-phase extraction (LPE), liquid-
liquid extraction (LLE), liquid–phase micro-extraction (LPME), solid-phase 
extraction (SPE) and solid-phase micro-extraction (SPME). Effective metabolite 
extraction from a given sample is essential to the success of any metabolomic 
experiment. When considering untargeted metabolomics, the extraction method must 
liberate a broad range of metabolites from the sample. In contrast when performing a 
target metabolomics experiment, the extraction protocol should focus on the efficient 
extraction of the metabolite class of interest. Recently, Chen et al. present a review on 
the current sample preparation techniques [92]. Liquid-liquid extraction is further 
discussed in this chapter as the other extraction techniques are outside the scope of 
this research.  Liquid-liquid extraction converts specific analytes of interest from a 
liquid-liquid matrix into another immiscible liquid-phase, taking into account 
solubility differences.  Typical LLE approaches are carried out in separating funnels 
in order to extract analytes from the aqueous biological/environmental solution into a 
less polar organic solvent, Figure 1-3. Other extraction methods include membrane-
separated liquid extraction (MSLE) [93], counter-current chromatography (CCC) 
[94], single drop micro-extraction (SDME) [95], and laminar flow techniques etc.  
 
 
Figure 1-3: Liquid-liquid extraction principle 
Chapter 1: Introduction to Metabolomics 
Chapter 1: Introduction to Metabolomics 
 Chapter 1 – Introduction to Metabolomics 
 ~39~ 
1.5. Chemical derivatization for GC-MS analysis 
 
 
The low molecular mass compounds of interest to metabolomics include amino acids, 
fatty acids, organic acids, carbohydrates, alcohols and many more. However most of 
these compounds are polar and have poor GC characteristics, therefore they cannot be 
analysed by GC/MS without chemical derivatization. This process allows the 
reduction of polarity and increases volatility.  
However just like with any other method concerns with derivatization include: 
 Metabolites can form more than  one derivative 
 Unless the derivatization reaction has gone to completion for all metabolites in 
a sample, the metabolite profile depends both on the composition of the 
original sample and the derivatization time. 
Gas chromatography offers substantial advantages over many other methods for the 
comprehensive analysis of amino acids, due to its speed, accuracy, precision and 
sensitivity. The quantitative preparation for the analysis of amino acids by GC is not 
an easy task, due to the variation in their structure and their differing chemical 
properties. One of the earliest reviews of amino acid analysis by GC covers up to 415 
different publications ranging from 1956 through to 1974 [96]. This review provides 
over 100 distinct chemical methods for the preparation of derivatives for GC 
belonging to two types: the first requires two derivatization steps (esterification of the 
carboxyl group and acylation of the amino and other functional groups). The second 
derivatization method is a one-step derivatization approach, which is advantageous 
due to its simplicity, although these derivatives also have their limitations due to their 
instability and the silylation can give rise to partial derivatization (if the correct 
derivatization parameters are not optimisedd). 
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1.5.1. Silylation of metabolites 
 
Ruhlmann and co-workers implemented the use of trimethylchlorosilane (TMCS), 
hexamethyldisilazane (HMDS), trimethylsilyldiethylamine (TMSDEA) as 
derivatization reagents [97]. Silylation of metabolites could be referred to as a two-
step process, in which the carboxyl groups are generally known to silylate faster than 
amino groups, thus producing two products. HMDS or TMCS are efficient for the 
silylation of carboxyl groups, and are also catalysts for the chemical derivatization 
reaction. Other functional groups require stronger reaction conditions, with amino and 
guanidine groups typically being the most difficult to silylate, requiring higher 
derivatization temperatures and longer derivatization times.N,O-bis(trimethylsilyl) 
acetamide (BSA) and N,O-bis(trimethylsilyl) trifluroroacetamide (BSTFA) were 
introduced soon afterwards, as they are stronger silylating agents which assist in 
achieving a complete derivatization reaction. Klebe et al. prepared derivatives of 22 
metabolites using BSA with acetonitrile as a solvent [98]. From the chromatogram 
obtained it was noted that arginine decomposed on the column and overlapping peaks 
were observed with the alanine and glycine peaks respectively.  
  
 
            
 
Figure 1-4: Examples of methoximation of a carbonyl functional group 
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Figure 1-5: TMS groups formed for selected different functional groups through the 
addition of BSTFA + 1% TMCS. 
 
A comparison of TMSDMA, TMSDEA, BSA, BSTFA, MSA and TMSI as silylating 
agents for  preparation of derivatives of phenylalanine, tyrosine and lysine was 
studied by Smith and Shewbart [99].  Their experiment involved varying parameters 
and observing the optimum conditions achieved, concluding that TMS-amines are 
more efficient than TMS-amides as silylating agents. The resulting solution of the 
derivatives was more stable; therefore an increase in the volatilities of the compounds 
was observed. Gehrke and co-workers [100] carried out a detailed study on the 
silylation of amino acids using BSTFA as the derivatizing agent. Several 
methodologies were studied including different reaction conditions, polar and non 
polar solvents; the best results were obtained with the silylation of 17 amino acids 
with a mixture of BSTFA-acetonitrile (1:1) at 150 °C for 15 mins. The TMS 
derivatives were able to be stored in sealed vials for 7 days remaining stable and no 
obvious decomposition observed.  
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Table 1-3: Most common derivatization reagents/groups. 
 
Amino group Carboxyl group Comments 
TFA Butyl Most widely used 
TFA Methyl Most volatile 
HFB                                           Propyl Capillary columns 
Acetyl                                            Propyl Stable 
Butyloxycarbonyl                                              Methyl Acylation and isolation  
TMS TMS Widely used, single step 
derivatisation 
Dimethylamino-methylene Methyl For Nitrogen detector 
 
 
Recently, Kouremenos et al. developed a microwave-assisted derivatization method 
using a set of standards spanning a wide range of metabolites in order to demonstrate 
the potential of microwave-assisted derivatization for metabolic profiling [101]. A 
final power setting of 150 W for 90 s was selected as the optimum microwave 
derivatization condition, based upon the study of each chemical class (amino acids, 
fatty acids, sugar and sugar alcohol). Concentrations tested ranged from 1 g/mL to 
1000 g/mL, and the calibration curves for the standard mixtures were satisfactory 
with regression coefficients generally better than 0.998. 
1.6. Multidimensionality of Gas chromatography – mass 
spectrometry (GC/MS)  
 
The methodology of gas chromatography (GC) has advanced by achieving greater 
separation of individual compounds using (two dimensional separations (e.g. GC/MS) 
and three dimensional separations which have been reviewed by Mitrevski et al [102] 
and will be discussed in greater detail later in this chapter. Mitrevski discusses in 
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detail the role of the separation step in GC, then the detection step, and finally 
multidimensionality of the total method [102]. The instrument includes the samples 
injector, gas supplies, the column (which is situated in an oven), the detector, flow 
controllers and display units. Gas chromatography offers better separation and 
sensitivity including overall shorter analysis times, but still has some disadvantages; 
mainly in the need for chemical derivatization prior to GC analysis.  
Chemical derivatization is an important step in GC for the analysis of many classes of 
compounds; otherwise analysis would not be possible. There is a need to convert 
compounds into volatile derivatives, as there are a variety of polar groups in these 
types of compounds. Many different derivatization methods exist to date, which are 
discussed in greater detail below. Table 1.3 depicts the most common derivatives. 
 
 
1.6.1. Multidimensional Separation in metabolomics 
 
Today, there is much interest in newly available multidimensional methods in gas 
chromatographic analysis. The history of multidimensional GC (MDGC) is extensive 
[103], and has long played a key role in providing improved separation for regions of 
a primary chromatographic separation that are poorly resolved. The breakthrough of 
expanding the peak capacity of one dimensional GC through application of principles 
of MDGC occurred in 1991, when Liu and Phillips introduced the GC × GC method 
[104]. This tactic involved the use of a short, fast-eluting 2D column directly coupled 
to the 1D column, whilst ensuring that 2tR (retention on the 2D column) was faster 
than the peak width of the peaks eluting from the 1D column. Therefore, the strategy 
of GC × GC depends on the continuous transfer of small fractions of effluent from 1D 
to 2D in a predefined time, known as the modulation period (PM). The PM value 
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usually ranges from 2 to 8 s; it is important to ensure that the maximum 2tR is less 
than PM, in order for all the components introduced to the 2D column are eluted 
before the next portion of effluent enters the 2D column.  The literature in GC × GC is 
growing including theory and application - as researchers test and apply the technique 
to address a broad range of separation problems, including sample from 
environmental, petrochemicals, foods and beverages, essential oils, and industrial 
areas [105, 106]. The collective term ‘multidimensionality’, refers to a range of ‘two-
dimensional’, ‘three-dimensional’ and even ‘four-dimensional’ techniques, and has 
attracted the attention of many researchers as they explore the ‘informing power’ 
[107] of such systems. The purpose of these techniques extends from a reduction of 
the total analysis time per identified peak (identification productivity), improvement 
of the quality of characterisation of compounds, and simply maximising the number 
of components identified. As the power of multidimensional methods improves, 
increased information in both amount and quality address the needs of the analyst to 
better characterise samples. The relevance of multidimensional techniques to 
metabolite analysis, including reasons for the interest expressed by the scientific 
community is further discussed. 
One of the most common strategies is to arrange a non-polar (NP) 1D column phase 
with a polar (P) 2D phase. This logical separation process proposes that the 
compounds eluting from the 1D column will be similar in volatility, whilst the 2D 
column allows separation by polarity, providing their polarity is sufficiently different. 
There is at present no definitive report on the magnitude of difference in polarity that 
can achieve separation in the experiment. In many cases, solute classes of similar 
‘polarity’ will cluster in a narrow region along the 2D axis. 
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In the past years some work has been completed on amino acid analysis by using 
GC×GC, commencing with that by Mayadunne [108] and co-workers, who performed 
a study on amino acid analysis of standards and selected samples. Their work 
involved the separation of amino acid derivatives which were prepared using the 
‘Phenomenex amino acid kit’, based on the use of alkylchloroformate derivatisation. 
A selection of beverage samples (different types of beer) and diluted honey were 
analysed. The use of a low-polarity/polar column (5% phenyl polysilphenylene-
siloxane (BPX5) - 50% phenyl polysilphenylene-siloxane (BPX50)) set was initially 
implemented, however the separation achieved was not as efficient in the best use of 
the 2D space, with somewhat correlated retentions. However with a polar/low-polarity 
(solgel wax – 100% methyl polysiloxane (BP1)) column set a much better separation 
was achieved, with greater spread over the 2D separation space.  
 
Mayadunne et al. reported the polar/low-polarity column to show less correlation 
between the derivatised amino acids, and had narrower peak widths [109]. The 
reported method was relatively straightforward, and can be used in a fingerprint mode 
to allow quick and efficient identification of amino acids in a variety of samples. Thus 
the same amino acid derivative is expected to have the same retention position in 2D 
space, and so provided the retention position is the same, there is a high likelihood 
that the amino acids will also be the same. In this manner, GC × GC has greater 
identification power than a 1D GC method, which does not achieve the high 
separation power of that of GC × GC. Junge et al. [110] reported the separation of 
amino acid ethyl chloroformate derivatives using GC × GC.  An enantioselective 
capillary column was used in the first dimension and a variety of non-enantioselective 
columns with different polarities and lengths in the second dimension. The most 
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suitable column for the analysis of amino acids in different beer samples was the non-
polar BP1 (100% dimethyl polysiloxane) phase as the 2D column. According to the 
reported method, proline was the major amino acid present in the beer samples and a 
number of less-abundant AA were noted. Overall the samples contained 
predominantly the L-enantiomers of the amino acids. 
 
The above studies focused on amino acids as the primary goal. However, many 
studies address a broader range of components in a multi residue analytical procedure 
such as those associated with metabolite profiling of biological samples. Hope and co-
workers reported a study of metabolites in rye grass samples using comprehensive 
two-dimensional gas chromatography with time-of-flight mass spectrometry (GC × 
GC/TOFMS) detection [111]. This study included the metabolic profiling of amino 
acid as well as organic acid trimethylsilyl derivatives, including preparation of 
standard mixtures used for quantification. The application of GC × GC/TOFMS 
provided a rapid and comprehensive metabolite analysis, in reference to target 
analysis and in evaluating pre- and post-harvest physiology.  
Most 1D chromatographic data require some statistical alignment algorithms to ensure 
that the chromatographic data can be directly – automatically – compared. Thus, it is 
logical that GC × GC data will also be subject to alignment protocols. Zhang and co-
workers recently developed a two-dimensional correlation warping algorithm for the 
alignment of GC × GC/MS data [112]. This algorithm has a wide application base, as 
it can also be applied to other comprehensive 2D separation data i.e. LC×LC, 
LC×GC, LC×CE and CE×CE. This was achieved by partitioning raw 
chromatographic profiles and warping the grid points along the first and second 
dimensions. Chemical standards covering a wide range of chemical classes (amino, 
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fatty and organic acids) were prepared using N-methyl-N-tert-butyldimethylsilyl) 
trifluoroacetamide (MTBSTFA) derivatisation reagent yielding stable tert-butyl-
dimethylsilyl (TBDMS) derivatives. Serum samples were then extracted using a 
typical 2:5:2 ratio of water/methanol/chloroform, and derivatised similarly to the 
chemical standards, then analysed with respect to the alignment of homogeneous and 
heterogeneous chromatograms. In another study, Weltagen et al. used 
GC×GC/TOFMS for high resolution metabolomics analysis, by comparing spleen 
tissue extracts of obese NZO lean C57BL/6 mice [113]. GC × GC/TOFMS lead to the 
detection of 1,200 metabolites compared to the 500 metabolites detected using 1D 
GC-TOFMS. Another important aspect of this study was the enhanced spectral purity 
obtained through the use of GC×GC/TOFMS afforded by effective component 
separation in 2D space, which improves mass spectral deconvolution and similarity 
matches. Finally, it was shown that data extraction and normalization tools can be 
applied for tentative biomarker detection, which is of great interest in the 
metabolomics community. 
 
As previously mentioned, Kouremenos and co-workers [101] investigated the use of a 
fast microwave derivatisation method using a combined reagent comprising a 
methoximation first (methoxyamine hydrochloride) approach followed by silylation 
(BSTFA+1%TMCS), as a one-pot synthesis of derivatives relevant to metabolomics. 
Methoximation and derivatization was performed as a one-step protocol using 
microwave derivatization, as differences were not noted by completing two separate 
steps. Separate methoximation and derivatisation using conventional heating is a 
lengthy process that can be reduced to a few min by the use of a microwave process. 
GC×GC was used for the analytical measurement of the derivatised products. The 
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classes of compounds tested included a range of compound classes (amino acids, 
organic acids, fatty acids, sugars and sugar alcohols). 
Today, when discussing the term ‘multidimensionality’, which in turn contains terms 
such as ‘two-dimensional’, ‘three-dimensional’ and even ‘four-dimensional’ 
techniques, has drawn the attention of many researchers. The main purpose of all 
these techniques is: the reduction of total analysis time and maximising the number of 
components identified. The improvement in multidimensional methods is of great 
interest, as it provides more information, and of course more valuable information, 
which addresses the increasing needs of the analyst. 
 
1.7. Data Analysis in one-dimensional and two-dimensional gas 
chromatography 
 
The technologies mentioned above are continuing to contribute solidly to the 
comprehensive analysis of the metabolome, and with the support of advances in 
software design which can manipulate (often downsize) the enormous amount of data 
involved. This area is referred to as ‘bioinformatics’ and comprises particular methods 
obtained from a broad range of areas (statistics, mathematical modelling and three 
dimensional structural solution algorithms), with its main focus based on the 
computational analysis of pre-existing experimental data rather than on new 
experimental work. There are several online databases containing information for 
biologically-based small molecules (Table 1-4). 
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Table 1-4: Online database containing information for biologically-based small 
molecules (reproduced from 
[101]
). 
One common issue with gas chromatographic data is the shift in the retention time 
(tR). Although this is generally minimal it can still greatly influence data 
interpretation, particularly in computerised unsupervised analysis, with large sample 
throughput and where poor peak resolution arises. Chromatographic condition 
variation, column changes, or presence of major components are typical causes of 
these effects. Today there are many programs available which are optimisedd for 
GC/MS peak picking, baseline correction, noise reduction and peak alignment, 
including: MZmine [54], XCMS [54], MetAlign [114], MET-IDEA [115], MetaQuant 
, MathDAMP and more recently MetaboliteDetector [116].  
 
Database Number of 
metabolites 
URL 
KEGG Ligand 13480 http://www.genome.ad.jp/keg/ligand.html 
BioCyc 3558 http://biocyc.org/ 
ChEBI 6559 http://www.ebi.ac.uk/chebi/ 
PubChem 37 million http://pubchem.ncbi.nlm.nih.gov/ 
ChemBank 1.1 million http://chembank.broadinstitute.org/ 
Human Metabolome 
Database 
6500 http://www.hmdb.ca/ 
Zinc 13 million http://www.docking.org/ 
ChemDB 4.1 million http://cdb.ics.uci.edu/CHEM/Web/ 
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For instance MetaQuant is often used for target metabolomic analysis and searching 
GC/MS chromatograms for compounds of interest therefore allowing absolute 
compound quantification to be determined. MET-IDEA can also be used for target 
metabolic analysis and further quantification, however prior to the use of the program, 
an input list of retention time pairs needs to be generated either by Automated Mass 
spectral Deconvolution (AMDIS) software  and identification system or manually. 
MathDAMP uses the language Mathematica and highlights obvious differences 
between metabolic profiles, with the added advantage of the elimination of peak 
detection steps, due to the fact that all the chromatograms data are used for 
comparison. MetAlign uses peak detection algorithms and multivariate clustering 
tools to filter out differences in a statistical manner. Metabolite Detector is often used 
for automated analysis, as it performs a comparison of multiple chromatograms in the 
choice of both target and non-targeted modes. However all of the above programs 
require input parameters and data processing tasks require optimization to avoid false 
positives and negatives [54]. A review of data processing for mass spectrometry-
based metabolomics by Katajama et al. gives general key steps involved in 
metabolomic data processing [117]. 
Recently, Lu et al. conducted a study comparison of three different software packages 
for deconvolution of metabolomics data based on GC/TOFMS [118]  The quantitative 
capabilities of the basic GC/TOFMS method were studied by processing data using 
three common packages (LECO ChromaTOF, AMDIS and SpectralWorks 
AnalyzerPro)[138]. The overall results showed important differences between these 
packages.  It was found that AMDIS and ChromaTOF produced a large number of 
false positives, AnalyzerPro produced a larger number of false negatives. Component 
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widths was found to be the single most significant parameter in defining the 
appropriate quantitative measurement of compounds [118]. 
Often in metabolomics biologically-based samples tend to be very complex, 
containing hundreds of completely or partly overlapping peaks. Deconvolution or 
curve resolution is used to obtain clean chromatographic and spectral profiles, in 
particular to distinguish between overlapping peaks. There are several classes of 
deconvolution (iterative, non-iterative, and hybrid) approaches. The non-iterative 
approaches, such as orthogonal projections (OP) and heuristic evolving latent 
projections (HELP) involve rank analysis of evolving matrices. However these 
approaches can be difficult to automate, due to the need to define compound elution 
windows through local rank analysis. The iterative methods, such as iterative target 
transformation factor analysis (ITTFA) and alternating regression (AR), all define 
start profiles but differ in the methods involved for selecting initial estimates. For the 
iterative methods, it is necessary to first estimate the chemical ranks of profiles 
properly in the order to generate the right solution.  
Another well researched approach to alignment but not a deconvolution technique is 
correlation optimisedd warping (COW). This method aims to remove shift-related 
artifacts by the use of linear stretching and compression of the time axis of the 
chromatogram. Two variables, flexibility and section length, can be estimated from 
the peak width, without the need for the detection of separate peaks. COW is an 
important approach and useful for many types of chromatographic data [119]. 
Generally the statistical tools for metabolomics data analysis should be selected 
according to the aim of the study. If the aim is sample classification and prior 
information about the sample identity is unknown, unsupervised methods such as 
hierarchical clustering analysis (HCA), principal component analysis (PCA), or 
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independent component analysis (ICA) are used. On the other hand, sample identity is 
often known and the aim of the study is to discover characteristic biomarkers (e.g., 
search for biomarkers of a disease comparing samples from healthy and diseased 
subjects). In this case, supervised methods such as partial least square (PLS) or soft-
independent method of class analogy (SIMCA) can be used as well. The supervised 
methods use prior information about sample class and perform better in biomarker 
discovery [120]. The supervised methods are also the preferred option for diagnostics 
studies (especially SIMCA), when classes of some samples are known and identities 
of others need to be determined (e.g., cancer diagnosis by comparing a patient's 
metabolic fingerprint with the fingerprints of healthy and diseased subjects).  
 
The most popular data analysis tool in metabolomics is PCA which is available in 
many statistical software packages. Principal component analysis (PCA) is also a 
well-researched data analysis technique which has widespread use and has been 
referenced as early as 1901 by Pearson [121]. The focus is to firstly determine general 
relationship between complicated data sets, based on the amount of variance in these 
data sets.  Compounds showing greater variance plotted on principal component 1 
(PC1) with compounds showing less variance plotted on PC2. PCA provides the 
scores plot which shows the degree of similarity between chromatographic profiles 
and the loadings plot.  The loading plot corresponds to the quantitative differences 
found between each class for each distinct chromatographic feature. The number of 
significant PCs can be predicted by using a number of methods, including calculating 
the size of eigenvalues or cross-validation.  
Zhang et al. developed a two-dimensional correlation optimised warping for 
alignment of GCxGC/TOFMS data [112], by partitioning the raw chromatographic 
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profiles and simultaneously warping the grid points along the first and second 
columns, non-grid points were interpolatively warped. The high data density of 
GCxGC makes chemometric translation advantageous, and is generally expected that 
the higher the dimensionality and greater separation of GCxGC with prove to be more 
informative in chemometric sense. 
 
1.8. Aim 
 
In recent years, a plethora of studies aimed at supporting mass-spectrometry based 
metabolite profiling and metabolic applications have emerged. Given the chemical 
complexity and dynamic range of metabolites present in micro-organisms and 
biologically-based samples, profiling the levels of a broad range of metabolites is 
highly challenging. Thus, discovery of metabolites is considered an essential step 
toward a better understanding of micro-organism and biological-based samples.  
In regards to human metabolomics, the most common diseases are caused by complex 
interactions between genetic factors such as diet and the environment. These factors 
can influence the range and concentrations of metabolites and other low molecular 
compounds in tissue and body fluids. An analytical method is described suitable for 
the analysis of infant blood plasma, consisting of an oximation and silylation 
derivatization reaction and subsequent analysis by gas chromatography coupled to 
mass spectrometry and GCxGC/ToFMS. Various metabolites are separated and 
quantified for possible biomarkers that can be used as useful diagnostic markers for 
specific disorders in infants.  
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Microorganisms in the form of yeasts are a sample type further explored in this thesis. 
The microorganism itself has played a significant role in human culture over 
thousands of years, due to its application in both traditional and modern 
biotechnology for the production of food and beverages. Separation and analysis of 
various yeast samples is undertaken by gas chromatography coupled with high 
resolution mass spectrometry (GC-HRMS).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
2.1. Abstract 
 
Yeast and yeast cultures are frequently used as additives in diets of dairy cows. 
Beneficial effects from the inclusion of yeast culture in diets for dairy mammals have 
been reported. The aim of this study was to develop an analytical method for the 
accurate mass identification of the ‘global’ metabolites in order to differentiate 
reliably different yeasts at different growth stages (Diamond V XP, Yea-Sacc and 
Levucell). The potential of microwave-assisted derivatization for metabolic profiling 
is demonstrated through the analysis of a variety of yeast samples developed for cattle  
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feed and which include a wide range of metabolites of interest in metabolic profiling. 
Identification and subsequent quantification of the components was undertaken using 
an accurate mass, GCT-ToFMS followed by principal component analysis. This 
represents the first study where different yeast cultures for cattle feed are directly 
analysed and compared using an accurate mass methodology for possible metabolite 
biomarker discovery. Metabolites identified using accurate mass gas chromatography 
has allowed for the tentative identification of 55 metabolites of which 20 (most 
abundant) have been quantified. These metabolites of interest include a wide range of 
amino acids, organic acids, sugars and sugar alcohols. Biomarker discovery is the 
major aim for this study, as currently there are no well-known biomarkers for yeast 
quality by GC which support the greater feed efficiency observed through the 
improved dry matter intake (DMI) and milk production in dairy cows. 
 
2.2. Introduction 
 
The microorganism yeast has played a significant role in human culture over 
thousands of years, due to its application in both traditional and modern 
biotechnology for the production of foods and beverages, and more recently enzymes, 
fine chemicals and pharmaceutical reagents [122]. There are many yeast-based 
products available, each having major chemical and functional differences which 
produce unique products with their own unique properties. Yeasts are microscopic 
fungi which grow in a wide range of habitats and differ from each other according to 
their origin, their cellular morphology or structure, their metabolization of different 
substrates and their reproduction [123]. Yeast can be found in cereal grain, grain by-
products, silage, hays, and can even be present in soil and water. Yeasts are able to 
tolerate large variations in temperature and the acidity in environment and undergo 
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“aerobic respiration”. They grow dynamically in warm and wet places that are rich in 
oxygen and low in carbon dioxide [123]. Yeast can also grow under two quite 
different conditions: aerobic fermentation and anaerobic fermentation (Figure 2-1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Metabolism of yeast under aerobic and anaerobic conditions, reproduced 
from [124]. 
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Of the wide range known, very few species of yeast are used commercially. 
Saccharomyces cerevisiae is one of the most extensively researched yeast species 
(bacterial microorganism), and has several industrial applications associated with the 
production of beer, wine, alcohol, baker’s yeast, and heterologous proteins [125]. 
Canadida utilis (classified as torulopsis utilis) is also an important yeast species, as it 
can utilize pentose sugars and is employed in the digestion of wood pulp used for 
making paper. A third useful yeast species is kluyveromyces marxianus which is 
sometimes referred to as dairy yeast due to its capacity to assimilate lactose 
[122].Yeast has also been fed to animals for more than hundred years, either in the 
form of yeast fermented mash produced on the farm (yeast by-products from 
breweries or distilleries), or as commercial yeast products specifically produced for 
animal feeding. 
Today, the practice of adding antibiotics to livestock diets to enhance production 
efficiency has declined and as a result there has been an increase in research aimed at 
developing alternatives with particular emphasis on the potential use of natural feed 
additives, one of which is yeast [126]. Yeast products are fed to high producing dairy 
cows on more than half of the dairy farms in the USA [127]. Yeast cultures consist of 
a complex mixture of the products of yeast fermentation, residual yeast cells 
(Saccharomyces cerevisiae) and culture media. Active dry yeasts (ADY) are also 
used; these products consist of purified dried cells, which have a viability of 15-25 × 
109 colony forming units (CFU) per gram. Three physical forms of ADY are 
commercially available: tunnel-dried yeast, fluid-bed—dried yeast and rotoluver-
dried. These products are not fermented yeast cultures and often consist of ADY 
diluted with a carrier (Figure 2-2).  
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Figure 2-2: Live yeast blends in distiller’s grains, ground corn and distillers’ 
solubles,[126]. 
 
Although yeast cultures contain some residual yeast viability, they are not considered 
a significant source of viable yeast cells or yeast biomass. They are produced in order 
to obtain the metabolites generated by the yeast cells. These metabolites can be 
classified into distinct biochemical classes of compound: including flavour 
compounds, nutritional compounds and aroma compounds. As well as providing 
nutrients when fed to animals as feed; the metabolites present within certain yeasts 
have a positive effect on stimulating bacterial growth in the digestive tract and 
optimizing feed intake in animals, [126-130], although these production responses are 
cited, the specific mode of action still remains elusive thus making the metabolite 
analysis of yeast important in order to have a better understanding as to what 
metabolites could be responsible for having a positive effect on rumen bacteria. 
 
There are several proposed modes of action associated with yeast culture as 
summarized by Wallace 
[131]
. In his scheme, removal of oxygen from the rumen 
environment by Saccharomyces cerevisiae plays a prominent role in increasing 
bacterial viability. Hession et al. suggest yeast has a limited ability to grow in the 
Yeast + distillers’ grain Yeast + round corn Yeast + distillers' 
Chapter 2 – Metabolic profiling of yeast using GCT-oa-ToFMS: application to biomarker 
discovery 
 
 ~60~ 
ruminal environment; therefore, the fact that yeast may grow in the rumen and 
directly stimulate a response is unlikely [132]. However, popular theories suggest 
yeast culture provides various growth factors, pro-vitamins, and/or micronutrients that 
help stimulate the growth of the ruminal bacteria in the rumen [133-135]. Another 
popular theory is associated with yeast having a positive influence on ammonia 
uptake [135, 136]. This could improve microbial protein production and efficiency or 
both, thus providing an increased supply of amino acids postruminally to the cow to 
serve in stimulating a production response [137]. There are several yeast products on 
the market with nuances in their manufacturing process that may have an influence on 
performance; however, very few studies have been conducted to compare yeast 
culture in the same experimental environment [138]. For example, Diamond V XP, 
Yea-Sacc and Levucell yeast cultures have been the subject of extensive research. 
These studies found that Diamond V XP in particular improved dry matter intake, 
milk production [128, 139, 140] and feed conversion efficiency [141], which has a 
positive effect on herd (social grouping of certain animals of the same species) 
profitability even though changes in production or feed intake may be very slight.  
 
Diamond V XP is a fermented yeast culture specifically developed for use in animal 
nutrition. It is the dried product composed of yeast and the media on which it was 
grown, dried in such manner as to preserve the fermenting activity of the yeast. It is 
obtained from the yeast Saccharomyces cerevisiae and it consists of the yeast itself, 
the nutrient medium on which the yeasts is grown, and the metabolites produced by 
the yeast. Examples of such metabolites are vitamins, iso acids, enzymes, minerals 
and amino acids (Table 2-1). The metabolites stimulate the growth of certain types of 
rumen bacteria. The yeast culture works more effectively than live yeasts. Live yeast 
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does not withstand conditions in the rumen, and the shelf life of live yeast in mineral 
mixtures and pelleted mixed feed is also a problem. Diamond V XP is suitable for 
direct use on a livestock farm (http://www.speerstra.com/). 
Table 2-1: Ingredients composition of Diamond V XP 
[142]
. 
 
Ingredient %Amount 
Crude Protein, not less than 12 
 
Crude Fat, not less than 3 
 
Crude Fibre, not less than 6.5 
 
Levucell SC is classified as natural rumen specific live yeast. It is also a strain of 
Saccharomyces cerevisiae and is selected for its high capacity to improve rumen 
function.  The choice of this strain is mainly due to its advertised specific properties: 
• Stabilization of rumen pH and reduction in acidosis risk 
• Stimulation of the microbial biomass of the rumen 
• Stimulation of the enzymatic and cellulolytic activities in rumen 
• Improvement of the anaerobic rumen environment 
Yea-Sacs is another live yeast culture based on Saccharomyces cerevisiae strain and 
has been reported to increase the amount of energy released from the animals total 
diet, and to improve the amount of fibre digested by the animal. These two areas are 
crucial in maintaining and satisfying an animal’s nutritional requirements. 
Nutritionist, veterinarians and other dairy professionals are looking for means to 
increase feed efficiency. Several reports in recent years have described increases in 
feed efficiency resulting from the use of live yeast cultures for animal nutrients 
purposes [128, 139, 140]. Kamande and co-workers conducted a study on the efficacy 
of dietary supplementation with yeast culture for grazing cows and for calves [126]. 
The study involved a review on the effects of Diamond V XP yeast on dairy cows and 
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calves. The trials were carried out in Victoria, Australia and it was found that XP 
supplementation increased milk production of Fresian cows by 2.2 L/d., while milk fat 
and protein content did not differ. In vivo and in vitro studies indicate that yeast 
products differ in terms of their efficacy. Alshaikh et al. compared the effects of 
Diamond V XP and Yea-Sacc, a live yeast product, on the performance of mid-
lactation dairy cows [143].  The trial found both yeast products to increase production 
efficiency but Diamond V XP had the greatest effect. Furthermore Bernard et al 
conducted a field trial in Florida in which 5, 472 Holstein cows were fed XP or Yea-
Sacc. Diamond V XP increased milk production to a greater extent than Yea-Sacc did. 
These results concur with those of Alshaikh et al. 
 
In addition, another study conducted in Canada has shown that adding probiotics 
(aspergillus oryzae) alone or with S. cerevisiae, to the feed of dairy cows results in an 
increase of up to 1.4 kg or 4% of daily milk production. The yeast has been shown to 
have a positive impact on rumen microbes [144]. However the study did not conclude 
the reason behind the increase in milk production. It would be useful to analyse the 
chemical composition of yeast culture to possibly identify classes of metabolites that 
could be responsible for the increase in milk production or to have a better 
understanding of the observed effects caused. It has also been reported that yeast in 
cattle feed helps to alleviate the effects of raised temperatures and humidity levels that 
can cause animals (specifically cows) to become uncomfortable as their internal 
temperature becomes elevated.  The addition of yeast culture helps cows with dry  
matter intake [145]. If cows are in good body condition, the lactation process will be 
more efficient. These findings have led to considerable interest in yeast product 
classification and differentiation. It is therefore important to be able to classify and 
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discriminate the various yeast products to appreciate how they can best and most 
appropriately be of benefit to the community. Analysis or profiling of metabolites in 
yeast is important as some metabolites present in the yeasts can have a positive impact 
on stimulating bacterial growth in the digestive tract and optimise feed intake to 
animals. Only in recent years has yeast culture been subjected to metabolite profiling 
as an aid to clarify the potential effects and gain further understanding of quality 
assurance. Due to their complex metabolism, yeast organisms are known to produce a 
broad range of metabolites of different classes (i.e. fatty acids, sugar, amino acids etc) 
at very different concentrations [146].  
 
The composition of the metabolome can vary greatly, depending on the organism 
analyzed; Saccharomyces cerevisiae, is the most prominent yeast used and has an 
estimated 600 metabolites. In order to obtain precise qualitative and quantitative 
results to broaden the understanding of yeast these metabolites have to be profiled 
accurately, with absolute identifications a necessity. For many years yeast has been at 
the forefront of research in modern genetics, molecular biology and cell biology, yet 
relatively little attention has been paid to its chemical composition and to sample 
preparation procedures. The analysis of metabolite profiles in a yeast culture can be 
performed using a wide range of analytical techniques. Most yeast metabolite 
analyses are undertaken using gas chromatographic methods due to the sensitivity and 
low detection limits, the selectivity (separation factor) and small sample amounts 
required. GC/MS can be used to analyse a wide range of derivatised non-volatile and 
volatile metabolites. An alternative to GC/MS is direct infusion (DI)-MS which can 
be used to identify the many metabolites rapidly in samples in order to obtain a 
general metabolic profile of the yeast. Developments in atmospheric pressure 
Chapter 2 – Metabolic profiling of yeast using GCT-oa-ToFMS: application to biomarker 
discovery 
 
 ~64~ 
ionization have led to reliable clean mass spectra being obtained without the need for 
a chromatographic separation [164]. This can be achieved in a short time period by 
directly infusing a biological sample into the MS, without the need for derivatization 
which adds to the sample preparation time. A comparison of DI-MS and GC/MS for 
the metabolic footprinting of yeast mutants was carried out by Mas and co-workers 
where five different yeast deletion mutants and wild-type strains were grown in 
triplicate in shake flasks on a glucose medium [147].  
 
Gene deletions were studied at the metabolite level by analysing DI-MS spectra and 
GC/MS chromatograms and spectra, where different metabolites were identified in the 
different yeast strains. The study concluded that both methods can be used to classify 
mutants, but the classification achieved depends on the specific metabolites measured. 
Since GC/MS primarily measures amino acids, organic acids, fatty acids and 
carbohydrates, it was found to be appropriate for the classification of mutants with 
altered nitrogen regulation, whereas GC/MS could not classify mutants involved in 
regulation of phospholipids metabolism as well as DI-MS (due to the larger MW of 
the phospholipids)[147]. Multi-dimensional techniques have also gained popularity 
recently in metabolomics, specifically comprehensive two-dimensional gas 
chromatography (GCxGC), comprehensive two-dimensional liquid chromatography 
(LCxLC) and two-dimensional NMR (2D NMR) [102]. This phenomenon can be 
explained by the need to comprehensively analyze biologically-based samples that are 
very complex and can contain metabolites numbering from a few hundred to a few 
hundred thousand. Comprehensive two-dimensional gas chromatography is a 
powerful analytical technique, particularly when coupled to a time-of-flight mass 
spectrometer (ToFMS). Four dimensions (4D) of analytical resolving power are 
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obtained using GCxGC/ToFMS, including: (1) first dimension chromatographic 
separation, (2) second dimension chromatographic separation, (3) mass spectral data 
acquisition and (4) signal deconvolution (a process for extracting ions from a complex 
total ion chromatogram (TIC)).  
 
In the analysis of yeast, Mohler and co-workers performed a study on the 
comprehensive analysis of yeast metabolite data, by combining discovery-base and 
deconvolution chemometric software [148]. Prior to analysis, the yeast samples 
required liquid-liquid extraction (LLE) and chemical derivatization. The metabolite 
extracts from yeast were freeze dried at room temperature and stored at -80 °C under 
argon. A two-step derivatization method was applied to the dried metabolite extracts 
comprising methoximation (for open-ring sugars and certain keto acids) and 
trimethylsilylation. Methoximation was conducted at 30 °C for 90 min and the 
silylation step at 60 °C for a further 60 min. The focus of the study was to observe the  
effect of lowering the Fisher ratio threshold for peak identification. A Fisher ratio is 
the class-to-class variation of the detector signal divided by the sum of the within-
class variations. Multiple samples from each sample type must be collected and the 
class of each sample specified [149]. The Fisher ratio information provides 
understanding into the class-differentiating power of every chromatographic location 
for every m/z.  One drawback to this method is that as the number of sample classes 
increase, the capacity to discover metabolites that are distinguished by class becomes 
more challenging [149]. In addition, a Parallel Factor Analysis graphical user 
interface (PARAFAC GUI) was used in order to select mass channels to obtain a 
concentration ratio for each of the metabolites.  PARAFAC uses alternating least 
squares to remove noise and separate overlapping components to produce cleaner 
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chromatographic profiles and mass spectra [148]. As a result, at the lowest threshold 
(just above the noise level), 73 metabolites were identified in addition to 81 unknown 
metabolites. The combination of the Fisher ratio method with PARAFAC provided 
high-throughput software for the discovery-based metabolomics research, and was 
novel for the GCxGC/ToFMS technique.   
Currently, there is considerable interest in developing a single derivatization method 
and separation method that satisfies the needs for metabolite analysis, recognizing the 
many chemical classes that constitute the metabolome. Thus there is a need for an 
enabling technology that can offer increased separation power to general 
metabolomics analysis. The chemical diversity of metabolites can be most 
appropriately identified if at least two different physiochemical properties of the target 
analytes are used, for instance gas chromatography-mass spectrometry (GC/MS: 
volatility and mass analysis) or high performance liquid chromatography-mass 
spectrometry (LC/MS: hydrophobicity and mass analysis). Mass spectrometry is fast 
emerging as a leading metabolic profiling tool and the elemental composition is 
greatly aided by ‘accurate mass’ measurement, or the use of a high resolution 
instrument. However, most mass spec instruments do not provide this information and 
only provide ‘nominal mass’ values i.e. to the nearest whole mass number, where the 
mass is rounded up or down to the nearest integral value. If the accurate mass of an 
ion from the high resolution MS (in this case an (orthogonal acceleration) oa-TOF) 
result is known, we can have more confidence in its identity. Orthogonal acceleration 
TOF mass spectrometers contain a pulsed acceleration region which extracts ions 
from the axial ion beam, which is then followed by a fixed field region that 
accelerates the ions to their final drift energy in the flight tube (Figure 2-4). The initial 
‘spatial spread’ allows for a further spread of ion energies in the drift region, where 
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ions whose initial position is further back will need more energy than the ions found 
further forward. Absolute and relative mass measurement error calculations can assist 
in confirming a 5 ppm maximum mass error, through the use of the equations: m = 
mtheoretical – mmeasured and ppmerror = m/mtheoretical x 10
6
. Furthermore, analyses 
involving metabolic profiling using GC/MS require derivatization, which is the 
process of chemically modifying a compound in order to increase and/or improve its 
stability and separation performance and sensitivity.  
In this chapter an analytical method for the accurate mass identification of the ‘global’ 
metabolites in order to differentiate reliably different yeasts at different growth stages 
(Diamond V XP, Yea-Sacc and Levucell) is investigated. Identification and 
subsequent quantification of the components was undertaken using an accurate mass, 
GCT-ToFMS followed by principal component analysis with the main aim being to 
study different yeast cultures for cattle feed using an accurate mass methodology for 
possible metabolite biomarker discovery 
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2.3. Experimental procedures 
 
2.3.1. Yeast culture samples 
 
Twenty three culture samples were obtained from Tall Bennett Group (Mona Vale, 
New South Wales, Australia) and maintained at 4°C until required for analysis. The 
sample types included: Diamond V XP yeast culture, cultivated in three different 
months (June, July, August of 2007) at different temperature condition, Levucell SC 
20 and Levucell SC (OU) and Yea Sacc yeast cultures. Overall twenty three yeast 
extractions were analysed (Table 2-2).  
 
Table 2-2: Summary of the total number of yeast extracts analysed (Diamond V XP, 
Yea-Sacc, Levucell) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE TYPE NUMBER OF SAMPLES 
XP June, 2007 
XP July, 2007 
XP August, 2007 
4 
 
5 
 
4 
Levucell 
Yea-Sacc 
 
Total 
6 
4 
 
23 
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2.3.2. Extraction and Derivatization parameters 
 
2.3.2.1. Reference compounds, internal standard and solvent 
 
The compounds and reagents were all of analytical grade except where otherwise 
stated and the reference compounds (Isoleucine, proline, propionic acid, alanine, 
serine, methionine, glucose and malic acid) were purchased from Sigma Aldrich, 
Castle Hill, Australia. The standards were prepared at an initial concentration of 1000 
µg/mL. From these standard solutions both individual, primary, working standards, 
and various mixtures were prepared. Primary standards mixtures contained 50 µg/mL 
of the reference compound. Standard mixtures were generally diluted 5-fold, 
providing a final concentration of 10 µg/mL. The diluted standard mixture (10 µL) 
was spiked to the yeast extract for further analysis. Naphthalene was used as an 
internal standard, 20 µL of a 1 µL/mL solution in pyridine, (Sigma Aldrich, Castle 
Hill, Australia).  
2.3.2.2. Liquid-liquid extraction 
 
To optimise the extraction, methoxymation and derivatization the effects of varying 
the solvent volume, sample weight, extraction duration were explored. Yeast 
extractions were performed by weighing approximately 15 mg of yeast culture into an 
aluminium cup and transferring it to a mortar and pestle for gentle grinding. The 
ground sample was added to a 20 mL crimp top glass vial followed by 5, 10 or 15 mL 
of 50% MeOH:H2O and 5 mL of 100% chloroform according to the design (Table 2-
3). Samples were vortexed for two mins, sonicated for another two mins, and allowed 
to extract for 1, 2 and 3 minutes. After this time, 1 mL of the top organic layer was 
taken, spiked with standard mixture and 20 µL of the internal standard and then 
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placed into a GC vial and dried under N2 at 60
o
C ready to be derivatised (Figure 2-3). 
Overall, the experiment design was constructed with nine different extractions 
resulting in a total of 36 experiments (including replicates of replicates) with the best 
results appearing to be under the conditions of 5 mL of 50% MeOH:H2O and 5 mL of 
100% chloroform, with two minutes extraction time (see results and discussion). 
 
Table 2-3: Experimental design for optimizing the extraction conditions for yeast 
analysis. 
 
STANDARD 
MIXTURE 
 100% CHLOROFORM  EXTRACTION TIME 
(MIN) 
Stand. mix 1 10 5 1 
Stand. mix 2 10 5 2 
Stand. mix 3 10 5 3 
Stand. mix 4 15 5 1 
Stand. mix 5 15 5 2 
Stand. mix 6 15 5 3 
Stand. mix 7 5 5 1 
Stand. mix 8 5 5 2 
Stand. mix 9 5 5 3 
 
2.3.2.3. Microwave derivatization 
 
In the present study a one-step derivatization process was employed by combining a 
methoximation reagent (methoxyamine hydrochloride) and a silylation reagent 
(BSTFA + 1%TMCS) in order to derivatise a series of chemical classes in yeast 
extracts. These extracts were subsequently analysed by accurate mass GCT-oa-
ToFMS in order to produce an accurate, sensitive and rapid applicable method for the 
analysis of yeast cultures. A set of experiments was performed using different 
microwave power and irradiation times of the samples in order to study the variation 
in peak response from standards  
 
50 % MeOH:H2O 
            (mL) mL 
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spiked in the sample whilst varying experimental factors. Naphthalene was used as an 
internal standard (I.S) to correct for systematic and gross rerrors; this allows checking 
for losses arising from evaporation or similar solute loss and to compare recovery 
across the different samples. Peak responses for naphthalene remained fairly constant 
across all the different sets of experiments undertaken, indicating that it is a suitable 
internal standard for this process. The experimental design was performed in a similar 
manner to the work undertaken and described by Kouremenos et al. [101].  
 
Thirty microliters of 20 mg/mL methoxyamine hydrochloride (MTAH) and 100 µL of 
BSTFA containing 1% TMCS (trimethylchlorosilane) (Sigma Aldrich, Castle Hill, 
Australia) was found to provide more efficient results when added to the dried extract 
for the derivatization process. The goal of microwave assisted derivatization (MAD) 
is to apply the most suitable conditions in order to maximise response as well as 
reproducibility using microwave irradiation [61]. In this study, the efficiency of MAD 
was investigated by varying factors time and power.  
The experiment was controlled by varying one factor and maintaining the other 
factors constant i.e. using different derivatization times 30 s, 60 s, 90 s and 120 s, 
keeping the power constant at 150 W then 300 W, 450 W and 600 W.  One of the 
extracts samples prepared and spiked with the standard solution with a concentration 
of 10 µg/mL for each standard, was used for the investigation of the microwave 
silylation reaction. 
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Figure 2-3: Flowchart of method developed for metabolomic screening of yeast 
extracts. 
Addition of 5 mL 50% MeOH: H2O & 5mLCH3Cl 
Addition of methoxyamine hydrochloride 
Microwave (90 sec) derivatization with BSTFA + 1% TMCS 
 
Statistical analysis (PCA) 
GCT-ToFMS analysis 
Deconvolution, alignment, identification 
15 mg of yeast sample 
Vortex, centrifuge and dry supernatant under N2 
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2.4. Instrumental analysis 
 
 
The analysis of yeast samples was performed using a Waters GCT Premier system 
(Waters Corporation, Milford, MA USA) equipped with a Waters orthogonal 
acceleration time-of-flight (oa-ToF) mass spectrometer.  The column used was a 30 m 
DB-5MS (5%-Phenyl)-methylpolysiloxane) capillary column (Agilent) with an 
internal diameter 250 µm and a film thickness of 0.25 µm. All injections were done in 
splitless mode with 1 µL injected volume, and an oven ramp beginning at 85 °C (hold 
for 2 min), then increasing at a program rate to 325 °C (4
o
C/min) with a hold time of 
5 min. Helium (carrier gas) was used at a rate of 1.0 mL min
-1
. The transfer line was 
maintained at 280 °C with an acquisition rate of 10 Hz. Manual tuning was performed 
using perfluorotributylamine as an internal standard. Exact mass spectra scans were 
obtained using the internal standard (perfluorotributylamine, m/z 218.9856 lock mass) 
that was infused into the source continuously during the run. At the start of the 
experiment the instrument was tuned so that the resolution ranged between 1000-6500 
FWHM (full width half maximum). 
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Figure 2-4: GCT-oa-TOFMS instrument schematic showing ion optics and accurate 
mass measurement. 
2.5. Library searching 
 
All GCT-oa-TOF/MS instruments are provided with computer operation, and contain 
a library of reference spectra, e.g. the NIST library which contains many thousands of 
reference spectra, collected under defined conditions. The NIST 2005 library [150], 
which contains 190,825 mass spectra as well as the Fiehn metabolomics library [151] 
was used in this work to seek a match with spectra from compounds detected. The 
match process provides a match statistic from 0 to 1000 - 1000 being a perfect match 
– with metabolites above a value of 700 being taken for further scrutiny. Data 
acquisition and processing were conducted using ChromLynx software, which 
provided the ability to perform rapid detection, identification and semi-quantitative 
determination of components in complex mixtures while enabling the comparison of 
sample and control extracts. 
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It uses accurate mass library scoring to verify the elemental composition of significant 
ions in the spectrum of an unknown sample component when compared with potential 
compounds in a library match.  ChromaLynx automatically performs exact mass 
confirmation of the library search. The formula from the library hit is submitted to 
elemental composition and the most intense ions are confirmed/rejected by exact 
mass, Figure 2-5. 
 
Figure 2-5: ChromaLynx browsing window showing screening results. 
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2.6. Statistical analysis 
 
2.6.1. Data pre-processing 
 
Correlation optimisedd warping (COW) was used to correct for misalignments or 
shifts in raw data, to align a sample data vector (a chromatogram) to a reference 
vector allowing limited changes in segments lengths on the sample vector.  COW was 
first introduced by Nielsen et al. [119, 152] as a method to correct for shifts in 
discrete data signals. It is a piecewise segmented data pre-processing technique that 
uses dynamic programming to align a sample chromatogram to a reference 
chromatogram by stretching or compression of sample segments using linear 
interpolation, optimising the correlation coefficients between corresponding segments 
in reference and sample [119, 152]. The COW algorithm involves two user input 
parameters: the segment length and the flexibility and these two parameters are 
typically selected on a trial and error basis by visual inspection of the 
chromatographic profiles (peak shape, width, etc.) 
2.6.2. Multivariate analysis: OPLS-DA 
 
Orthogonal projections to latent structures discriminate analysis (OPLS-DA) was 
performed in SIMCA-P+12.0 (Umetrics AB, Umea°, Sweden) on mean centered and 
unit variance scaled metabolite responses from the original dataset. The data set was 
examined by PCA followed by OPLS-DA to overview the relationships between 
extracted metabolites (variables) and samples (observations) as well as among the 
variables themselves and to reveal groups/trends and deviating behavior among the 
observations. Significant metabolites contributing to the class separation were 
determined using the loading column plots with confidence intervals calculated by 
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jack-knifing. The validation used here was implemented as a cross-validation 
procedure, where a small portion of the samples was kept out of the modeling and the 
data being remodeled seven times. This provided a predictive value regarding the 
classification for each sample, and based on this the Q
2
 value was calculated as a 
measure of the predictive robustness of the model. Q
2
 estimates the goodness of 
prediction and provides information regarding which variables are well explained and 
which are not. 
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2.7. Results and discussions 
 
2.7.1. Optimization of extraction duration and solvent volume 
 
Reaction solvent, microwave power and irradiation time can all affect derivatization 
processes [153]. In this work, the first step was to consider the optimization of solvent 
volume (5mL, 10 mL and 15 mL), followed by the extraction time (1 min, 2 mins and 
3 mins). Longer extraction times (5 and 10 mins) were also considered, but no 
information was gained after 3 mins, thus they are not reported here. As previously 
discussed the two solvents investigated were methanol and chloroform (50% 
MeOH:H2O and 100% CHCl3), as they are the most common solvent combinations 
used to extract many lower molecular weight compounds. Chloroform was used as the 
control solvent, and remained a constant volume at 5 mL for all experiments 
conducted. 
 
After processing the GC-oa-ToFMS data from the 23 extractions, analysis of eight 
metabolites present in the sample was conducted by recording the response of each 
standard in the sample. The total peak area of each standard was used to determine 
whether the eight standards are symmetrically affected by the different experimental 
conditions or not. Furthermore, the total peak area of each standard was measured 
against the internal standard (naphthalene) which was added after the derivatization, 
in order to obtain response area ratios (analyte of interest/internal standard). The 
response area ratios did not differ significantly under any of the experimental 
conditions investigated, and hence only normalization (response area /internal 
standard response area) was subsequently performed. Figure 2-6 shows the average 
peak areas of each standard under different solvent and extraction conditions. The 
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peak areas illustrate that the standards (trimethylsilyl derivatives) had similar 
responses to each other due to the concentration of each standard being the same and 
also as the conditions were not significantly different (i.e. only the use of different 
solvents). However, a clear trend is observed when selecting a specific solvent 
volume and extraction time. The  optimization of extraction and derivatization 
conditions showed that 5 mL of 50% MeOH:H2O and 5 mL CH3Cl including 15 mg 
of yeast sample, with an extraction time of only 2 mins is optimal for extracting yeast 
cultures, as it results in the highest peak area responses for each standard (Figure 2-6).  
 
Figure 2-6: The effect of solvent volume and extraction time on the yields of 
standards (isoleucine, proline, alanine, glucose, methionine, malic acid and propanoic 
acid). 
 
The optimization of extraction and solvent volume showed that 5 mL of 50% 
MeOH:H2O and 5 mL of 100% CHCl3 with 2 min extraction time seemed to provide 
Chapter 2 – Metabolic profiling of yeast using GCT-oa-ToFMS: application to biomarker 
discovery 
 
 ~80~ 
the highest peak area responses when compared to the 10 mL and 15 mL of 
MeOH:H2O. This was further investigated by using descriptive statistics, where a box 
plot was created to distinguish (visually) the difference between the different solvent 
volumes in Figure 2-7. From the box-plot it is clearly evident that the response ratio 
of each standard is decreased as the volume of 50% MeOH: H2O is increased. Five 
mL of 50% MeOH:H2O and 5 mL of 100% CHCl3 resulted in the highest response. 
This was clearly the best ratio to use for the extraction, showing a strong correlation 
between the different conditions. The box-plot was also useful in highlighting the fact 
that the second best extraction composition was 10 mL MeOH:H2O and 5 mL of 
100% CHCl3, followed by the 15 mL MeOH and 5 mL CHCl3, which had the lowest 
peak area response in the standards. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7: Box-plot analysis to visualize the response of each standard at different 
solvent volumes. 
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2.7.2. Analysis of yeast extracts using GC-oa-ToFMS 
 
All  23 yeast culture extracts were derivatised and analysed using GCT-oa-ToFMS, 
thirteen from Diamond V XP (yeast culture) differing by month of fermentation (June, 
July, August) and six from Levucell and four from Yea-Sacc (Table 2-2). 
Due to the polar nature of some of the metabolites present in the yeast, chemical 
derivatization was required before GC analysis and a well-established methoxymation 
and silylation derivatization method was used (as described previously in Chapter 1). 
TMS groups produced are small and allow for thorough derivatization of metabolites 
of a large number of compound classes (‘global’ metabolites): amino acids, organic 
acids, fatty acids, sugars, sugar alcohols and amines.  
The yeast metabolic extracts were shown to be sufficiently complex and suited for 
GCT-oa-ToFMS analysis. Typically, when metabolite samples are profiled using 
GC/MS, either m/z 73 or TIC are used to obtain an overview of the sample. Since the 
TMS groups design (Si(CH3)3) has a m/z of 73, any chemical species in a sample 
extract that is tagged with one or more TMS groups will have a peak at m/z 73. Mass 
channel 73 is typically used to monitor the yeast metabolite extracts, as they have 
been methoximated and trimethylsilylated, and therefore all trimethylsilylated adducts 
produce a significant fragment at m/z 73, shown in Figure 2-8. This confirms that the 
metabolites containing a TMS group (m/z 73) have indeed been derivatised. There are 
many m/z that should be scrutinized when analysing the MS data. Peaks in these other 
mass channels are more likely to be free of significantly overlapping components than 
peaks at m/z 73 [154]. Generally, metabolomic analysis involves the use of different 
mass channels. This is an important step for this type of analysis, as it reduces the data 
thus making the analysis less time consuming and easier to compare samples.  
 
Chapter 2 – Metabolic profiling of yeast using GCT-oa-ToFMS: application to biomarker 
discovery 
 
 ~82~ 
 
Figure 2-8: Typical GC-oa-TOF/MS chromatograms at a m/z 73 of (A) Levucell 
yeast extract, (B) Diamond V XP extract and (C) Yea-Sacc yeast extract sample. 
A 
C 
B 
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Figure 2-8 illustrates chromatograms of the typical yeast extracts from different 
samples, which are initially visually compared, followed by a comparison using total 
number of peaks detected. It is obvious by visually comparing the chromatograms 
from Figure 2-8 that Yea-Sacc is the most complex followed by Diamond V XP and 
finally Levucell. Additionally, the average signal-to-noise (S/N) ratio for the three 
samples was 97, with the limit of detection (LOD) at 0.115 mg/L and the limit of 
quantification (LOQ) at 0.732 mg/L, thus all the values obtained for S/N, LOD, and 
LOQ were all in the ranges expected for GC-MS. Whilst providing much useful 
information, the drawback to using this single mass channel for identifying 
differences in the samples is the complexity obtained from the TIC chromatogram. Of 
more than 300 recognizable peaks present in the 1D chromatogram, a significant 
number are also likely to be due to underivatised reagent artifacts. To exclude these 
artifacts from the analysis and at the same time investigate specific targeted classes of 
certain class of compounds, other m/z values were chosen that would be characteristic 
of a known class of compounds of interest. 
One goal in metabolomics is to identify as many metabolites as possible and here the 
use of GCT-oa-ToFMS detection enabled accurate masses to be recorded to enable 
‘absolute’ identification of the metabolites present in the yeast cultures. By 
monitoring selected (non-accurate) masses for the differing compound classes, the 
data can be simplified significantly, e.g. amino acids (m/z 117), organic acids (m/z 
147) sugars (m/z 204) and sugar alcohols (m/z 217) (these unique masses are by no 
means ‘unique’ to specific compound classes, but in our study we found that we could 
generally group compound classes together by using these specific masses).The 
extracted ion chromatogram (EIC) is a chromatogram created by plotting the intensity 
of the recorded signal at a chosen m/z value, or set of values as a function of retention 
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time. These ion fragments are illustrated in Figure 2-9. The organic acid diagnostic 
ion (m/z 147) has been described as the disiloxonium fragment (Me2Si=O-SiMe3) 
which originates from polysilyl derivatives and therefore indicates the presence of the 
O-TMS group. This fragmented ion was found in most organic acids identified in the 
yeast samples. The fragmented ion at m/z 117 (-CO-TMS) was found at lower 
intensities in all amino acids derivatives and aids identification of the amino acids in 
the yeast samples. This diagnostic ion correlates well with previous studies reported 
by Sparkman and co-workers [155].The yeast samples were also found to be rich in 
sugar, sugar alcohols and amino acids, particularly Yea-Sacc and Diamond V XP. 
DeJongh et al. [156] describe the fragmentation of TMS derivatives of sugars, and 
state that the comparison of retention times and fragment ions in mass spectra would 
help with identification.  
Generally, the fragmented diagnostic ion used for the TMS derivatives of sugars is the  
(CH3)3SiOCH=CHOSi(CH3)3 peak at  m/z 204. In this study mass spectra indicated 
other intense peaks at m/z 191 (CH3)3SiOCH=OSi (CH3) 
3+
 and m/z 217  
(CH3)3SiOCH=CH-CH=OSi (CH3)
3+
, which were indicative of specific structural 
features (TMS hexose). In some cases the m/z 204 peak was more intense than the 
peak at m/z 217, indicating that the hexose is in the pyranose form, compared if m/z 
217 peak is more intense than it is a furanose [155]. Although EIC was efficient in 
identifying the different classes of compounds and their ‘appearance region’ in the 
chromatograms, the complexity of samples made it a challenging task to identify all 
the metabolites present. It was not possible to extract all amino sugars and sugar 
alcohols (m/z 217), through EIC as some of the fragmented ion peaks in the mass 
spectra were similar to the sugars TMS, thus highlighting that obtaining accurate mass 
for each metabolite would result in absolute confirmation of the metabolites of 
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interest. Figure 2-9 demonstrates the chemical structure of each diagnostic ion 
mentioned above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9: Diagnostic TMS fragment for organic acids m/z 147 (a),the general ion   
m/z 73 (b), fragment for sugars m/z 204 (c), sugars m/z 204 (d), diagnostic sugar 
alcohols m/z 217 (e), and amino acids m/z 117 (f). 
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2.7.3. Accurate mass metabolite analysis of Diamond V XP, 
Levucell and Yea-Sacc 
 
 
Through the use of EIC it was possible to study specific peaks in the different yeast 
culture samples and over 100 metabolites were identified. The identified metabolites 
were subsequently classified by major chemical groups into ‘sugar’, sugar alcohols’, 
‘amino acids’, and ‘organic acids’. Each of the classes was represented by 15 or more 
identified peaks with a slightly higher representation for sugars, Table 2-4 illustrates 
some examples of the sugars identified and the most abundant ions (m/z). 
Furthermore, Figure 2-10 shows the selection of different m/z for Diamond V XP, 
corresponding to the different classes of compounds, where the green peaks 
correspond to m/z 73 and the red peaks to the selected m/z (specific class of 
compounds). 
Table 2-4: The most common ions (m/z) of TMS–sugars identified in the yeast 
culture extracts. 
 
 
TMS sugar m/z TMS sugar m/z 
D(-)-Xylulose 147, 218, 335 Xylitol 217, 307, 319 
L(+)-Arabinose 191, 204, 217 myo-Inositol 147, 204,361 
D(-)-Lyxose 191, 204, 217 Lactulose 147, 204, 361 
L(+)-Rhamnose 147, 191, 204 D-Sorbitol 205, 307, 319 
Galactosan 191, 204, 217 D(+)-Sucrose 204, 217, 361 
Mannosan 204, 217, 333 Lactose 191, 204, 306 
D-Allose 191, 204, 217 D(+)-Maltose 191, 204, 361 
D-Altrose 191, 204, 217 Turanose 147, 217, 361 
D(-)-Fructose 147, 217, 437 Cellobiose 204, 361 
D(+)-Galactose 191, 204, 217 Glucose 174, 191, 204 
D(+)-Glucose 191, 204, 217 D(+)-Talose 191, 204, 217 
D(+)-Mannose 191, 204, 217 Ribitol 217, 307, 319 
L(-)-Sorbose 147, 204, 437 D(+)-Arabitol 217, 307, 319 
Levoglucosan 204, 217, 333   
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Figure 2-10: GC-oa-ToFMS chromatogram of Daimond V XP extract at selected 
mass channels.(A) Mass channel (m/z 217) sugar alcohols, (B) Mass channel (m/z 
117) amino acids, (C) Mass channel (m/z 147) organic acids and (D) Mass channel 
(m/z 204) sugars. 
    D 
      C 
          A 
B 
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EIC analysis of Diamond V XP samples demonstrated that amino acids appear to be 
the first components to elute from the extracted sample, with retention times between 
10-25 mins. Diamond V XP was found to contain large amounts of sugars which were 
found in the middle latter part of the chromatogram with retention times between 30-
45 mins. One of the most important chemical properties of monosaccharides (sugars) 
is that they can act as mild reducing/oxidizing agents, since the aldehyde group can be 
either oxidized to form a carboxylic acid group (in the presence of Cu2
+
, Ag
+
, and 
Fe3
+
), or reduced to the corresponding alcohol (in the presence of NaBH4, KBH4), the 
latter property is also used in chromatography where sugars are reduced to the 
corresponding alcohols prior to their derivatization [157]. Sugar alcohols have the 
general formula H(HCHO)
n+1
H, whereas sugars have H(HCHO)nHCO - the sugar 
alcohols were the last components to elute and were therefore found towards the latter 
part of the chromatogram, at 46-55 mins.  
 
A non-polar BPX5 column (5% phenyl polysilphenylene-siloxane) allows for the 
separation to occur based on compounds which retain better on non-polar columns 
due to their chemical structure/boiling point properties. In this case, the elution of the 
compounds classes present was as follows, due to their polarity: amino acids, fatty 
acids, sugars, and finally sugar alcohols. Figure 2-11 illustrates the chemical structure 
of (a) sugar and (b) sugar alcohols. The organic acids seemed to be scattered 
throughout the chromatogram in no particular order, due to the fact that there were 
different types of organic acids present, e.g. carboxylic acids, keto acids etc.  
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Figure 2-11: Chemical structure of sugar and sugar alcohol metabolites, (a) Glycose 
and (b) Arabitol. 
 
 
As mentioned previously, for the confirmation of the identity of the metabolites the 
NIST library was used, in addition to the Fiehn library. Mass spectral deconvolution 
automatically finds peaks, deconvolutes spectra from co-eluting compounds using 
model ion traces that best describe the presence of unique peaks, and subsequently 
matches spectra against user-defined mass spectral libraries making searches quick 
and simple. The sample peak is automatically compared head-head with the reference 
library peak. Figures 2-12 and 2-13 demonstrate an example of the mass spectra of 
propanoic acid 2TMS that was identified in the Diamond V XP using the NIST 
database. 
 
 
 
 
 
 
 
 
 
 
Figure 2-12: Example of the propanoic acid mass spectra at m/z 147 (organic acid 
diagnostic ion) and the chemical structure 
       (a)        (b) 
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Figure 2-13: A full mass spectra of the propanoic acid 2 TMS (red label) in Diamond 
V XP, compared with the NIST library mass spectra (blue label). 
 
 
When targeting a specific compound with a high resolution accurate mass 
spectrometer, it is simple to plot an extracted ion chromatogram (XIC) of its exact 
mass. Because of the accuracy of the MS data, the selectivity of this technique is 
greatly enhanced and good signal-to-noise ratios are obtained. However if multiple 
residues are to be investigated, it can be time consuming to target them all 
individually. In this case it was quiet useful to process the data using the powerful 
chromatographic software provided by ChromaLynx.  
 
ChromaLynx automatically plots the XIC’s of up to eight most intense ions at any 
point in the chromatogram and displays its deconvoluted exact mass spectrum, while 
searching mass spectra against the selected library in order to provide elemental 
composition calculations. In this study, data were always acquired with accurate mass 
precision (7000 resolution FWHM).The lock compound, perfluorotributylamine, m/z 
218.9856 introduced to the GCT prior to analysis allowed for high mass accuracy of 
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<5 ppm. Figure 2-14 demonstrates mass spectra (exact mass) of an amino acid 
identified in Diamond V XP through ChromaLynx. Table 2-5 lists the accurate mass 
and elemental compositions of most abundant metabolites present in Diamond V XP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-14: Exact mass spectra of valeric acid TMS identified in Diamond V XP 
through ChromaLynx. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nominal mass spectra 
Exact mass spectra 
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Table 2-5: Most abundant metabolites present in Diamond V XP though the use of 
GC-oa-ToFMS.*Note: Da is the difference between the calculated exact mass and the 
accurate mass ChromaLynx. 
METABOLITE 
(TMS) 
FORMULA 
OF ION 
THEORY 
EXACT 
MASS  
EXPERIMENTL 
ACCURATE 
MASS  
M(DA) PPM 
 
propanoic acid 
 
C9H22O3Si2 
 
234.1108 
 
234.1106 
 
0.0002 0.8543 
 
glycerol 
 
C12H32O3Si3 
 
308.1659 
 
308.1655 
 
0.0004 1.2980 
 
silanamine 
 
C11H31NOSi3 
 
277.1713 
 
277.171 
 
0.0003 1.0823 
 
isoleucine 
 
C12H29NO2Si2 
 
275.1738 
 
275.1734 
 
0.0004 1.4536 
 
pentenoic acid 
 
C11H24O3Si2 
 
260.1264 
 
260.1262 
 
0.0002 0.7688 
 
glycine 
 
C11H29NO2Si3 
 
291.1506 
 
291.1504 
 
0.0002 0.6869 
 
valeric acid 
 
C11H26O3Si2 
 
246.2514 
 
246.2512 
 
0.0002 0.8122 
 
butanedioic acid 
 
C11H22O4Si2 
 
274.1057 
 
274.1055 
 
0.0002 0.7296 
 
xylulose 
 
C17H42O5Si4 
 
438.2109 
 
438.2107 
 
0.0002 0.4564 
 
malic acid 
 
C13H30O5Si3 
 
351.1401 
 
351.1397 
 
0.0004 1.1391 
 
proline 
 
C11H23NO3Si2 
 
273.1217 
 
273.1215 
 
0.0002 0.7323 
 
butanoic acid 
 
C13H33NO2Si3 
 
319.1819 
 
319.1817 
 
0.0002 0.6266 
 
octanoic acid 
 
C14H33NO2Si2 
 
303.2052 
 
303.2048 
 
0.0004 1.3192 
 
arabinofuranose 
 
C17H42O5Si4 
 
438.2109 
 
438.2106 
 
0.0003 0.6846 
 
ribitol 
 
C20H52O5Si5 
 
512.2661 
 
512.2657 
 
0.0004 0.7808 
 
fructose 
 
C21H52O6Si5 
 
540.261 
 
540.2607 
 
0.0003 0.5552 
 
myo-inositol 
 
C24H60O6Si6 
 
612.3006 
 
612.3004 
 
0.0002 0.3266 
 
turanose 
 
C33H78O11Si7 
 
846.3929 
 
846.3925 
 
0.0004 0.4725 
 
maltose 
 
C36H86O11Si8 
 
918.0109 
 
918.0107 
 
0.0002 0.2179 
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The analysis of Yeas-Sacc was found to be more challenging due to its complexity. 
Yea-Sacc was found to be very rich in sugars. As it was noted with the analysis of 
Diamond V XP, the amino acids in the Yea-Sacc were found in the early elution times 
of the chromatogram (Figure 2-15). The sugar alcohols in the Yea- Sacc were not 
completely isolated using its specific EIC m/z 217 – this was most likely due to the 
large number of sugars present in the sample - causing the sugar alcohols to co-elute 
with the sugars, therefore single (accurate) mass spectral analysis for each peak had to 
be used for further analyses. Figure 2-16 demonstrates an example of melibiose 
8TMS, one of the sugars identified in Yea-Sacc. In comparison to the previous yeast 
culture sample analysed (Diamond V XP), Yea-Sacc extracts were found to be very 
rich in most metabolites, specifically in sugars. 
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Figure 2-15: GC-ToFMS chromatograms of Yea-Sacc extract at selected mass 
channels. (A) mass channel (m/z 147) organic acids, (B) mass channel (m/z 217) sugar 
alcohols, (C) mass channel (m/z 117) amino acids and (D) mass channel (m/z 204) 
sugars 
A 
B  
C 
D 
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Figure 2-16: A full mass spectra of the melibiose 8TMS (red spectra) in Yea-Sacc, 
compared with the NIST library mass spectra (m/z 204) (blue spectra) 
 
Levucell was the least complex sample. In comparison to Diamond V XP and Yea-
Sacc, Levucell was found to also contain few sugars and sugar alcohols (Figure 2-17).  
Metabolites identified included amino acids, organic acids, fatty acids and fewer 
sugars. Table 2-6 and 2-7 list some of the most abundant metabolites present in Yea-
Sacc and Levucell.  
Figure 2-17: GC-oa-ToFMS chromatograms of Levucell at selected mass channel m/z 
204 and 217 (sugar and sugar alcohols). 
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Table 2-6: Selected most abundant metabolites present in Yea-Sacc identified using 
GC-accurate mass spectral analysis. 
METABOLITE FORMULATION 
ION 
THEORY 
EXACT 
MASS 
EXPERIMENTAL 
ACCURATE 
MASS 
M(DA) PPM 
 
 
alanine 
 
C9H23NO2Si2 
 
233.1267 
 
233.1265 
 
0.0002 0.8579 
 
glycine 
 
C8H29NO2Si2 
 
291.1506 
 
291.1503 
 
0.0003 1.0303 
 
furancarboxylic 
acid 
 
C8H12O3Si 
 
184.0556 
 
184.0553 
 
 
0.0003 1.6299 
 
malonic acid 
 
C13H28O4Si2 
 
304.1526 
 
304.1522 
 
0.0004 1.3151 
 
ethyl phosporic 
acid 
 
 
C8H23O4PSi2 
 
 
270.0873 
 
 
270.0871 
 
 
0.0002 0.7405 
 
Lyxose 
 
C17H42O5Si4 
 
438.2109 
 
438.2107 
 
0.0002 0.4564 
 
valine 
 
C11H27NO2Si2 
 
262.1421 
 
262.1417 
 
0.0004 1.5258 
 
pentenoic acid 
 
C11H24O3Si2 
 
260.1264 
 
260.1262 
 
0.0002 0.7688 
 
serine 
 
C12H31NO3Si3 
 
321.1612 
 
321.161 
 
0.0002 0.6227 
 
threonine 
 
C13H33NO3Si3 
 
335.1768 
 
335.1764 
 
0.0004 1.1934 
 
lactic acid 
 
C11H23NO3Si3 
 
306.1319 
 
306.1317 
 
0.0002 0.6533 
 
methanamine 
 
C11H29NO3Si3 
 
263.1737 
 
263.1735 
 
0.0002 0.7599 
 
methyl valerate 
 
C15H36O4Si3 
 
364.1921 
 
364.1917 
 
0.0004 1.0983 
 
threitol 
 
C16H42O4Si4 
 
410.216 
 
410.2157 
 
0.0003 0.7313 
 
gluconic acid 
 
C16H35NO6Si3 
 
421.1772 
 
421.1768 
 
0.00041 0.9734 
 
aspartic acid 
 
C13H31NO4Si3 
 
349.1561 
 
349.1559 
 
0.00025 0.7160 
 
lysine 
 
C18H46N2O3Si4 
 
450.2586 
 
450.2584 
 
0.0002 0.4442 
 
glutamine 
 
C14H33NO4Si3 
 
363.1717 
 
363.1713 
 
0.0004 1.1014 
 
arbinonic acid 
 
C14H32O5Si3 
 
364.1158 
 
364.1156 
 
0.0002 0.5493 
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Table 2-7: Selected metabolites of Levucell identified using accurate mass spectral 
analysis. 
 
 
 
The method described can be used to monitor abundant metabolites, as identified 
using accurate masses. The most abundant metabolites can be used to obtain a rapid 
metabolic profile in order to be able to monitor the effect that yeast culture has as feed 
nutrient on livestock. Literature indicates that there is considerable interest in the 
different commercial yeast cultures currently used as feed additive for animals to 
improve performance, strengthening immune systems; some are even concerned with 
greater milk production [144-147]. Finding major changes in metabolite 
concentrations (possible biomarkers) between samples would be of great interest. 
Although EIC helped in reducing the data, and accurate mass enabled metabolite 
METABOLITE FORMULATION 
ION 
THEORY 
EXACT 
MASS 
EXPERIMENTAL 
ACCURATE 
MASS 
M(DA) PPM 
alanine C9H23NO2Si2 233.1267 233.1265 0.0002 0.8579 
 
glycine 
 
C8H21NO2Si2 
 
291.1506 
 
291.1502 
 
0.0004 
 
1.3738 
 
malonic acid 
 
C13H28O4Si2 
 
304.1526 
 
304.1523 
 
0.0003 
 
0.9863 
 
Lyxose 
 
C17H42O5Si4 
 
438.2109 
 
438.2107 
 
0.0002 0.4564 
 
valine 
 
C11H27NO2Si2 
 
262.1421 
 
262.1417 
 
0.0004 1.5258 
 
pentenoic acid 
 
C11H24O3Si2 
 
260.1264 
 
260.1261 
 
0.0003 1.1532 
 
serine 
 
C12H31NO3Si3 
 
321.1612 
 
321.1609 
 
0.0002 0.6227 
 
threonine 
 
C13H33NO3Si3 
 
335.1768 
 
335.1764 
 
0.0004 1.1934 
 
lactic acid 
 
C11H23NO3Si2 
 
306.1319 
 
306.1317 
 
0.0002 0.6533 
 
methanamine 
 
C11H29NO2Si3 
 
263.1737 
 
263.1735 
 
0.0002 0.7599 
 
threitol 
 
C16H42O4Si4 
 
410.2160 
 
410.2157 
 
0.0003 0.7313 
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identification, it was still difficult to summarise major differences between the 
samples due to sample complexity and as a result principal component analysis (PCA) 
was undertaken. 
2.8. Principal Component Analysis 
 
PCA reduces the data required to describe samples whilst maximising the information 
gained. It involves the rotation and transformation of the original axes into new axes 
that lie along the directions of maximum variance of data and that are “orthogonal” 
[158]. On the basis of total variances, vectors are determined by linear combination of 
all metabolite data. The resulting vectors are ordered by decreasing amount of total 
variance resulting in a minimum of loss of information content when data are 
visualized. Each sample can then be represented in a two- or three-dimensional space 
spanned by these vectors. Orthogonal partial least squares OPLS-DA was also used 
for verification of the results obtained from PCA and for the identification of possible 
biomarkers.  
 
OPLS-DA was introduced as an improvement of the PLS-DA method to discriminate 
two or more groups (classes) using multivariate data [159]. In OPLS-DA a regression 
model is calculated between the multivariate data and a response variable that only 
contains class information. The main idea of OPLS is to separate the systematic 
variation in X (variation in the first principal component) into two parts, one that is 
linearly related to Y (variation in the second principal component) and one that is 
unrelated (orthogonal) to Y. This partitioning of the X-data facilitates model 
interpretation and model execution on new samples. Prior to performing PCA or 
OPLS-DA analysis it is necessary for the chromatograms from the samples to be 
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aligned. Correlation optimisedd warping (COW) was used to correct for 
misalignments or shifts in raw data, to align a sample data vector (a chromatogram) to 
a reference vector allowing limited changes in segments lengths on the sample vector.  
The selection of segment length and slack size were set at 200 and 5.  
A score  plot of the first principal component (PC1) versus (PC2) from the yeast 
extracts m/z 73 chromatograms of 13 Diamond V XP, 4 Levucell and  6 Yea-Sacc  
yeast extracts from PCA of spectra obtained is presented in Fig 2.18. The score plot of 
the produced principal components allowed visualization of the data and clear 
separation between the yeast strands. Principal component analysis (PCA) was 
applied to detect possible outliers and to identify variability within the data that 
correlates with yeast strands classification. The genotype clustering of the samples 
was confirmed by PCA pattern recognition, with scores being clustered in three 
groups according to the three different types of yeast. 
 
The first principal component separated the Diamond V XP samples from the Yea-
Sacc and Levucell by capturing 63.35% of the total variance. Principal component 
two separated the Levucell from the Yea-Sacc cluster and captured 22.98% of the 
total variance. To a smaller extent, PC 2 seemed to show a separation between the 
Diamond V XP samples fermented in months of June, July, August. The first two PCs 
(largest eigenvalues) showed the greatest separation and thus contained the 
chemically relevant variance (most significant metabolites in terms of concentration 
change), and therefore PC 1 and PC 2 were used for further data analysis. 
Additionally, PCA data were used to analyze which metabolites exert the largest 
influence on the basic vector calculation. A typical approach of metabolomics 
research is the manual interpretation of the score and loadings plots.  
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Figure 2-18: PCA Scores plot of the first two principal components obtained from 
yeast extracts (m/z 73) chromatograms demonstrating differentiation between the 
yeasts. 
 
Typical manual interpretation involves the inspection of the scores plot which shows 
the separation between the yeast samples along the first principal component (PC1). 
For example, for computing the most powerful PCA vectors 1 and 2, many 
metabolites did not have values near zero, thus significant variances were observed. 
Metabolites including isomaltose, propanoic acid, serine, threonine, alanine, lyxose 
and lactic acid derivatives had a comparatively strong impact on the calculation of 
PCA vector 1, which separated predominantly the yeast extracts in the three clusters. 
Before fitting the PCA/OPLS-DA models, all variables were transformed with a low 
min/max ratio or high skewness.  
Diamond V 
Yea-Sacc 
Levucell 
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Table 2-8 illustrates a summary of R
2
X, R
2
X cum, eigenvalue, Q
2
 and Q
2 
cumulative 
based on four principal components. For the PCA model a cumulative R
2
Y of 0.89 
and Q
2
Yof 0.81 were calculated and the model validation plot showed intercepts of 
the R
2
Y and Q
2
Y regression lines with the vertical axis at 0.142 and 0.396, 
respectively, indicating a valid model, Table 2-9. Based on the coefficients and 
loadings from this model the responsible metabolites for the discrimination of the 
three groups were identified. As shown in Figure 2-18 a clear separation is visible 
amongst the yeast samples. All the XP extracts were also grouped together. 
 
Table 2-8: Summary of R
2
X, R
2
X cum, eigenvalue, Q
2
 and Q
2 
cumulative 
           (PCA-X Observations (N)=23, Variables (K)=14789 (X=14789, Y=0) 
 
 
The models were also assessed using a Hotelling’s T2 range plot, which shows if 
there are any sample outliers (none were observed in this case).The normal probability 
plot of residuals was used to assess the normal distribution of standardized results and 
a lack of outliers and as seen from Figure 2-19, thus indicating that the formed cluster 
is due to true metabolite differences rather than experimental variability. 
 
Components R
2
X R
2
X(cum) Eigenvalue Q
2
 Limit Q
2
(cum) Significance 
1 0.503 0.503 11.6 0.48 0.0435 0.477 18 
2 0.228 0.731 5.24 0.39 0.0455 0.681 9 
3 0.0658 0.796 1.51 0.09 0.0477 0.709 38 
4 0.0512 0.847 1.18 0.15 0.0501 0.753 30 
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Figure 2-19: PCA Hotelling’s T2 range plot demonstrating that there are no 
significant sample outliers at 95% & 99% critical confidence intervals. 
 
The OPLS-DA method was used to test the differences in metabolite alterations 
related to yeast extracts samples, and to assess the overall experimental variability (if 
any). Compared to the traditional principal component analysis and factor analysis, 
OPLS-DA methods are known as supervised statistical methods (class within class). 
OPLS-DA revealed an evident and statistically significant separation (P <0.05) 
between the three different samples (Fig. 2-20) defined by specific time points, where 
the metabolomic pattern was substantially changed as a whole. The OPLS-DA fitted 
model resulted in three predictive and five orthogonal components. 66.6% of variation 
in the data set (R
2
X cum) was used to account for 96.6% of the variance in the class 
separation (R
2
Y cum). The cross-validated predictive ability of the model was 92.9% 
(Q
2
 cum), which is conclusive for supporting the presented separation into three 
different groups according to the sample type. 
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Figure 2-20: OPLS-DA Score Scatter Plot showing the clusters produced from the 
three different types of yeast culture extracts. 
 
Similarly to the PCA, R-square and Q-square measures were calculated for overall 
model assessment and a cumulative R
2
Y of 0.86 and Q
2
Yof 0.76, respectively, 
indicated a valid and accurate model. Based on the coefficients (Table 2-9) and 
loadings from this model the responsible metabolites for the discrimination of the 
three groups were identified. Again the model was also assessed using a Hotelling’s 
T2 range plot, Figure 2-21.The normal probability plot of residuals was used to assess 
the normal distribution of standardized results and a lack of outliers and as seen from 
Figure 2-20 corresponding well with PCA analysis. 
 
 
 
 
Diamond V 
Yea-Sacc 
Levucell 
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Table 2-9: Summary of R
2
Y and Q
2
Y  for OPLS/PLS-DA models 
 
Figure 2-21: PCA Hotelling’s T2 range plot demonstrating no outliers and that the 
samples are all within the 95% and 99% critical confidence intervals. 
 
To find out precisely which regions of the chromatogram have caused the separation 
between the derivatisedd yeast extracts, the loadings plot of the related OPLS-DA 
model is shown in Fig. 2-22. Analysis of PCA vector loading supplies information for 
the interpretation of metabolic profiles that extends the results obtainable by accurate 
mass analysis. Locations of highly loaded variables corresponded with locations of 
chromatographic peaks that most influenced the clustering in the PCA scores plot. 
The highly loaded variables indicated the chemical compounds that distinguished 
sample types in Figure 2-22. The most influential loadings in the OPLS-DA model for 
the separation of the yeast extracts are summarized in Table 2-10. 
No.  Model Type Samples R
2
X(cum) R
2
Y(cum) Q2(cum)   
2 M2 OPLS/PLS-DA 23 0.86 0.89 0.76    
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Figure 2.23: The loadings plot of the OPLS model for the yeast extracts. 
  
 
 
Figure 2-22: Loadings plot of the OPLS-DA model for the three different types of 
yeast extract (including some labelled metabolites of interest). 
 
Analysis of the model loadings revealed several metabolites to be discriminatory 
between the yeast samples. In particular Diamond V XP samples illustrate a 
significant increase in amino acids and organic acids, namely: propanoic acid, alanine, 
valine, proline, serine and butanoic acid, thus causing separation from Yea-Sacc and 
Levucell extracts.  In addition the total propanoic acid levels was found to be  higher 
in the XP samples in comparison to the  Yea-Sacc and Levucell, by a factor of nearly 
3 and therefore could be proposed as a possible biomarker for the differentiation 
between the three different types of yeast extracts. Most propanoic acid produced is 
consumed as a preservative for both animal feed and food for human consumption 
[160]. For animal feed, it is used either directly or as its ammonium salt.  
Other specific possible biomarkers for Diamond V XP samples identified by OPLS-
DS were Melibiose, which increased 3-fold, D-Fructose, with a 2.5-fold increase and 
Propanoic acid 
Myo-Inositol Melibiose 
Manitol 
Threitol 
Threitol 
D-Mannitol 
Glucopyranoside 
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Myo-Inositol with a 5-fold increase. The loading plot of the OPLS-DA model was 
useful in identifying four possible biomarkers for Yea-Sacc: Threitol was found  to 
have a 1.5-fold increase, D-Mannitol showed a 2-fold increase, D-Fructose a 2.5 fold 
increase and D-Glucopyranose increased 2-fold overall. Levucell demonstrated the 
least similarities between XP and Yea-Sac samples, which could be also due to the 
low amount of sugar and sugar metabolites present, whereas XP and Yea-Sacc had 
many sugar compounds present. Loading plots identified six possible biomarkers for 
Levucell: D-Ribose showed a decrease of 4-fold, followed by Myo-Inositol a 5-fold 
increase, L-phenylalanine, Glucopyranoside, Fructose and Threitol increased 3-fold, 
2-fold and 4-fold respectively. In addition, the most abundant metabolites found 
across the three different types of yeasts are presented in Table 2-10, in order to 
provide an overall summary of the different types of metabolites present. 
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Table 2-10: List of metabolites present in the yeast extracts identified by PCA 
analysis 
 
 
 
ID NUMBER METABOLITE RETENTION TIME  
(MIN) 
1 Propanoic acid TMS 10.7261 
 
2 L-alanine 2TMS 11.7242 
 
3 L-valine TMS 14.6719 
 
4 Trimethylsilyl ether glycerol 16.284 
 
5 L-proline trimethysilyl ester 16.8424 
 
6 L-serine trimethysilyl ester 18.5242 
 
7 Butanoic acid 4TMS 23.5221 
 
8 Glutamine tris trimethylsilyl 24.995 
 
9 L-propene 1,2,3 3TMS 27.8214 
 
10 2,-keto-gluconic acid penta trimethylsily 28.0551 
 
11 D-fructose 1,3,4,5,6 pentakis 
0(trimethylsilyl) 
29.05 
12 Pentaric acid 2,3-dieoxy4-0trimethylsilyl 29.1923 
 
13 D-altrose 2,3,4,5,6-pentakis-o-
trimethylsilyl 
30.6412 
14 D-mannitol TMS 31.2661 
 
15 D-gluconic acid 2,3,4,5,6 TMS 32.42 
 
16 Inositol 1,2,3,4,5,6 hexakis 0TMS 34.419 
 
17 Α-D-glucopyranoside 1, 3,4,6 43.5461 
 
18 Maltose octakis TMS 44.7521 
 
19 Fructose heptakis TMS 45.204 
 
20 Melibiose octakis TMS 47.263 
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Since these components are the most abundant metabolites in the yeast extracts, it was 
hypothesised that most of the variations in PC1 were due to these metabolites. 
Furthermore, limited discrimination information is achieved using PC3, however it 
still seemed to cause a degree of separation within the Diamond V XP yeast extracts. 
Given that the Diamond V XP extracts were cultivated at different months (June, July, 
August) it was interesting to see that PCA analysis was able separate the XP yeast 
extracts according to the month. This cluster is shown in Figure 2-23. However, the 
cause for the separation of the XP samples according to the month is a little more 
difficult to interpret due to the fact that the information on growth conditions was not 
provided, additionally (increase/decrease) of metabolites across the XP samples was 
further investigated and different levels of metabolites were determined for the cause 
of separation. 
Figure 2-23: The scores plot obtained from PCA 3 of the yeast extracts (m/z 73) 
demonstrates differentiation between Diamond V XP samples. 
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OPLS-DA analysis of loading three was conducted to evaluate the temporal changes 
associated with the cluster within the Diamond V XP samples. Analysis provided 
some functional information regarding the levels within the Diamond V XP samples. 
In particular, changes in glycine, alanine, ether glycerol, were revealed. Due to the 
complexity of the samples and the large number of sugar and sugar alcohols 
metabolites present in the yeast, it made it a challenging task to observe more 
metabolites to be discriminatory between the Diamond V XP samples, however the 
OPLS-DA assisted in defining the levels of metabolites present in the XP samples. XP 
extracts from the June month were found to have an increase in some of the amino 
acids, leucine, valine and serine in comparison to the other two months; extracts from 
July appeared to have an increase in one of the amino acids (e.g. alanine) but also a 
moderate decrease in ethyl glycerol metabolite.  
 
Extracts from the July showed a significant increase in propanoic acid and in many of 
the sugar compounds. The hypothesis here was that the cluster formed between the 
XP extracts was a result of the different conditions (i.e. temperature) that the yeast 
was fermented under, thus possibly indicating a change in the concentration 
(increase/decrease) of the metabolites identified. However due to the fact that 
information regarding the condition that the XP yeast culture was fermented during 
the different month were not provided, made it difficult to state the exact reason for 
the separation.  
 
 
 
2 12 
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2.9. Conclusion 
 
 
In recent years, many studies have been aimed at supporting mass-spectrometry based 
metabolite profiling. The discovery of metabolites is considered an essential step 
toward a better understanding of micro-organisms. Given the chemical complexity 
and dynamic range of metabolites present in micro-organisms, profiling the levels of a 
broad range of metabolites is highly challenging. This study demonstrates the 
optimization of a microwave-derivatization method aiming at reducing the overall 
analysis time needed (due to the necessary derivatization required for GC analysis), 
and the significant enhancement in identification power achieved by using accurate 
masses obtained by using GCT-oa-ToFMS.   
 
In this study samples showed clear cluster according to the different yeast culture 
products. Further separation in the Diamond V XP samples was clear depending on 
the condition that yeast was cultivated under (however conditions not provided). 
Loadings on the PCs were very efficient in the identification of the metabolites that 
caused the samples to be different and resulted is such clusters (significant changes in 
metabolite concentrations). Similarities were noticed with the samples where sugars 
and sugar alcohol metabolites were similar across the yeasts. Accurate mass 
measurements and composition prediction by MS analysis were conducted based on 
the absolute m/z values obtained from unknown metabolites. Yeas-Sacc was found to 
contain more metabolites generally, followed by the Diamond V and Levucell with 
each containing less identifiable metabolites.  
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All compounds were identified using the NIST08 and Fiehn libraries. PCA was used 
to analyse and to obtain a clear differentiation of the samples. The ability to assign 
yeast extract samples to groups using PCA of metabolic profiles offers an exciting 
perspective for the study of micro-organisms. Accurate mass analysis allows for the 
absolute identification of a broad range of metabolites present in yeast extracts, and 
the use of chemometrics techniques such as PCA and OPLS-DA enabled 14 defining 
elements (significantly altered concentration of metabolites) to be distinguished. The 
use of accurate masses allows the absolute (correct) identification of the altered 
metabolites (significant increase or decrease in concentration – at a semi-
quantification level), which can thus be proposed to be used as possible biomarkers 
for future yeast differentiation. The 14 possible biomarkers found (either in 
significantly increased or decreased concentration levels) included melibiose, myo-
inositol, threitol, mannitol, glucopyranose, ribose, phenylalanine and fructose.  
 
A proposed future validation method could include larger samples sizes, many 
different samples types, the use of multiple instrumental platforms in confirming 
significant changes in concentration (for e.g. LC in parallel with GC) and finally the 
calculation of absolute concentration levels of metabolites through quantification. 
Furthermore, with metabolic analysis, response of metabolic networks to changes in 
single-gene is very complex, indicating how important it will be to have good 
methodologies in functional genomics that are capable of distinguishing cause from 
effect. 
 
 
 
  
 
 
 
 
 
 
 
 
3.1. Abstract 
 
Various efficient methods for the analysis of IEMs have been reported (which will be 
discussed further in this chapter); however the greatest disadvantage with most of 
them (apart from decreasing the heating treatment time) is that most studies conducted 
report one method for one disorder. For a practical analysis of IEMs disorders, three 
essential requirements must be fulfilled: a completely automated sample preparation, 
the shortest sample preparation time, and computer algorithm for the interpretation of 
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profiles. In this study a microwave derivatization procedure for the simultaneous gas 
chromatographic-mass spectrometric analysis of metabolites in infant plasma is 
reported. Various metabolites were extracted from plasma and derivatised with 
BSTFA+1%TMCS using a microwave that required only 90 s for heating treatment. 
The method established successfully performed differential diagnosis of metabolite 
deficiencies from the confirmed patient’s plasmas. This simple method offers cost-
effective and time-saving alternative to traditional conventional heating which 
generally requires over 1 h, also samples with different diseases were able to be 
analysed with the same method without the requirement of one method for one 
disorder.  
 
3.2. Introduction 
 
The most common diseases are caused by complex interactions between genetic 
factors such as diet and the environment [161]. These factors can influence the range 
and concentrations of metabolites and other low molecular weight compounds 
(LMCs) in tissue and bodily fluids. The LMCs that are involved in or affected by 
disease processes may serve as disease biomarkers. Compounds such as 
carbohydrates, nucleic acids, amino acids, lipids, amines, organic acids, fatty acids, 
various hormones, and phenolics have usually been individually measured in studies 
of diseases. Recent advances in NMR, GC/MS, or LC/MS methodology, have 
improved the analysis of LMCs and thereby enabled more global metabolomic 
approaches for identifying novel markers for specific diseases and understanding 
more about the biology, as well as life style and dietary factors behind the disease [23, 
162, 163]. To date, metabolite analysis has been shown to provide useful information 
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in such diverse areas as clinical diagnostics of coronary heart disease [164], analysis 
of genetic disorders [165], responses to toxins [166] and characterization of the effects 
of environmental stressors [167].Sample preparation for metabolic profiling of plasma 
sample is somehow different to that of urinary metabolic profiling. A major difference 
to urine metabolic profiling is that plasma samples are not incubated with urease 
enzyme - literature reports that plasma samples are required to be incubated for at 
least 2 hr after methoximation and 30 min derivatization time depending on the choice 
of derivatization agent (MSTFA or BSTFA) [168]. 
 
Human plasma contains an extensive variety of chemically diverse LMCs, which vary 
widely in concentrations and stabilities and which are commonly noncovalently 
bound to proteins [57]. Therefore the method development for deproteinization, 
extraction and analysis of plasma can be challenging. Since large numbers of samples 
are generally analyzed in studies of diseases, single procedures allowing the study of a 
wide variety of LMCs - such as metabolic profiling using GC/MS - are desirable and 
can provide initial evidence for the subsequent molecular diagnosis of many inborn 
errors of metabolism. 
 
IEMs are a cause of genetic mutations that affect an enzyme involved in intermediate 
metabolism. Fatty acids are involved in many areas of intermediate metabolism and 
there is a corresponding large number of IEMs in which fatty acids accumulate in 
vivo as a result of a deficient enzyme. The diagnosis of these IEMs can be based on 
the detection in plasma of abnormally elevated concentrations of the fatty acids 
associated with each disorder [169]. Inborn errors of metabolism (IEMs) are 
individually rare but collectively numerous (that is including all classes of metabolites 
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amino acids, organic acid and urea cycle disease), affecting the metabolism of many 
human organs [170, 171]. These metabolic defects are congenital and represent single 
or multiple enzyme deficiencies, which if left untreated can lead to life threatening 
conditions, with a current incidence rate of 1 : 800 live births [172]. IEMs can be 
grouped into three diagnostically meaningful groups: [173] (i) disorders giving rise to 
intoxication, via accumulation of intracellular compounds overtime, (ii) disorders 
involving energy metabolism, and (iii) disorders involving metabolism of complex 
molecules.  
Not all IEMs can be easily diagnosed and treatment does not exist for many, although 
many disorders of the first group can now be treated by changing the patient’s diet 
[171]. The use of new technologies used for early detection and identification of 
humans affected with genetic disorder has led to unexpected discoveries associated 
with the natural history of the disorder or choice of therapy. Early detection of IEMs 
makes possible the development of therapies that may include simple dietary 
alterations, enzyme replacement therapy, enzyme inhibitors or bone marrow 
transplantation [174]. Early diagnosis is considered essential for timely treatment and 
counselling. Prior to any analysis for early diagnosis biological samples require 
derivatization (silylation).  
 
For silylation, MSTFA can also be used in place of BSTFA, only differing to BSTFA 
in that it is most volatile [175]. Generally trimethylsilylation is performed with or 
without methoximation. The methoximation reaction occurs only with keto and 
aldehyde functional groups and therefore it has no effect on most of the other 
metabolites in the plasma. In the GC/MS analysis of plasma, TMS derivatives are 
usually preferred over tertbutyldimethylsilyl derivatives due to the latter derivatives 
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being bulkier than the TMS moiety which may limit the complete silylation of polyols 
or hexoses and result in the production of multiple derivatives [174]. Certain plasma 
metabolites have been detected by fully-automated GC/MS measurements in a clinical 
environment. GC/MS is necessary for both qualitative and quantitative analysis of 
plasma metabolites, and the specific elevated metabolites arising from various IEMs 
including isovaleric academia [42], propionic academia [43], pyroglutamic academia 
[38] and 3-methylcrotonylglycinemia [44] have been discovered by this technique. As 
early as 1966 Tanaka et al. developed a methodology in which the identification of 
155 metabolites was achieved, helping to demonstrate the importance of GC/MS in 
diagnostic medicine [45].  
 
In 2005, Jiye and co-workers developed an extraction and derivatization protocol, 
using experimental design theory, for analysing human blood plasma metabolome by 
GC/MS [57].Using design-of-experiment procedures, together with multivariate 
analysis, they investigated how different parameters (choice of extraction solvents, 
derivatization, physical conditions) affect the extraction and derivatization of LMCs’ 
from human blood plasma. After screening for the best solvent, extraction and 
derivatization conditions for extraction for the LMCs’ from plasma the method was 
optimised by evaluating the data for more than 500 chromatographic resolved peaks 
using multivariate statistical tools including principal component analysis and partial 
least-squares projections to latent structures. From the results a rapid and reproducible 
method was established, resulting in low detection limits when combined with 
GC/TOFMS analysis. However prior to GC/MS analysis, the samples were 
methoxymated at room temperature for 16 h (with 30 µL of 15 mg mL-1 
methoxyamine in pyridine) and trimethylsilylated with 30 µL of MSTFA for 1 h. 
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Although Jiye et al. reported an efficient experimental design for metabolite analysis 
of LMCs in plasma, sample preparation required over 17 h. This is a drawback as 
researchers are seeking to develop efficient, reproducible methods and a completely 
automated sample preparation with the shortest possible analytical time [176]. 
In 2010, Zeng et al. conducted a study on plasma metabolic fingerprinting of 
childhood obesity by GC/MS in conjunction with multivariate statistical analysis 
[177]. The work proposed a new strategy for metabolic fingerprinting in order to 
exploit the disorders of metabolic patterns and biomarker candidates of childhood 
obesity. Plasma samples from children of normal weight and those overweight or 
obese were first profiled by GC/MS. Isoleucine, glyceric acid, serine, 2,3,4-
trihydroxybutyric acid and phenylalanine were identified as potential biomarkers of 
childhood obesity. Overall, the results showed that the suggested metabolic 
fingerprinting technique could be effective for the discovery of metabolic 
abnormalities and serve as possible biomarkers for identifying and warning childhood 
obesity. Bruce et al. reported a global metabolic profiling methodology based on gas 
chromatography coupled to time-of-flight mass spectrometry (GC–TOFMS) for 
human plasma, which was applied to a human exercise study focused on the effects of 
beverages containing glucose, galactose or fructose taken after exercise and 
throughout a recovery period of 6 h was required [178].  
 
Furthermore, Chen and co-workers applied biomarkers discovery-based metabolomics 
technology to characterize plasma metabolic profiling during atherosclerosis 
development by comparing with healthy subjects using GC/MS analysis [179]. Pattern 
recognition analyses (principal components analysis, orthogonal partial least-squares 
discriminate analysis, and hierarchical clustering analysis) were used to classify 
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changes in the plasma metabolome between the healthy subjects and the patients. The 
study revealed three fatty acids, palmitate, state, and 1-monolinoleoyglycerol as 
potential biomarkers used for clinical diagnosis of atherosclerosis however a tradition 
derivatization method was used which required over 1 hr.  
A very recent study has been conducted by Han et al. on plasma esterfied fatty acids 
(EFA) and non-esterfied fatty acids (NEFAs) metabolic profiling using GC/MS and 
its application in the study of diabetic mellitus (DM) and diabetic nephropathy (DN) 
[180]. Metabolic profiling method was established to assess the levels of non-
esterified fatty acids (NEFAs) and esterified fatty acids (EFAs) in plasma. The 
extraction method was simple and robust without removing protein process, however 
having said that the samples and standards were incubated at 70°C for 30 min. With 
this method 25 fatty acids (FAs), both EFAs and NEFAs, were recognized 
simultaneously with only 10 µL of plasma. 
 
Metabolites occur at different concentrations in complex biological matrices, from 
which they must be extracted without affecting the structural integrity and relative 
abundances. Generally care must be taken in preparing aqueous sample of fatty acids 
as they are sparingly soluble and can bind to plastic surfaces. Plasma fatty acids are 
most commonly extracted using a liquid-liquid extraction procedure similar to the 
following: fatty acids are extracted with ethyl acetate under specific acidic condition 
with or without the addition of sodium chloride, dehydrated with sodium sulfate and 
finally evaporated to dryness and derivatised in order to increase the volatility, as to 
be compatible with GC/MS analysis. Methyl esters and trimethylsilylation are usually 
the two derivatization methods used [181].  
Chapter 3 – Application of fast derivatization methods with GC/MS for the analysis of 
infant plasma for inborn errors of metabolism 
 
 ~119~ 
Amusquivar et al. [181]  reported a study aimed to establish the best methods for 
quantitative analysis of fatty acids in blood plasma. The two methods used for 
comparison were the “two steps” and “direct”. In the “two steps” method, internal 
standards of C15:0, C19:0, C19:1, or C21:0 fatty acids were added to plasma and lipids 
were extracted in chloroform/methanol (2:1). Lipid extracts resuspended in  
acetyl chloride were processed as above. The study concluded that the “two steps” 
method is more appropriate and reliable for the quantitative analysis of fatty acid 
profiles in plasma samples, and C19:0 but not C15:0 should be used as the internal 
standard. 
In the study reported here, blood plasma from infants with different metabolite 
deficiencies was investigated (i.e. carnitine palmitoyl transferase I and II deficiency, 
propionic acidaemia, carnitine uptake defect, etc). The carnitine palmitoyl transferase 
enzyme system (CPT), consisting of CPT I and CPT II, mediates the entry of long-
chain fatty acids into the mitochondrial matrix for β-oxidation (Figure 3-1). It’s 
deficiency is a metabolic disorder characterized by an enzymatic defect that prevents 
long-chain fatty acids from being transported into the mitochondria for utilization as 
an energy source [182]. 
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Figure 3-1: Schematic of the transfere Acyl-CoA from cytosol to the mitochondrial 
matrix 
[182]
. 
 
Carnitine uptake defect is another inborn error of metabolism which is also known as 
primary carnitine deficiency and is an inherited disorder characterized by reduced 
transport of carnitine into cells [182]. Without carnitine, fats cannot be processed 
correctly and are not converted into energy. Initial signs and symptoms of this 
disorder typically occur during infancy or early childhood and often include 
encephalopathy, cardiomyopathy, confusion, vomiting, muscle weakness, and 
hypoglycaemia. Moving on to propionic academia, this deficiency is a rare disorder 
that is inherited from both parents. Being autosomal recessive, neither parent shows 
symptoms, but both carry a defective gene responsible for this disease. It takes two 
faulty genes to cause PA, so there is a 1 in 4 chance for these parents to have a child 
with PA. However this disorder is one of the dangerous ones as it can be life 
threatening, due to secondary hyperammonemia, infection, cardiomyopathy, or basal 
ganglial stroke [183].  
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Gas chromatography–mass spectrometry (GC/MS) is one of the most popular 
techniques for metabolic profiling analysis. Metabolic profiling based on GC/MS can 
reflect the metabolites and their levels clearly. Although lots of research articles have 
discussed GC methods for metabolite analysis [184] and [185], few articles offered 
metabolic profiling method for analyses of more than one disease IEM fatty acid 
deficiency under the same microwave derivatization conditions. 
Kouremenos et al. proposed microwave derivatization (using BSTFA+1%TMCS) 
with GCxGC/ToFMS as an alternative method for IEM analysis. As mentioned 
previously, the derivatization reaction requires generally longer than 45 min at the 
reaction temperature of 100 ºC in order for the metabolites present to be completely 
derivatised [186]. The Royal Children’s Hospital in Melbourne uses conventional 
derivatization method for their analysis of infant plasma for different IEMs. Their 
method requires more than 70 min for the silylation reaction to take place and reaction 
temperatures of up to 120 °C. 
The ability to isolate minor components is obviously of importance in metabolomics, 
as a slight increase in a low level of metabolites can be indicative of a specific 
deficiency, and ‘masked’ (overlapping) compounds may be simply overlooked due to 
the fact that their presence is neither acknowledged nor evaluated. Chromatograms in 
metabolic profiling of biological samples are often complex as a result of large 
number of metabolites present and due to the multiple derivatization products 
observed. Metabolite profiling for biologically-based samples generally involves six 
steps thus is it very important to develop an efficient routine, hence the importance of 
this study.As described by Kopka et al.[59] the six steps include: 
“ 
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 Extraction of metabolites from biological samples, which should be as 
comprehensive as possible, while at the same time avoiding duration or 
modification of metabolites. 
 Derivatization of metabolites to make them volatile and amenable to gas 
chromatography. Trimethysilylation was shown to be the most favoured 
treatment for this study. 
 Separation by GC usually involves highly standardised conditions of gas-
flow, temperature programming, and standardised column material to 
achieve reproducibility results. 
 Ionisation of compounds as they are eluted from the GC, which is required 
for subsequent mass spectrometry. Electron impact (EI) is most widely 
used and was used for this study. 
 Detection of low molecular ion in biological samples can be a challenging 
task but can be achieved with different mass detection devices, including 
single quadrupole detectors (QUAD), ion trap technology (TRAP), and 
time-of-flight detectors (TOF), however for this study single quadrupole 
detectors (QUAD) were used. ” 
 
Evaluation of data should be the final step, but extremely important for the 
interpretation. This study involved matching chromatographic retention times and 
mass-spectral fragmentation patterns to identify the metabolites present in the samples 
(the NIST library, an in-house library and pure standards were used). 
This chapter aims to simplify the assessment of metabolites in infant plasma (both 
control and diseased samples). Firstly, method developments were essential and 
primarily the use of different solvent mixtures for protein precipitation and extraction 
Chapter 3 – Application of fast derivatization methods with GC/MS for the analysis of 
infant plasma for inborn errors of metabolism 
 
 ~123~ 
was investigated, followed by chemical derivatization. The microwave-assisted 
derivatization technique was optimised for rapid GC/qMS analysis of metabolites in 
infant plasma samples, with the aim being to improve on the method currently 
employed at the Royal Children’s Hospital that employs conventional heating for 70 
min. Over the past 5 years several improvements have been described to shorten the 
duration of heat treatment and increased the efficiency of the chemical derivatization 
reaction [187, 188]. The most recent was microwave-assisted (MA) [187] or 
microwave accelerated derivatization (MAD) [186] that uses domestic microwave 
oven instead of a conventional derivatization method (e.g. heating block or oven) 
which successfully accelerated the derivatization step by decreasing the overall time 
of heating treatment down to 3 mins.  
Literature also provides various efficient methods for the analysis of IEMs [203-206], 
however the greatest disadvantage is that most studies conducted report one method 
for one disorder. As previously mentioned, for a feasible analysis of IEMs disorders 
three essential requirements must be fulfilled: a completely automated sample 
preparation, the shortest sample preparation time, and computer algorithm for the 
interpretation of profiles [176]. The work presented in this chapter covers all the three 
points and this is the first study to report an optimal method that requires only 90s for 
the derivatization process of samples for ten different IEMs. The method is rapid and 
reproducible for the analysis and identification of metabolites in infant blood plasma 
for IEM analysis and results correlate well with the conventional analysis conducted 
at the Royal Children’s Hospital. 
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3.3. Experimental 
 
3.3.1. Reagents, standards and infant blood plasma samples 
 
The compounds and reagents were all of analytical grade except where stated 
otherwise. Methanol, acetonitrile, ethyl acetate were purchased from Sigma-Aldrich, 
Australia. Anonymous blood plasma samples, (n=25) were provided by the Royal 
Children’s Hospital, Melbourne from a central diagnostic metabolic laboratory 
servicing the states of Victoria and Tasmania. The samples were from infants and 
children with both normal metabolic screening results, and patients with a range of 
IEMs as confirmed by independent testing. Ten control samples were pooled samples 
from healthy laboratory volunteers and 15 samples were from patients with the IEMs 
listed in Table 3-1. Samples were stored at -20°C until analysis and were then allowed 
to thaw at room temperature; repeated freeze thaw cycles were minimized. Twelve 
standards, and an internal standard (1 mmol/L 3, 3-dimethylglutaric acid) were also 
provided by the Royal Children’s Hospital, Melbourne. 
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Table 3-1: List of samples from healthy volunteers and patients with specific IEMs. 
 
Inborn errors (IEMs) Abbreviation No. of 
samples 
long chain acyl CoA hydroxy acyl CoA dehydrogenase, (LCHAD) 3 
 
medium chain acyl CoA dehydrogenase,  (MCAD) 2 
 
carnitine palmitoyl transferase 2 deficiency,  (CPT2) 2 
 
very long chain acyl CoA dehydrogenase, (VLCHAD) 3 
 
propinoic acidaemia, (PA) 2 
 
carnitine palmitoyl transferase 1 deficiency  (CPT1) 2 
 
Ketogenic diet   1 
 
Controls  10 
 Total 25 
 
3.3.2. Preparation of standard solution and extraction solvents 
 
Standard solutions: The 12 fatty acids standards (Table 3-2), were prepared at an 
initial concentration of 1000 µg/mL of each compound listed in. From these separate 
standard solutions, both individual working standards and various mixtures were 
prepared. Primary standard mixtures were prepared containing 50 µg/mL and the 
standard mixture was diluted 5-fold, providing a final concentration of 10 µg/mL. The 
diluted standard mixture (20 µL) was transferred to a GC vial which was dried under 
N2. Once dry, 10 µL of 20,000 µg/mL methoxyamine hydrochloride in pyridine was 
added followed by 80 µL BSTFA + 1% TMCS with 3, 3-dimethylglutaric acid added 
as an internal standard. This mixture was prepared for the final step using microwave 
irridation to heat the mixture. 
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Table 3-2: List of fatty acid standards 
used for the experiment 
 
 
 
 
 
 
 
 
 
 
Sample extraction: Initially the reaction solvent was considered with three different 
solvents being investigated (methanol, acetonitrile, ethyl acetate). Twenty microliters 
of internal standard solution (1 mol/L 3, 3-dimethylglutaric acid) and 1 mol/L 
methoxyamine hydrochloride (Sigma-Aldrich, Australia)) in H2O was added to 200 
µL of collected blood plasma. The sample was subject to vortex for 2 min, and 
following 90 s of microwave derivatization the sample was allowed to cool and 
further saturated with 200 µL of sodium chloride and 50 µL of 6 mol/L hydrochloric 
acid was added. Then the solution was extracted with 2 mL of ethyl acetate on a 
rotary mixer. The upper organic layer was separated by centrifugation for a further 2 
minutes, and then transferred to clean glass tubes containing 10 µL of 25% ammonia 
to minimize evaporative losses of volatile organic acids and dried under N2 at 70°C, 
as demonstrated in Figure 3-2. 
 
Number  Standard name 
1 pentadecanoic acid 
2 mysteric acid 
3 heptadecanoic acid 
4 heptanoic acid 
5 hexanoic acid 
6 capric acid 
7 tridecanoic acid 
8 n-caproic acid 
9 dodecanoic acid 
10 n-octaic acid 
11 nonoic acid 
12 oleic acid 
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Figure 3-2: Metabolomic method for infant blood plasma extraction. 
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3.3.3. Optimization of MAD 
 
Reaction solvent, microwave power and irradiation time can affect the derivatization 
reaction process. The three parameters, microwave power, irradiation time and solvent 
reaction were studied. A standard solution with a concentration of 50 µM for each of 
the 12 fatty acids was used for investigation of the microwave-assisted silylation 
reaction. Overall twelve different conditions were examined for each standard, Table 
3-3. A volume of 50 µL of the standard solution was introduced into a 2 mL GC vial 
and evaporated to dryness under a stream of  N2 at 70°C and  TMS (trimethylsilyl) 
derivatives were formed by adding 100 µL BSTFA (bis 
(trimethylsilyl)trifluoroacetamide) containing 1% TMCS (trimethylchlorosilane) to 
the dried extracts from the liquid extraction. The residue was reacted with BSTFA 
under microwave assisted derivatization (CEM MARS-5, Buckingham, UK) at 
different microwave power (300, 450 and 650W) and different times (30, 60, 90 and 
120 s). After the reaction the solution was then taken for GC analysis. The controlled 
reaction was performed using conventional heating. The standard solution was 
introduced into another vial and after evaporating to dryness with N2, the residue was 
reacted with 80 µL of BSTFA + 1% TMS mixture at 100ºC for 45 min. The mixture 
was then analysed by GC/MS using the same conditions.  
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Table 3-3: Summary of the different conditions used for microwave method 
development for the 12 fatty acid standards. 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4. Gas chromatography/mass spectrometry analysis 
 
A 1-µL aliquot of derivatised sample was injected splitless by an Agilent 7683 Series 
auto sampler (Agilent Technologies, Nunawading, Australia) into an Agilent 6980 GC 
equipped with a30 m x 0.18 mm i.d. fused-silica capillary column chemically bonded 
with 0.25-µmphenyl polysilphenylene-siloxanestationary phase (BPX5-MS, SGE 
International, Ringwood, Australia). The injector temperature was set at 270 °C. 
Helium was used as carrier gas at a constant flow rate of 1 mL min
-1 
through the 
column. For every analysis, the purge time was set to 60 s at a purge flow rate of 20 
mL min
-1
 and an equilibration time of 1 min. The column temperature was initially 
kept at 70 °C for 2 min and then increased from 70 to 320 °C at 30 °C min
-1
, where it 
was held for 2 min. The column effluent was introduced into the ion source of a 
Agilent HP MD5973 quadrupole mass spectrometer (qMS). The transfer line 
temperature was set at 250 °C and ion source temperature at 200 °C. Ions were 
generated by a 70-eV electron beam at a current of 2.0 mA. Mass spectra were 
Standards Microwave power (W) Time (sec) 
X1 300 30 
X1 300 60 
X1 300 90 
X1 300 120 
X1 450 30 
X1 450 60 
X1 450 90 
X1 450 120 
X1 650 30 
X1 650 60 
X1 650 90 
X1 650 120 
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acquired from m/z 50 to 600 at a rate of 30 s
-1
, and the acceleration voltage was turned 
on after a solvent delay of 170 s. 
3.4. Results and discussion 
 
3.4.1. Method optimization (solvent and microwave optimization) 
As mentioned previously, prior to GC/MS analysis derivatization is required. To show 
the influence of the choice of the silylating agent and solvent effects, pentadecanoic 
acid and oleic acid were chosen as a model to demonstrate the effect. Analysis of the 
reactions performed in the silylating agents is shown in Figure 3-3. The intensity of 
the peak depended greatly on the solvent mixture that was used. Based on the solvents 
chosen to perform the analysis it is evident (Figure 3-3) that ethyl acetate (EAT) gave 
the largest peak areas and had the most complete reactions, acetonitrile (ACN) also 
showed a higher response compared to methanol (MeOH) which had the lowest peak 
area. Thus EAT was the ultimate choice for the extraction of fatty acids in plasma. 
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Figure 3-3: Relative mean peak area responses for oleic acid and pentadecanoic acid 
of the different solvents used. 
 
With the aim being to report the shortest silylation method and most efficient 
microwave power and irridation time was also studied. Conventional derivatization 
uses heat which is transferred from the vessel wall to the reactants, whereas in 
microwave-assisted derivatization the energy is directly distributed evenly to the 
solvent and the sample by microwave heating.  
According to the conventional method employed by the Royal Children’s Hospital, 
120 °C for 2 h was required to achieve complete silylation, compared to 450 W for 90 
s for microwave derivatization method optimised in this chapter. More than 10 
samples were placed simultaneously in the microwave for derivatization and the 
derivatised samples were stable for about two weeks at 4 °C.  After derivatization the 
metabolite extracts were analysed by GC/MS using the same conditions as mentioned 
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previously. In this study, a controlled derivatization method was performed by using 
conventional heating. To show the effect of microwave power and irridation time six 
standards were chosen. Figure 3-4, shows the average peak areas of each fatty acid 
standard under different conditions. As it is observed from Figure 3-4 the peak area of 
each fatty acid derivatives at different microwave power with the same irradiation 
time of 90 s were close to those by conventional heating. Based on the results 
described above, a reaction solvent ethyl acetate, a microwave power of 450W and 
irridation time 90 s were selected as the optimal reaction conditions. 
Figure 3-4: The effect of micro-wave power and irridation time on the yields of fatty 
acid silylation. 
 
Figure 3-4 shows the response (peak area) of each standard to microwave parameters 
settings. We observed that dodecanoic acid had the lowest response followed by 
pentadecanoic acid. Also mysteric acid had the highest response followed by 
tridecanoic acid, whereas heptanoic and oleic acid had a similar response overall. The 
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analysis for these standards is important for this study as they are all possible 
metabolites present in the infant plasma. As per literature [189-191], analysis of fatty 
acids in plasma seems to be a valuable examination in order to assess the fatty acids in 
IEMs, thus being able to extract and identify particular fatty acids could lead to a 
possible biomarker(s) discovery in IEMs. In addition, it was also possible to observe 
the metabolites which had the lowest response (completion of reaction) when 
microwave derivatization was performed. 
 
Comparing the thirteen different microwave conditions for the response of the fatty 
acids shows that time and irradiation power has somehow a negligible effect on the 
response of each fatty acids. Results demonstrate that 450 W with 90 sec microwave-
heating, has the highest peak area response (about 32,000 pA), 650 W 120 s has the 
least variable peak area response. The results obtained are fairly close thus indicating 
that that there is not a great difference between the responses obtained for each 
standard which is expected as all the standards investigated were from the same 
chemical class (fatty acids). If the analysis was performed on different metabolite 
classes, perhaps more variation would have been observed. In Table 3-4, the response 
column clearly shows that 90 s at 450 W gives the greatest response (8.3), and the 
closest to the conventional heating reference method (RCH) which was calculated to 
be 8.1 – furthermore the analysis confirmed that overall 90 s resulted in the highest 
completion of reaction for each standard, thus indicating the optimal time for 
complete derivatisation. 
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Table 3-4: Frequency table, showing the effect of different microwave parameters 
settings on fatty acid standards. 
Micro-wave conditions 
(Watts and seconds) Total Area Response 
300 W 30s 139804 7.3 
300 W 60s 145371 7.6 
300 W 90s 151245 7.9 
300 W 120s 144365 7.6 
450 W 120s 144489 7.6 
450 W 30s 146401 7.7 
450 W 60s 150319 7.9 
450 W 90s 159489 8.3 
650 W 120s 140274 7.3 
650 W 30s 141614 7.4 
650 W 60s 143541 7.5 
650 W 90s 148613 7.8 
Conventional 154916 8.1 
Total 1910441 100 
 
3.4.2. Method validation 
 
The obtained optimum MAD conditions were used for method validation. The linear 
range of the proposed method was studied by determining calibration curves in the 
concentration range of interest. The line of best fit between peak area and fatty acid 
contraction was determined by linear regression Table 3-5. 
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Table 3-5: Detection limits, precision and recoveries 
 
Fatty acid R2 Precision (%) Det. Limit (µg/mL) Recovery (%) 
Oleic acid 0.996 3.85 1.23 93 
Heptanoic acid 0.993 4.65 0.78 96 
Pentadecanoic acid 0.992 9.32 2.86 98 
Tridecanoic acid 0.993 10.49 1.89 97 
Mystiric acid 0.994 7.65 1.14 92 
Dodecanoic acid 0.998 5.35 2.42 95 
 
The linear range for each fatty acid was 10-1000 µg/mL (R
2
>0.98) Furthermore, 
detection limits were determined by replicate analyses of 30 µL aliquots of the 
calibration solution at the lowest concentration (10 µg/mL), the detection limits were 
calculated on the basis of a signal-to-noise (S/N) ratio of 3 and as can be seen from 
the table the detection limit for the fatty acids ranges from 0.78-2.86 µg/mL. Precision 
is another important factor when conducting experiments and therefore for this study 
precision was measured via 3 replicate analyses and was expressed in RSDs, with 
values obtained ranging from 3.85-10.49% (Table 3-5). In conclusion, the method 
developed has good precision, detection limits and recovery, and can therefore be 
used confidently for analysis of IEMs in infant plasma. 
3.4.3. Qualitative analysis of normal and disease blood plasma 
sample. 
Samples from fifteen patients with IEMs, ten without evident metabolic abnormalities 
(‘normal’ samples) and a control sample (pooled sample) were analysed using a 
‘conventional’ 30m BPX5 (phenyl polysilphenylene-siloxane) capillary column. The 
ten normal samples were analysed in order to establish an approximate range of what 
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could be referred to as ‘normal’ metabolite levels in infant plasma. Samples from 
patients with the following IEMs were analysed: medium chain acyl CoA 
dehydrogenase, (MCAD, OMIN 201450), very long chain acyl CoA dehydrogenase, 
(VLCADD, OMIN 201475), long chain acyl CoA hydroxyl acyl CoA dehydrogenase, 
(LCHAD, OMIN 201485), carnitine palmitoyl transferase 2 deficiency, (CPT2), 
propinoic acidaemia, ketogenic diet, carnitine palmitoyl transferase 1 deficiency 
(CPT1), carnitine uptake defect. The OMIN numbers indicate the “Online Mendelian 
Inheritance in Men” database indices (http://ncbi.nlm.nih.gov/omin/) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: Total ion chromatogram of a plasma sample from a ‘normal’ patient 
without any evident deficiency: 1-propanoic acid; 2-internal standard (3, 3-
dimethylglutaric acid) 3-nonanoic acid; 4-dodecanoic acid; 5-glycine; 6-isoleucine; 7-
urate; 8-cystine; 9-tertradecenoic acid; 10-tetradecanoic acid; 11-octadecadienoic 
acid; 12-octadecenoic acid;13-octadecanoic acid; 14-arachidic; 15- cholesterol; 
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The analysis of normal infant plasma illustrated a broad range of metabolites, at 
varying concentration levels, which correlated well with metabolites observed at the 
HMDB (human metabolome database – www.hmdb.ca). Several key metabolites 
(previously well-known biomarkers) were found and compared with the metabolites 
present in the plasma samples with inborn error deficiencies. However, the peak area 
ratios (metabolite of interest/internal standard) of certain metabolites were 
significantly higher in the diseased samples (as expected) compared to the normal 
samples. Figure 3-5 demonstrates some of the metabolites identified. More than thirty 
metabolites were identified in the control with fifteen illustrated in Figure 3-5; also 
isomers of C18 were separated and identified through the analysis (however some 
peaks overlapped and appeared to be at very low concentration levels) thus indicating 
that a more sensitive instrumental platform could be used (i.e. 2DGC). Figure 3-6, 
illustrates the total ion chromatogram (TIC) of a plasma sample from a patient with 
long chain acyl CoA hydroxy acyl CoA dehydrogenase, (LCHAD).  
Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency is a rare 
condition that prevents the body from converting certain fats to energy, particularly 
during periods without food. Signs and symptoms of LCHAD deficiency usually 
appear during infancy or early childhood and can include feeding difficulties, lack of 
energy (lethargy), low blood sugar (hypoglycemia), weak muscle tone (hypotonia), 
liver problems, and abnormalities in the light-sensitive tissue at the back of the eye 
(retina). Samples from patients with this disorder were found to have an increase in 
the 3-hydroxyfatty acids, a significant increase mainly in myristoleic acid (C14:1), 
moderate increase C18, Figure 3-6.  
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Furthermore infant plasma diagnosed with CPTI and CPTII showed a consistent 
pattern with an increase in most fatty acids, in particular the long chain fatty acids, 
Figure 3-7. 
Propinoic acidemia was another deficiency investigated, which has been reported as a 
disorder that is inherited from both parents. Figure 3-8 illustrates the specific 
metabolites identified that could be of potential biomarkers discovery for this 
deficiency. In this case increases in odd chains fatty acid were identified (C15 and 
C17), therefore it was hypothesised that the increase in the fatty acid was correlated 
with the disorder, this hypothesis was also reinforced from other reported studies, 
where the increase in odd chain fatty acids are associated with propinoic acidemia . 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6: Total ion chromatogram of a plasma sample from a patient with very long 
chain acyl CoA hydroxy acyl CoA dehydrogenase, (LCHAD) illustrating C14:0 and 
C16:0 and C16:1. 
 
 
C14:1 
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Figure 3-7: Total ion chromatogram of plasma sample from a patient with propinoic 
academia. 
 
 
 
 
Figure 3-8: Total ion chromatogram of a plasma sample from a patient with propionic 
acid. 
 IS  
 IS  
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Figure 3-9: Total ion chromatogram of a plasma sample from a patient with medium 
chain acyl CoA dehydrogenase deficiency. 
 
The Royal Children’s Hospital uses specific fold changes (1-3, 3-10 and over 10 fold 
increases) in marker metabolites to confirm specific deficiencies, and therefore semi-
quantitative data (peak area ratio comparisons and fold changes) is sufficient. Hence, 
in order to apply an objective basis to the semi-quantitative data analysis, peak areas 
of the total ion chromatograms were expressed as a percentage of the total area.  A 
greater than 10-fold component concentration increase was classified as ‘highly 
significant’ increase, a 3-to 10-fold component concentration increase was considered 
as ‘moderately significant’ increase and up to 3-fold component concentration 
increase was regarded as a ‘slightly significant’ increase. Furthermore, relative peak 
area ratios using the extracted ion chromatogram (EIC) were measured on the basis of 
the increased metabolite that was found in each specific sample, and were evaluated 
IS 
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in accordance to the relative area ratios obtained from the blood plasma control 
sample. Fiehn and co-workers [192] illustrated that the major component in plasma is 
glucose, sometimes called ‘blood sugar’ as it is regulated in humans around a 
concentration of 5mM to provide energy to all organs - most notably to the brain.  
As mentioned in this study other abundant metabolites expected are free cholesterol, 
saturated free fatty acids and a range of amino acids (particularly alanine) with 
changes in these metabolites being of importance to human metabolomics as it can 
result in early detection of specific IEMs. In this study the extent of change in the 
metabolite components was calculated based on a cut-off level which was determined 
for the blood plasma control. Figure 3-10 demonstrates some of the metabolites 
identified in the control plasma. 
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Figure 3-10: Total ion chromatogram of the control plasma (pooled) sample : 1-
propanoic acid; 2-internal standard (3, 3-dimethylglutaric acid) 3-nonanoic acid; 4-
dodecanoic acid; 5-glycine; 6-isoleucine; 7-urate; 8-cystine; 9-tertradecenoic acid; 
10-tetradecanoic acid; 11-octadecadienoic acid; 12-octadecenoic acid;13-
octadecanoic acid; 14-arachidic; 15- cholesterol; 
 
Identification of metabolites was investigated using PBM Quick search in Agilent’s 
ChemStation, where specific ions were used to obtain mass spectra and metabolite 
identification. As an example cholesterol was the chosen peak, Figure 3-11.  
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Figure 3-11: Upper panel: Identification of cholesterol using PBM Quick search in 
Agilent’s ChemStation. Lower panel: Identification of cholesterol using NIST Library 
for reinforcement. 
Considering that the identification method for some disorders has been discussed in 
detail above, we move on to the more imperative part of the study where the increased 
concentrations of metabolites in plasma are investigated and discussed. Table 3-6 
summarises the results for individual samples aiming to provide information on the 
expected metabolic abnormalities in the plasma through GC/MS analysis. 
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Table 3-6: Diseased samples with examples of increased metabolite component 
indicative of a specific IEM. 
 
 
Results from GC/MS analysis illustrate that samples from patients with VLCAD 
appeared to have a highly significant level of increase in the long chain in fatty acids , 
moderately significant increase in C18:1 and highly significant increase C16:0, this 
measurement correlates well with the previous studies conducted where patients with 
VLCAD have been investigated and similar metabolites have been reported to be 
present, however, it is important to note that these metabolites have not been tagged 
as only specific to this VLCAD deficiency thus can be found in other IEMs.  In 
patients with MCAD, medium chain fatty acids (C10:1 and C8), moderate significant 
increase in (C10:0) and no detection of slightly significant increase was observed. 
However, studies conducted at the Royal Childrens hospital have identified hexanoyl 
glucine as the main marker for MCAD whereas fumaric and succinic acid do not seem 
DISEASED 
SAMPLE 
HIGHLY SIGNIFICANT 
INCREASE (>10FOLD) 
MODERATELY 
SIGNIFICANT 
INCREASE (3-10 FOLD) 
SLIGHTLY 
SIGNIFICANT 
INCREASE (1-3 
FOLD) 
 
VLCAD 
 
Long chain FA (C16:0,) 
 
Long chain fatty acids 
C18:1 
 
 
 
LCHAD 
 
3OHAs (C14:0 and C16:0) 
 
long chain fatty acids 
(C14:1) 
 
Medium chain fatty 
acids (C10:0) 
 
MCAD 
 
Medium chain fatty acids 
(C10:1 and C8) 
 
Medium chain fatty acid 
(C10:0) 
 
 
Propionic 
acidaemia 
 
Odd chain fatty acid C13 
 
Odd chain fatty acid C15 
 
 
CPT1 
 
Long chain fatty acids C16 
  
Long chain fatty acids 
C18:1 
 
CPT2 
 
Long chain fatty acids C16 
  
Long chain fatty acids 
C18:2 
Chapter 3 – Application of fast derivatization methods with GC/MS for the analysis of 
infant plasma for inborn errors of metabolism 
 
 ~145~ 
to be associated with IEMs, however these two metabolites are still used as markers 
for MCAD through urine analysis. In this work, 1-monolinoleoylglycerol was not 
detected using GC/MS. This will be discussed further in Chapter 4, where a more 
powerful separation technique (GCxGC/ToFMS) was used for the analysis of blood 
plasma with the focus being on the analysis of fatty acids. 
LCHAD has been reported as a fatty acid oxidation disorder (together with MCAD) 
and although the increased dicarboxylic acids identified in urine analysis are 
consistent with the disorder to my knowledge it has not yet been reported as 
diagnostic. Therefore plasma analysis would be a more accurate way to determine 
patients affected with the deficiency. In this research patients with LCHAD had 
significant increase in 3-hydroxyfatty acids, where moderate increase in (C14:1) and 
slightly significant increase in the medium chain fatty acids C10:0. The findings 
discovered correlate well with previous studies conducted and can be very beneficial 
to the metabolomics field. Some of the metabolites discovered were diagnostic (as 
confirmed by the Royal Children’s Hospital but in some circumstances the change in 
concentration of a particular component were referred to as abnormal but regarded as 
less specific (PA, VLCADD).  
 
In metabolic fingerprinting PCA is usually employed for visualizing the trends of 
samples. In this study, PCA was employed to examine the clustering of samples for 
difference between the samples. Figure 3-12 shows the score plot (PC1 vs PC2) of the 
infant plasma. As shown in the figure although the first two PCs can explain up to 
75% of the total variance of the data, the samples scattered into each other, thus 
indicating that the unsupervised method of PCA cannot separate the groups 
satisfactorily, this can be expected as there were only 15 diseased samples (different 
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diseases) and generally more samples from the same background are required for 
PCA analysis to be able to show any cluster. The first two PCs showed some degree 
of separation between the disease and the control plasma samples. The control 
samples were clustered more closely in the middle with the diseased samples more 
scattered.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12: PCA score plot (PC1 versus PC2) of plasma samples from normal and 
specific IEMs samples. 
 
In the score plot three diseased samples seem to be the furthest from the centre, (in 
this case the samples with VLCAD) have been circled. This was an interesting 
observation considering that the three disease samples were from the same 
background disease the so called fatty acid deficiency and were all found to contain 
higher levels fatty acids (C14-C18), these findings correlates well with the GC/MS 
analysis and were the only samples to show an increase in 3OHFAs. 
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3.5. Conclusion 
 
In the analysis of IEMs, the greatest disadvantage appears to be the previously 
discussed one method for one disorder analysis [176]. This study demonstrates the 
analysis of 15 different IEMs cases with the same method and using a fast 90 s 
derivatization time. Blood plasma contains several thousand compounds, and the 
number can vary with diet, physical activity (exercise), genetic background and 
environmental factors. Estimation of the concentration of compounds with high 
accuracy and reproducibility requires elevated extraction efficiency.  
This study reports a method that is rapid, reproducible and results in low detection 
limits when combined with GC/MS. Overall, previously known marker metabolites 
were found which correlated well with a specific disorders present in the plasma. The 
main advantage of the method developed in this work is that it required a much 
shorter derivatization time (90 s) in comparison to the Royal Children’s Hospital 
which requires a derivatization time of 70 mins. 
 
  
 
 
 
 
 
4.1. Abstract 
 
Detection of abnormal metabolites in plasma is important for the diagnosis of many 
inborn errors of metabolism (IEM), which are commonly diagnosed by GC/MS 
analysis after extraction and trimethylsilylation [102]. For metabolic profiling of 
biologically-based samples, which contain many different classes of chemically-
diverse compounds, sensitive and rapid comprehensive analytical methods are 
required. In this study, a new strategy using two-dimensional gas chromatography 
CHAPTER 4  
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(GCxGC) with time-of-flight mass spectrometry (ToFMS) was developed. Multiple of 
median analysis (MoM) analysis was used to explore the disturbance of fatty acid 
metabolic patterns and possible biomarker discovery for different IEMs. Abnormal 
profiles were obtained from all the infant plasma samples with IEMs. Long-chain 3-
hydroxyacyl-CoA (LCHAD) and medium-chain acyl-CoA (MCAD) deficiencies gave 
diagnostic profiles while very-long-chain acyl-CoA dehydrogenase (VLCAD), 
propionic acidaemia and carnitine uptake gave profiles with significant increase in 
various fatty acids. In particularly propionic acidaemia showed increases in the odd 
fatty acid in particular C15 and C17, whereas VLCAD confirmed increased levels in 
most fatty acids. The superior resolving power of GCxGC with ToFMS detection was 
useful in separating isomeric fatty acids that were not resolved using one-dimensional 
GC. A novel metabolite, 1-monolinoleoylglycerol, was also discovered in carmitine 
palmitoyl transferase 2 deficiency sample which may be a useful specific diagnostic 
marker for this disorder. Overall the results showed that this selective and sensitive 
method is a powerful tool in the diagnosis of fatty acid disorders in infant plasma. 
This method might be a complement or an alternative to pathogenesis and 
pharmacodynamics research concerned with IEMs and other human metabolic 
profiling.  
4.2. Introduction 
 
Analysis of fatty acid composition in different blood plasma seems to be valuable to 
assess the fatty acid status in human in terms of biomarker discovery [193]. In recent 
years, a growing number of genetically distinct inborn errors of mitchochonrial fatty 
acid β-oxidation have been described [194]. The analysis of plasma free fatty acids 
and their 3-hydroxyfatty acid diagnosis analogs have been reported as an approach for 
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the diagnosis of fatty acid oxidtaion disorders [195, 196]. Additionally, defects of 
fatty acid β-oxidation have been recognized as theoretically dangerous inborn errors 
of metabolism therefore method development is a priority for many researchers.  To 
date, the most frequent of the β-oxidation defects is medium –chain acyl-CoA 
dehydrogenase (MCAD) deficiency, others include VLCAD, LCAD and SCAD. 
MCAD is an autosomal disorder of fatty acid oxidation, affecting between 1 in 10, 
000 to 27, 000 babies of northern European decent [197]. MCAD results in reduced 
ability to break down fatty acids to meet demands during periods of metabolic stress. 
Typically deficiency in the activity of medium-chain acyl-CoA dehydrogenase 
(MCAD) presents with a Reye-like syndrome, mild hypoglycemia, or sudden death 
[198]. It has been reported that up to a quarter of previously undiagnosed children die 
during their initial critical period, with a further 16 % surviving with a severe 
neurological disability [198].  
 
Similarly to MCAD, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and 
very long-chain 3-hydroxyacyl-CoA dehydrogenase have also been reported as 
condition that prevents the body from converting certain fats to energy, particularly 
during periods without food (fasting).Signs and symptoms typically appear during 
infancy or early childhood and can include feeding difficulties, lack of energy 
(lethargy), low blood sugar (hypoglycemia), weak muscle tone (hypotonia), liver 
problems, and abnormalities in the light-sensitive tissue at the back of the eye (retina). 
Later in childhood, people with these conditions may experience muscle pain, 
breakdown of muscle tissue, and a loss of sensation in their arms and legs (peripheral 
neuropathy). Individuals with LCHAD deficiency are also at risk of serious heart 
problems, breathing difficulties, coma, and sudden death. 
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As discussed previously, the detection of abnormal metabolites in plasma is important 
for the diagnosis of many IEMs. The provision of reliable, functional biochemical 
tests for IEMs will remain an important aspect for many laboratories (genetic) for the 
foreseeable future, despite impressive advances in the ability to test for these 
conditions at the gene level [199].Currently, two complementary approaches are used 
in metabolomics: metabolic profiling and metabolic fingerprinting [200]. Metabolic 
profiling focuses on the analysis of a group of metabolites either related to a specific 
metabolic pathway or a class of compounds. The quantitative analysis of fatty acids as 
fatty acid methyl esters by GC-FID (flame ionization detection) or the analysis of 
amino acids are examples for metabolic profiling. An even more directed approach is 
target analysis that aims at the measurement of selected analytes, such as biomarkers 
of disease or toxicant exposure, or substrates and products of enzymatic reactions [1].  
 
“Metabolic profiling is a hypothesis-driven approach rather than a hypothesis-
generating one” [8]. Depending on the questions asked, metabolites are selected for 
analysis and specific analytical methods are developed for their determination. The 
remarkable technology advances over the past few years allow a constant expansion 
of the number of analytes that are quantified simultaneously in a single analysis. 
Technologically, the analysis of single biomarker is often as complex as profiling all 
related key metabolites in a given biochemical pathway. The results of metabolic 
profiling are quantitative and dependent on the analytical techniques therefore the 
choice of techniques requires careful consideration. The use of a gas 
chromatography–mass spectrometry (GC/MS) procedure in the selected ion 
monitoring mode at m/z 233, a common ion of all bis-trimethylsilylated 3OHFAs, has 
been proposed by Hagenfeldt et al.[196]. The problem with the reported method was 
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the co-elution of some 3OHFAs commonly found FFAs [195], which are in 
concentrations 3–100 times higher, can interfere with the fragmentation of target 
compounds and thus create serious problems for an accurate quantitation.  
The biological specimens used in human metabolomic studies are e.g. urine [54], 
blood plasma [201], and saliva [202]. Overall (not only IEMs) all of them can play an 
important role in the diagnostic processes of problem illnesses. As concerns the 
analytical techniques applied in metabololmics, chromatographic techniques coupled 
to mass spectrometry play an important role. For the analysis of organic acids, amino 
acids, and sugars gas chromatography-mass spectrometry (GC/MS) after 
derivatization is widely applied. Biological materials represent a very complex matrix 
classical and although one-dimensional GC/MS offers significant chromatographic 
resolution, peak overlapping is inevitable due to the large number of extracellular 
metabolites. Poor chromatographic separation may result in incorrect biomarker 
identification, inaccurate estimation of metabolite concentrations, and poor predictive 
chemometric models.  
 
Comprehensive two-dimensional gas chromatography time-of-flight mass 
spectrometry (GC×GC-TOFMS) is a maturing technique noted for its ability to 
analyze complex mixtures and has been successfully applied in metabolomics [203-
205]. GC×GC/TOFMS is superior in terms of chromatographic peak resolution 
(separation power) when compared to conventional 1D gas chromatographic 
techniques [148, 168, 206]. In a GC×GC system, analytes eluting from the first 
column, over a defined time window, are focused and released (via a process termed 
modulation) onto a second column where further separation is achieved. Typically, a 
non-polar column is selected as the first column and relatively polar column as the 
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second column [148]. This configuration achieves orthogonality of retention on the 
two different phase columns, allowing much more complete separation of metabolites 
in complex matrices. Additionally, the fast spectral acquisition rate (up to 500 Hz) 
using TOFMS enables deconvolution of the mass spectra of closely eluting peaks if 
the spectra are sufficiently distinct. The ability to deconvolute the mass spectra 
robustly and accurately is paramount in the analysis of moderately complex samples 
in metabolic footprinting. The principles and instrumentation of comprehensive two-
dimensional gas chromatography have been reviewed in detail in several papers 
previously by Cortes et al. and Marriott et al. [207, 208]. In this respect, 
comprehensive two-dimensional gas chromatography (GC×GC) brings significant 
benefits and its coupling with time-of-flight mass spectrometry (GC×GC/TOFMS) 
has become an emerging technique in metabolomics field [209].Since its introduction 
in 1991 [104], the GC×GC technique has gone through the years of rapid 
development. Today, GC×GC is widely used in many diverse areas which cover an 
interesting variety of applications. In general, the usage possibilities of GC×GC can 
be divided into three areas – fingerprints of very complex matrices, target analyses, 
and identification of unknown compounds. An excellent review on GC×GC basics 
and applications was written by Adahchour et al. who outline the use of the technique 
from its introduction in following fields – petrochemical products, environmental 
studies (soils and sediments, airs and aerosols, cigarette smoke), organohalogen 
compounds, food analysis (fats and oils, essential oils, alcoholic beverages), through 
to biologically-based samples [210]. 
 
Recently, significant progress is observed in the biosciences applications. In the field 
of human metabolomics, we see applications in e.g. metabolomic profiling of infant 
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urine [211, 212] biomarker discovery of diabetes mellitus [203], defining the 
“metabolome” of psychical disorders like schizophrenia [213], accelerating analysis 
for metabolites, drugs and their metabolites in biological samples [102], analyses of 
tumorogenic cells [214], identification of anabolic agents in doping control [215], or 
enatioselective analyses [216].Although various research has been conducted for the 
analysis of fatty acid analysis concerning IEMs, the majority of the reported studies 
involve the use of GC/MS analysis. As mentioned previously, as an alternative 
GCxGC  is recognised as a method that can provide a very high separation power, as 
well as enhancement of sensitivity and structured chromatograms [208] and therefore 
is further explored in this chapter.  
GCxGC is a multidimensional technique in which the resolving power of two or more 
different columns is applied to some or all of the components in a sample. It basically 
increases peak capacity for complex separation involved in a particular sample by 
exposing the entire chromatogram to an orthogonal separation technique and 
generally various advantages are associated with this technique including: 
 Complex samples can be separated into many distinct peaks (providing an                 
alternative for group-type analyses) 
 Superior resolution when compared to one-dimensional GC 
 Boling-point/polarity distributions for various classes of analytes concurrently. 
 
The second dimension of chromatographic resolution in 2DGC is added by the use of 
two unique stationary phases, which include polar and non-polar within a single 
analysis.  Basically 2DGC involves the separation of a sample to firstly be separated 
on a high-resolution capillary GC column in the programmed temperature mode. 
Secondly, effluent is focused in narrow fractions at regular, short intervals and 
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injected onto a second short narrow capillary GC column that results in faster 
separation. Analytes are able to elute from the first column at different temperatures 
of the oven, though with co-eluting compounds having similar volatilities at the time 
of elution. The second dimension separation is obtained by the activity coefficient 
differences of the solutes on the more polar phase. Compounds belonging to the same 
chemical assembly will have similar activity coefficients and demonstrate similar 
second dimension retention times, thus resulting in clusters in contour plots at a 
similar second dimension retention time (
2
tR) horizon.Although the separation of 
compounds is improved as compared to one dimension GC, it should be noted that the 
GC×GC separation space still contains a large number of overlapping peaks. While 
current commercially available software such as ChromaTOF (LECO Inc., USA) can 
perform complex peak detection and spectral deconvolution, several other approaches 
are also being investigated for processing of data generated by GC×GC/TOFMS in 
metabolomic studies [149]. Certainly, the GC×GC/TOFMS technology illustrates 
great promise in the global metabolic profiling of biofluids in the near future.The 
main advantage of a TOFMS over other GCxGC detectors is its ability to aid in the 
identification of a large number of compounds in very complex samples.  
In this work, demonstration of GCxGC with ToFMS detection as a diagnostic tool for 
the evaluation of fatty acids from patients with inborn errors of metabolism is 
investigated, followed by qualitative and quantitative aspects for the diagnosis of 
possible biomarkers associated with specific IEMs. 
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4.3.  Experimental 
 
4.3.1. Chemicals 
 
 
All of the fatty acids standards, decanoic acid (C10:0), lauric acid (C12:0), myristic acid 
(C14:0), palmitic acid (C16:0), palmitoleic acid (C16:1n-9), stearic acid (C18:0), oleic acid 
(C18:1n-9), petroleic acid (C18:1n-11), linoleic acid (C18:2), arachidonic acid (C20:4), 
eicosapentaenoic acid (C20:5), eicosatrienoic acid (C20:3), eicosadienoic acid (C20:2), 
arachidic acid (C20:0), docosahexaenoic acid (C22:6) and monostearin were purchased 
from Sigma Aldrich, Castle Hill, Australia; all standards purity was above 99.5% 
(v/v) H2SO4/CH3OH was freshly prepared by diluting H2SO4 (>98% purity) with 
chromatographic grade CH3OH; 0.4M KOH/CH3OH was freshly prepared by 
dissolving reagent grade KOH in CH3OH. Ultra-pure water was prepared using a 
Milli-Q system (Millipore, Milford, MA). All other reagents and solvents were of 
analytical grade and obtained from RMIT University, Melbourne Australia. 
4.3.2. Infant plasma samples 
 
In this study 25 infant plasma samples from 15 patients with various fatty acid defects 
were analysed. Three plasma samples with long-chain 3-hydroxyacyl-CoA 
dehydrogenase (LCHAD) deficiency, three samples with medium-chain acyl-CoA 
dehydrogenase (MCAD), three samples with very-long-chain acyl-CoA 
dehydrogenase (VLCHAD), and also four samples had a defect in the so-called 
carnitine cycle, two at one step involving CPTI and the other two CPTII. Finally two 
patients had propionic acidaemia.  
The ten control samples were selected paediatric patients whose age ranged from a 
few days to 5 years. None of the controls received a special diet.  
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Twenty microliters of internal standard solution (1 mol/L 3, 3-dimethylglutaric acid 
(Royal Children’s Hospital, Melbourne ) and 1 mol/L methoxyamine hydrochloride 
(Sigma-Aldrich, Australia)) in H2O was added to 200 µL of diluted blood plasma. The 
sample was allowed to vortex for 2 mins and saturated with 200 µL sodium chloride, 
50 µL of 6 mol/L hydrochloric acid was added and then the solution was extracted 
with 2 mL of ethyl acetate on a rotary mixer. The upper organic layer was separated 
by centrifugation for a further 2 mins, and then transferred to clean glass tubes 
containing 10 µL of 25% ammonia for minimizing evaporative losses of volatile 
organic acids and dried down under N2 at 70°C. 
 
4.3.3. Derivatization of fatty acids and calibration 
 
Stock solutions for each standard were prepared at a concentration of 1–1000 g/mL 
in CH3OH and stored at −20 ◦C. The blending standard solutions, which were 
prepared freshly, contained 15 free fatty acids (FAs): C10:0, C12:0, C14:0, C16:1n-9, C16:0, 
C18:2,C18:1n-9, C18:1n-11, C18:0, C20:4, C20:5, C20:3, C20:2, C20:0 and C22:6. Different 
concentrations of the mixed standard solution were dried under a mild stream of N2 
and solubilized with 500 µL of H2SO4/CH3OH (5%, v/v). The vials were then sealed 
and allowed to vortex for 2 min. Extraction was conducted by adding 500 µLn-
hexane. Upper layers containing FAs TMS derivatives were removed to new vials for 
injection. Linear regression curves were constructed by plotting peak areas versus 
concentration in µgmL
−1
. The regression equations were calculated and all curves had 
high correlation coefficients (r > 0.998). External calibration was used for quantitative 
analysis. Calibration curves were obtained from plots of peak areas versus calibration 
standard concentrations. The FA concentrations in samples were determined using 
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linear regression equations obtained from the calibration curves. Next as discussed 
previously in Chapter 2, the two parameters of microwave power and irradiation time 
were studied.  
 
A standard solution with a concentration of 200 µM for each fatty acid was used for 
investigation of the microwave-assisted silylation reaction. A volume of 35 µM of N2 
standard solution was introduced into a 2 mL GC vial and evaporated to dryness 
under a stream of  N2 at 70°C and  TMS (trimethylsilyl) derivatives were formed by 
adding 100 µL BSTFA (bis-(trimethylsilyl)trifluoroacetamide) containing 1% TMCS 
(trimethylchlorosilane) to the dried extracts from the liquid extraction. Microwave 
assisted derivatization (CEM MARS-5, Buckingham, UK) was applied at 400 W for 
60 s, followed by the addition of iso-octane. This solution was then taken for GC 
analysis. 
 
4.3.4. GCxGC/ToFMS analysis 
The analysis of the 25 different blood samples was performed using an Agilent model 
6890 GC system (Agilent Technologies, Nunawading, Australia) equipped with a 
LECO Pegasus III (LECO Corporation, St Josephs, MI) ToFMS system, operated in 
GCxGC mode. The column used in 
1
D was a 30 m BPX 5 (5% phenyl 
polysilphenylene-siloxane) capillary column (SGE International) with an internal 
diameter of 250 µm and 0.25 µm df. The 
2
D column was a 1.0 m BPX 50 (50% 
phenyl, 50% dimethylpolysilphenylene-siloxane) capillary column (SGE 
International) with an internal diameter of 100 µm and 0.1 µm df.   
 
Chapter 4 – Evaluation of GCxGC/ToFMS for the diagnosis of pathological 
metabolites in infant plasma 
 
 ~159~ 
All injections were completed in splitless mode with 1 min vent open including 1 µL 
injected volume, and an oven ramp beginning at 70 ºC with a hold of 2 mins, 
increased at 3 ºC/min to 300 ºC with a hold time of 5 mins. Helium gas was used at a 
flow volume of 1 mL/min. The transfer line was held at 320 ºC. Mass spectra were 
collected from 45-650 m/z (acquisition rate 100 Hz). The modulator used was a 
longitudinal modulated cryogenic system (LMCS) (Chromatography Concepts, 
Doncaster, Australia), with the modulation temperature kept at 0 ºC and a modulation 
period of 4 s was applied throughout the duration of the analyses. Mass spectra were 
acquired from 50 to 650 m/z. In this case the ToFMS detector was turned off until the 
TMS by-products were eluted from the column, as they are usually present in very 
high concentrations and can therefore lead to saturation of the ToFMS detector. Data 
acquisition and analyses were conducted by ChromaTOF software (LECO Corp., St 
Joseph, MI, USA). Specific quantification ions were used to quantify key metabolites 
using eight different metabolite fatty acid standards in order to provide calibration 
curves ranging 500 to 12.5 µmol/L. Repeatability and reproducibility of second 
dimension retention times were also calculated for the fatty acid analysis in plasma. 
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4.4. Results and discussions 
 
Samples from fifteen patients with IEMs, and ten plasma controls were analysed using 
the preferred polar/nonpolar column set (BPX5-BPX50). The ten ‘normal’ samples 
without any evident metabolic abnormalities were analysed in order to establish an 
approximate range of what could refer to as ‘normal’ metabolite levels in infant 
plasma. Samples from patients with the following IEMs were analysed, three plasma 
samples with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, 
two samples with medium-chain acyl-CoA dehydrogenase (MCAD), three samples 
with very-long-chain acyl-CoA dehydrogenase (VLCHAD), and also four samples 
had a defect in the so-called carnitine cycle, two at one step involving CPTI and the 
other two CPTII. Finally two of the patients had propionic acidaemia. 
 
The ability to identify minor components is of importance due to the fact that 
significant increases in low concentration levels of a particular metabolite can also be 
indicative of a particular deficiency, and can thus also serve as a biomarker. Herein, 
the advantage of the resolving power of GCxGC was demonstrated by several fatty 
acids (isomers) that were not separated in the previous study using a 1D-GC analysis. 
The enhanced sensitivity of GC x GC/ToFMS allowed the detection of trace levels of 
many metabolites present in the samples. Figure 4-1 shows a chromatogram of the 
GCxGC profile from a normal infant plasma sample. This representation of the data is 
known as the contour plot. In this display, the peaks found by the software (LECO 
Inc., USA) at lower concentration are indicated as black dots. 
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Figure 4-1: GC×GC/TOFMS total ion chromatogram showing the metabolic profile 
of ‘normal’ infant plasma. 
 
The choice of column was considered in this work and the polar/non-polar column set 
was the chosen combination as it allows for better use of the 2D separation space. 
Koek and co-workers concluded that using a polar/non-polar column setup for 
biologically-based samples in GCxGC/MS provided better separation in comparison 
to the non-polar/polar column set [64]. This generally occurs as the polar metabolites 
elute at lower temperatures and these temperatures consequently have higher retention 
times on the non-polar phase with which they are more compatible therefore resulting 
in better separation. Over 50 peaks were identified by library searching. A signal to 
noise ratio (S/N) of 100 and a mass threshold of 20 were used for identification, and 
metabolite identifications were performed using NIST 2005 library 
(http://www.nist.gov/srd/nist1.htm). NIST similarities can range from 0 indicating no 
match to 999 for a perfect match. In this study, similarities greater than 800 were 
considered reasonable, acceptable matches and were therefore assigned the respective 
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name and further confirmation was obtained by authentic fatty acid standards. 
Compound detected are labelled with a black dot indicating possible metabolite as 
shown in Figure 4-1 (all the black dots are not ‘real’ metabolites, as there are also 
unavoidable artifacts due to the derivatization process). In order to apply an objective 
basis to the qualitative data analysis firstly areas of the total ion chromatogram were 
expressed as a percentage of the total area. Secondly relative peak area ratios were 
calculated using the extracted ion chromatograms (metabolite area/internal standard 
area) with the mean, median and standard deviation calculated for each metabolite. At 
last multiple of median values were calculated by dividing the ratio value calculated 
by the median and compared with the normal samples. 
Patients with LCHAD deficiency were characterised by an increase in 3-hydroxyfatty 
acids (3OHFA), in particular the long-chain acids, in this case ion m/z 233 was used 
as a diagnostic ion. On the other hand, the patients whose metabolic defect did not 
give rise to the accumulation of 3OHFAs (MCAD, VLCAD, CPTI, and CPTII) 
presented long-chain 3OHFA concentrations within the normal range, similar amount 
to the normal sample plasma. Infants with propionic acid deficiency also showed an 
increase in 3OHFA however the increased levels were still within the normal range 
and not characteristic to the disorder. Figure 4-2 illustrates the fatty acid profile of a 
patient with MCAD disease.  
The MCAD-deficient patient presented a FFA pattern characterized by an increase of 
mainly in the medium chain fatty acids C8, C10:1, and C10. The area which has been 
labelled as Region A in Figure 4-2 emphasises the section where these metabolites 
were located in the chromatogram. The average range of the C8, C10:1, and C10 in the 
normal plasma were calculated to be between 0.87-2.35 for the C8 and 0.56-3.2 for the 
C10 however in this case this number significantly increased at a value of 11.25 for the 
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C8 in the plasma samples from infants with MCAD and C10 ranged between 14.65-
16.65 for the Affected infants. Figure 4-3 displays an example of the peak true 
deconvoluted spectra of octanoic acid TMS by Leco, providing deconvoluted spectra 
clean of matrix and coelution interference. The example shows a raw spectrum at the 
top, the middle spectrum illustrates the deconvoluted peak true sample where the ions 
not belonging to this analyte have been removed through patented automated 
deconvolution technology. The bottom spectrum is the resulting match from the NIST 
library which is referred to as the reference spectrum, and as it can be seen the match 
for the identification of the fatty acid is 914 thus indicating a true peak.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2: GCxGC/ToFMS chromatogram of plasma from infant with MCAD 
disease 
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Figure 4-3: Example of ToFMS fragmentation for the identification of octanoic acid 
in MCAD.  Upper and middle layer referring to the peak in the real sample. Bottom 
layer NIST Library hit comparison for verification of a true metabolite. 
 
 
 
As mentioned previously plasma fatty acid profiles are most important in the 
diagnosis of MCAD, VLCAD-deficient patients as well as LCHAD. We discussed 
that patients diagnosed with MCAD deficiencies illustrated a fatty acid configuration  
characterized by a significant increase in the concentration of C8 and  C10:1 and C10 
fatty acids and low concentration of the long chain fatty acids (Figure 4-3). Analysis of 
plasma from infants with VLCHAD was characterized by the increase of long-chain 
fatty acids, mainly C14, C16:1, C18:2, C18:1 and C18:0, Figure 4-4. The C16:1 levels of fatty 
acids in the normal plasma samples ranged between 0.75-3.25MoM, however in this 
case for plasma samples with VLCHAD showed an increase of up to 17.25MoM. 
 
Reference library spectrum 
 
Peak true deconvoluted 
spectrum 
 
Peak true raw spectrum 
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Figure 4-4: GCxGC/ToFMS chromatogram of patient with a VLCHAD disease. 
 
 
Samples from infants with LCHAD were characterized by a clear increase in 3-
hydroxyfatty acid. Figure 4-5 demonstrated the increase in 3-hydroxypalmitoyl that 
was determined in the samples with such deficiency. Other 3OHFAs increased 
however the mentioned 3OHFA had the highest increase levels. From the normal 
infant plasma samples the 3OHFAs levels should range between 0.05-1.2 MoM 
(multiple of median), for 3-hydroxypalmitoyl however in this case those levels were 
recorded to be 21 MoM, please refer to Figure 4-5. 
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Figure 4-5: GCxGC/ToFMS chromatogram of a patient with LCHAD disease 
focusing on 3OHFA zoomed region. 
 
The chain-length pattern of plasma fatty acids in controls was characterized mainly by 
the long-chain fatty acids with 16 and 18 carbon atoms, whereas the concentrations of 
the shorter chain fatty acids (C6 to C14) were much lower in terms of multiple of 
median ratios. This profile generally replicates the breakdown of fat stores that are 
generally composed of C16 and C18 fatty acids, both saturated and unsaturated [217]. 
When fasting, these fatty acids are released into the bloodstream and rapidly 
metabolized through mitochondrial β-oxidation. In this study none of the patients 
were reported to be under any special condition (i.e. fasting) however the analyst 
should be aware of this type of information for precise and efficient results. Overall 
the 3OHFAs was detected in normal plasma in very low concentrations, which is in 
agreement with the values reported by Hagenfeldt et al. [218, 219].  Furthermore 
infants with a defect in the carnitine transport system (CPTI and CPTII) presented a 
1
st
 Dimension time (s) 
2
nd
  Dimension time (s) 
3-hydroxypalmitoyl  
IS 
Cholesterol 
C18 
Chapter 4 – Evaluation of GCxGC/ToFMS for the diagnosis of pathological 
metabolites in infant plasma 
 
 ~167~ 
very similar plasma FFA pattern, characterized by an increase of long-chain fatty 
acids, mainly the C16 and C18 species, whereas the medium-chain fatty acids were 
within the normal range Figure 4-6. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4-6: An expanded GCxGC/ToFMS chromatogram of patient with 
CPT1disease, illustrating the increase in the long chain fatty acids. 
 
Apart from the increase in the long chain fatty acid determined in the infants with 
CPT1 and CPTII, another metabolite identified was 1-monolinoleoylglycerol. The 
levels of this fatty acid were only increased in this specific deficiency and not noticed 
in any of the other samples, it can be hypothesised that this could be a potential 
biomarker discovery for this CPT1 and CPII.  This is mainly due to the fact that 1-
monolinoleoylglycerol was not detected in any of the control of diseased samples. 
However more analyses are required for more precise results and conclusion but the 
fact that this metabolite was identified was an interesting finding for this study. 
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Table 4-1: List of the most abundant fatty acids identified in infant plasma including 
1
st
  and 2
nd
 dimension retention time, NIST Library similarity hit and area 
 
 
 
 
 
 
 
Most abundant metabolites  1st 
dimension 
retention 
time (s) 
2 nd 
dimension 
retention 
time (s) 
Similarity 
(/1000) 
Area (pA) 
Benzoic acid trimethylsilyl ester 1025 2.61 945 59291736 
 
Butanoic acid, 2-[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
659 3.16 872 2.29E+08 
 
Hexanoic acid, trimethylsilyl ester 635 2.69 860 9608562 
 
Silane, trimethyl[1-methyl-2-oxo-2-
(trimethylsilyl) 
659 2.52 888 16804472 
 
Propanoic acid, 2-[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
593 2.83 941 1.44E+08 
 
Octanoic acid, trimethylsilyl ester 905 3.21 928 8609847 
 
Allonic acid, 2,3,5,6-tetrakis-O-(trimethylsilyl)-
, lactone 
1079 5.06 893 147577 
 
Urea, N,N'-bis(trimethylsilyl)- 983 3.07 875 29884783 
 
Propanedioic acid, methyl-, bis(trimethylsilyl) 
ester 
1025 3 872 16481971 
 
Nonanoic acid, trimethylsilyl ester 1409 3.35 896 14741079 
 
Benzeneacetic acid, trimethylsilyl ester 1121 2.56 840 25872569 
 
Pentanedioic acid, 3,3-dimethyl-, 
bis(trimethylsilyl) ester 
1169 3.5 900 4.59E+08 
 
Dodecanoic acid, trimethylsilyl ester 1457 3.6 818 16380443 
 
Octanedioic acid, bis(trimethylsilyl) ester 1157 3.2 823 2817438 
 
n-Tridecanoic acid, trimethylsilyl ester 1589 3.65 746 300851 
 
Malonic acid, bis(2-trimethylsilylethyl ester 1685 3.09 865 223488 
 
Tetradecanoic acid, trimethylsilyl ester 1703 3.9 835 42825418 
 
9,12-Octadecadienoic acid (Z,Z)-, 
trimethylsilyl ester 
2159 3.62 822 27148293 
 
Linolenic acid, trimethylsilyl ester 2189 3.45 855 1847239 
 
3-[(Trimethylsilyl)oxy]cholest-5-ene  # 2993 1.34 772 21982638 
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4.4.1. Repeatability and quantitative performance of 
GCxGC/ToFMS 
 
Eight metabolites of interest from the control sample by GCxGC/ToFMS were 
selected for comparing retention time shifts through the 
2
D control samples by 
GCxGC/ToFMS were selected for comparing retention time shifts through 2D RSD 
(%) for repeatability (n=5). The performance of the instrument was investigated by 
observing the variability of a range of fatty acids used in the identification of IEMs. In 
this case the control sample was extracted and derivatised five times in order to 
observe changes in the peak intensity and retention time shifts. RSDs values were 
calculated based on second dimension retention times for the three modulated peaks 
obtained for each of the eight fatty acids and were all within 5% most of them within 
3%, which indicates that the reproducibility of the second dimension retention times 
are acceptable (Table 4-1 and 4-2). The repeatability and reproducibility studies 
conducted indicate that minimizing the variability present is important, and the 
analysis has shown that the differences observed between samples is probably due to 
the varying metabolite concentrations (overloaded peaks), and not to instrumental 
variables (e.g. retention time drift). 
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Table 4-2: Repeatibility (n=5) of 8 metabolites of interest in respect to peak retention 
times (3 modulated peaks per compound: RSD%) 
 
 
 
 
 
 
METABOLITE 1D, 2D MEAN 
RETENTION 
TIME 
(S) 
MEAN 2D 
RETENTION 
TIME RSD (%) 
MODULATED 
PEAK 1 
RSD (%) 
MODULATED 
PEAK 2 
RSD (%) 
MODULATED 
PEAK 3 
RSD (%) 
 
Hexanoic acid, 
  
trimethylsilyl ester 
  
635 2.69 
 
1.01 
 
3.89 
 
3.75 
 
3.95 
 
Octanoic acid,  
 
trimethylsilyl ester 
 
905, 3.21 
 
1.34 
 
3.5 
 
3.8 
 
2.65 
 
Propanoic acid, 2- 
 
[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
 
1025, 2.830 
 
4.65 
 
4.20 
 
3.95 
 
5.07 
 
Pentanedioic acid, 
3,3-dimethyl-,  
 
bis(trimethylsilyl) 
ester 
 
1169, 3.5 
 
3.52 
 
4.3 
 
3.85 
 
5.2 
 
Dodecanoic acid, 
 
trimethylsilyl ester 
 
 
1457, 3.6 
 
1.83 
 
1.35 
 
2.35 
 
4.5 
Octanedioic acid,  
 
bis(trimethylsilyl) 
ester 
 
  
1157, 3.2 
  
2.00 
 
2.60 
 
3.80 
 
4.20 
Tetradecanoic acid,  
 
trimethylsilyl ester 
 
1703, 3.9 
 
2.85 
 
3.30 
 
4.20 
 
3.95 
Linolenic acid,  
 
trimethylsilyl ester 
 
2189, 3.45 
 
1.53 
 
1.9 
 
2.5 
 
3.8 
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4.4.2. Quantification of diseased infant plasma samples 
 
Quantification of the fatty acid compounds in plasma samples is important for IEMs, 
as an increase in specific metabolite is indicative of a particular type of IEM. In 
GCxGC, integration is achieved using a raw chromatogram, which may be performed 
by summation of each modulated peak, or a representative subset of the modulated 
peaks [27] derived for that metabolite. Eight metabolites standards were used to 
generate calibration curves in order to quantify the metabolites of interest in the 
analysed samples, hexanoic acid, octanoic acid, heptanoic acid, decanoic acid, 
tetradecanoic acid, hexadecanoic acid, octadecanoic acid, and pentadecanoic acid. 
Figure 4-7 illustrates the separation of the fatty acid standards used listed in Table 4-1 
at m/z 117 used as a diagnostic ion for fatty acids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: GCxGC/ToFMS chromatogram illustrating the separation of the 14 fatty 
acid standards at m/z 117.  
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Figure 4-8: Example of ToFMS fragmentation for one of the standards used 
(dodecanoic acid). 
 
 
 
Quantification was performed by calculating relative peak area ratios of the eight 
metabolite standards against the internal standard and quantification ions were 
selected for each metabolite (Figure 4-6). Upper and lower standards were used for 
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the determination of the calibration. Table 4-3 shows the quantification ions, the 
upper and lower standards, calibration equation and R
2
 values, also the RSD. The 
original metabolite standard solution was diluted by a factor of 2 and 4 respectively. 
RSD and R
2
 values were all within the acceptable limits: RSDs values all being below 
10% and R
2
 values greater than 0.98.  
 
Table 4-3: Repeatability (RSD), R
2 
and relative responses vs. internal standard at 
different concentration levels of relative response of selected fatty acids (n=3) EIC 
mode m/z 117 TMS derivatives in GCxGC.  
 *values are given 1000 g/mL, 10g/mL and 1g/mL  
 
 
Compound equation & R2 relative response    
vs. 
Internal standard 
RSD (%) 
Hexanoic acid y=0.019x-0.318  
R
2
=0.998 
18.87, 
0.104, 
0.007 
9.7 
6 
7.9 
Octanoic acid Y=0.005x-0.004  
R
2
=0.999 
5.37 
0.048 
0.004 
6.5 
6.2 
5.9 
Heptanoic acid y=0.0013x-0.113  
R
2
=0.999 
13.2 
0.107 
0.011 
2.5 
1.5 
3.2 
Decanoic acid y=0.019x-0.318  
R
2
=0.998 
18.87 
0.104 
0.007 
14.2 
6.5 
7.5 
Tetradecanoic acid Y=0.004x+0.007 
R
2
=0.999 
4.83 
0.052 
0.0059 
3.8 
1.7 
2.1 
Hexadecanoic acid y=0.013x-0.079  
R
2
=0.997 
13.32 
0.18 
0.02 
2.4 
1.7 
3.6 
Octadecanoic acid y=0.009x-0.31  
R
2
=0.998 
9.25 
.05 
0.012 
3.6 
2.3 
1.9 
Pentadecanoic acid Y=0.017x+0.076  
R
2
=0.999 
7.85 
0.205 
0.018 
5.5 
2.9 
3.5 
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4.4.3. Limit of detection (LOD) and limit of quantification (LOQ) 
 
The limit of detection (LOD) and of quantification (LOQ) were determined using the 
standards with the lowest concentration (10 µmol/L) which was still detectable at this 
lower level and to rebuild the respective EIC for each metabolite of interest. Detection 
limits were calculated by determining the S/N ration and extrapolating to the S/N=3 
level for (LOD) and S/N=10 level for (LOQ). According to this method LOQ was 0.1-
.35 µmol/L and the LOQ obtained was 0.9-1.1 µmol/L across the five samples. The 
LOQ was below the lowest standard, which is in agreement with the concentration 
chosen to accumulate the calibration curve. It must be noted though, that in GCxGC 
the analyst must be very careful when determining LOD and LOQ as S/N depends on 
the modulation period and phase shift, thus figures can be taken only as an 
approximate measurement, this is further explained by Ong et al [220]. 
4.4.4. Biomarker discovery possibilities using GCxGC/ToFMS 
 
The diagnosis of fatty acid oxidation disorders, or for that matter any other error of 
metabolism can be based on the metabolite analysis. The main focus of metabolite 
analysis involves recognising the different patterns of metabolite accumulation 
specific to different fatty acid oxidation enzyme defects, usually this requires the use 
of sensitive instrumentation. In this chapter the importance of using a 
multidimensional technique such as GCxGC/ToFMS through its improved 
capabilities in the field of possible biomarker discovery is demonstrated through the 
identification of 1-monolinoleoylglycerol in the sample from infants with carnitine 
uptake defect (CPT2), which can possibly be a useful diagnostic marker for this 
disorder. This important finding implies that there is a greater possibility for 
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GCxGC/ToFMS to be used in many different application areas for biomarker 
discovery, and it would be even more efficient with chemometric analysis. 
 
4.5. Conclusion 
 
This chapter depicts the value of GCxGC/ToFMS infant plasma fatty acid profiling 
for the diagnosis and investigation of different IEMs. Analytical profiles were 
obtained from 15 patients with known inborn errors of metabolism which 
recapitulated with the findings of 1D GC/MS. The results demonstrated that GCxGC 
provides increased peak capacity for biological based samples and is a very efficient 
method for this type of analysis as it provides a second dimension of chromatographic 
resolution by using the distinct stationary phases (polar/non-polar).   It can also be a 
useful tool for the identification of ‘possible biomarkers which was demonstrated by 
the unexpected finding of increased 1-monolinoleoylglycerol in the sample from 
infants with carnitine uptake defect, which was not detected in the analysis conducted 
when using GC/MS. The enhanced resolving power of GCxGC/ToFMS was also 
beneficial in the detailed analysis of complex profiles (cleaner mass spectra and 
greater sensitivity) obtained when patients are in metabolic imbalance.   
 
 
 
 
 
 
  
 
 
 
 
 
 
5.1. Conclusions 
 
In the work underlying this thesis, one dimensional GC (GC/qMS and GCT-oa-
ToFMS) and comprehensive two-dimensional gas chromatographic with time-of-
flight mass spectrometry (GCxGC/ToFMS) methods have been developed which can 
be used to compare and differentiate metabolic profiles from two very different 
human application areas - yeast as well as infants with different IEMs. One-
dimensional GC (with MS detection) is applied as a routine technology for the 
screening of metabolites in both human and plant metabolomics, and has been used in 
this field since the 70s [38, 39, 62, 221]. GCxGC has now extended the GC approach 
in this area by providing greater separation power, lower detection limits (greater 
sensitivity, and therefore cleaner MS spectra), smaller sample amounts and less 
overall analysis times. In addition, quantification of compounds of interest has 
improved immensely over the past few years [222], and summed peak responses can 
now be used (and have been implemented throughout the quantification studies 
undertaken in this thesis). Relative response factor determinations in 2DGC are 
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approximately equivalent to that obtained in 1DGC, although 1DGC in some cases 
undergoes interference where unknown peaks overlap and cause inaccurate peak area 
measurements.  
 
The use of GCxGC with TOFMS detection allowed for an enhanced separation and 
sensitivity through the detection of trace levels fatty acids present in the infant plasma 
samples, as compared to a one dimensional separation approach. Overall, the 
decreased derivatization time allowed for a longer separation time in order to execute 
the comprehensive GCxGC separation. The total analysis time when comparing a 
1DGC to a 2DGC approach has not changed greatly, as the excess time taken to 
perform 2DGC approach has been offset by a decrease in the derivatization time due 
to the development of microwave derivatization techniques. Importantly, a 2DGC 
method which has a similar total analysis time (including samples preparation) to a 
1DGC method can now be applied to different biologically-based samples, with the 
added advantages of enhanced separation power and sensitivity, and containing more 
information. Microwave derivatization has been successfully applied to two main 
application areas: human (plasma) and microorganisms (yeast) metabolite profiling. 
The method presented is rapid (significant decrease in derivatization time, therefore 
overall decreasing the total analysis time), sensitive and produces less side reactions 
(a more complete derivatization reaction). The work undertaken in the microorganism 
metabolic profiling area comprised of the comparison of the different yeasts, 
Diamond V XP, Yea-Sacc and Levucell through the detection, identification and 
quantification of metabolites using GCT-oa-ToFMS. Accurate mass analysis allows 
for the absolute identification of a broad range of metabolites present in yeast extracts, 
and the use of chemometrics techniques such as PCA and OPLS-DA enabled 14 
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defining elements (significantly altered concentration of metabolites) to be 
distinguished. The use of accurate masses allows the absolute (correct) identification 
of the altered metabolites (significant increase or decrease in concentration – at a 
semi-quantification level), which can thus be proposed to be used as possible 
biomarkers for future yeast differentiation. The 14 possible biomarkers found (either 
in significantly increased or decreased concentration levels) included propanoic acid, 
melibiose, myo-inositol, threitol, mannitol, glucopyranose, ribose, phenylalanine and 
fructose. 
In the infant plasma metabolite profiling abnormal profiles were obtained from all 15 
‘diseased’ patients studied. Infant plasma with MCAD deficiencies presented a fatty 
acid profile by a strong increase in C8, C10 and C10:1, whereas the VLCAD-deficient 
infants, the plasma fatty acid profile was characterized by the obvious increase of the 
long chain fatty acids, C14, C16 and C18. LCHAD deficient infants were characterized 
by the general increase in the 3OHFA   – indicative of the respective disorders. 
Furthermore GCxGC with ToFMS detection was useful in separating isomeric 
compounds that were otherwise not resolved using 1DGC. 1-monolinoleoylglycerol 
was discovered in one of the samples with carnitine uptake defect as a possible 
biomarker for the disorder. Correlation coefficients for linear calibrations of the 
analytes ranged from 0.977 to 0.999 (R2) and analytical recoveries from 77 and 99%. 
The study illustrated the potential of GC×GC/ToFMS for the diagnosis of fatty acid 
deficiencies and the comprehensive analysis of the complex profiles that are often 
linked with these disorders.  
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5.2. Future perspectives 
 
Gas chromatography has a rich and extensive history in the study of compounds 
derived from biological processes. The multidimensional GC tools (GC/MS, 
GC/ToFMS, GC/MS/MS, GC/HRMS, MDGC/MS, GCxGC/ToFMS) that are 
currently available to the analyst for metabolic profiling are mature and flexible 
enough to allow for their widespread use in the study of biochemical processes. 
Despite the numerous studies presented, it is obvious that detection of the full 
complement of small molecules in biological matrices (i.e. the broader field of 
‘metabolomics’) still escapes researchers. Metabolite measurements will continue to 
have a central diagnostic role in screening at least until methods to detect all possible 
mutations became available, which seems like a difficult task at present time. 
Target analysis for a limited number of compounds is more successful for detecting a 
greater proportion of the compounds of interest; specific implementation of selective 
methods capable of covering a limited component suite is technically easier. From 
this, it seems that the full potential of metabolic profiling and metabolomics though, 
has not yet been accomplished due to the sheer complexity of the task.  
 
Whilst the emerging GC×GC technique has thus far shown encouraging results, 
although for limited applications studies, it should play a major role in metabolic 
profiling. Current applications in GC×GC still address basic tasks such as 
optimization of various hardware configurations, development of software tools 
which provide the capacity to handle large data sets produced by high-resolution 
instrumentation, and MS detection protocols. The availability of a more complete 
metabolite complement of isotopically-labelled standards would assist in 
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quantification. Whilst dedicated MS libraries are available, construction of more 
comprehensive databases continues 
This progressive development suggests that more work is still required for precise 
peak identification. Indeed, it is reported that 60-90% of the total metabolites which 
are detected in a biological matrix are unidentifiable, even with the use of fast-
scanning mass spectrometers such as TOFMS with deconvolution [223], so the 
challenge is clear; approaches which allow the rapid identification of ‘general 
unknowns’ must be created; currently this low rate of compound identification is 
credited to the lack of absolute structural information offered by mass spectrometers 
(i.e. isomers cannot be fully characterized; MS spectral matching is imprecise). 
GC×GC may assist through 3-dimensional correlation of 1tR, 2tR and MS data, along 
the lines of present retention index/MS spectral matching in 1DGC/MS.  
Frequently related more with the sampling process, sample replicates need to pass 
acceptability criteria with respect to both biology and to the measurement process; 
biological replicates have been suggested to be more important than technical or 
methodological replicates [224]. Whether greater dimensionality of the analytical 
methods increases the certainty of analysis, and reduces some sources of biases needs 
to be determined. Metabolomics should now progress into the complete discovery 
platform, which is supported by complementary and parallel platforms, in order to 
progress our understanding of complex biological living systems. The potential 
behind metabolomics is immense, in terms of both diagnostic and prognostic value. In 
regards to the tools needed for metabolite identification, in order to assist in a more 
comprehensive study of the metabolome, the importance must lie with 
multidimensional techniques which can be used to complement one another.  
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